Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23

ABSTRACT

The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/069,840, filed on Mar. 18, 2008; U.S. Provisional Application No.61/095,275, filed on Sep. 8, 2008; and U.S. Provisional Application No.61/207,904, filed on Feb. 18, 2009, the entire contents of each of whichare incorporated herein by reference.

SUBMISSION ON COMPACT DISC

This application incorporates by reference the ASCII text fileidentified by the name 2009-09-02 117813-32903 ST25.txt, containing 223KB of data, created on Sep. 28, 2009 and filed in computer-readableformat (CRF).

BACKGROUND OF THE INVENTION

Psoriasis is a T cell-mediated inflammatory disease that is consideredto be one of the most common autoimmune diseases, affectingapproximately 2% to 3% of adults, though the global prevalence varieswidely (Stem R. S., et al., J Investig Dermatol Symp Proc 2004, 9:136-39; Davidson A and Diamond B. N Engl J Med 2001, 345: 340-50;Langley R. G. B., et al., Ann Rheum Dis 2005, 64(Suppl II): ii18-23).Psoriasis has a major impact on quality of life (de Korte J, et al., JInvestig Dermatol Symp Proc 2004, 9: 140-7; Krueger G, et al., ArchDermatol 2001, 137: 280-4; Finlay A Y and Coles E C, Br J Dermatol 1995,132: 236-44) and is associated with a number of psychological andpsychosocial problems (Kimball A B, et al., Am J Clin Dermatol 2005, 6:383-92; Russo P A, et al., Australas J Dermatol 2004, 45: 155-9). Manytraditional psoriasis therapies have toxic adverse effects; therefore,their long-term use is limited (Lebwohl M. and Ali S., J Am AcadDermatol 2001, 45: 487-98; Lebwohl M. and Ali S., J Am Acad Dermatol2001, 45: 649-61). In addition, many patients with psoriasis aredissatisfied with traditional therapies (Stem R S, et al., J InvestigDermatol Symp Proc 2004, 9: 136-39; Finlay A Y and Ortonne J P, J CutanMed Surg 2004, 8: 310-20); thus, there is a clear need for therapiesthat are safer and easier to use and that can be prescribed on along-term basis.

Interleukin-12 (IL-12) and the related cytokine IL-23 are members of theIL-12 superfamily of cytokines that share a common p40 subunit (AndersonE J R, et al., Springer Semin Immunopathol 2006, 27: 425-42). Bothcytokines contribute to the development of the type 1T helper cell (Th1)immune response in psoriasis, but each has a unique role (Rosmarin D andStrober B E, J Drugs Dermatol 2005, 4: 318-25; Hong K, et al., J Immunol1999, 162: 7480-91; Yawalkar N, et al., J Invest Dermatol 1998, 111:1053-57). IL-12 primarily stimulates differentiation of Th1 cells andsubsequent secretion of interferon-gamma, whereas IL-23 preferentiallystimulates differentiation of naïve T cells into effector T helper cells(Th17) that secrete IL-17, a proinflammatory mediator Rosmarin D andStrober B E, J Drugs Dermatol 2005, 4: 318-25; Harrington Le, et al.,Nature Immunol 2005, 6: 1123-32; Park H, et al. Nature Immunol 2005, 6:1132-41). The overexpression of IL-12 p40 and IL-23 p40 messenger RNA inpsoriatic skin lesions suggests that the inhibition of IL-12 and IL-23with a neutralizing antibody to the IL-12/23 p40 subunit protein mayoffer an effective therapeutic approach for the treatment of psoriasis(Yawalkar N, et al., J Invest Dermatol 1998, 111: 1053-57; Lee E, etal., J Exp Med 2004, 199: 125-30; Shaker O G, et al., Clin Biochem 2006,39: 119-25; Piskin G, et al., J Immunol 2006, 176: 1908-15). Suchtherapeutic approaches for the treatment of psoriasis are clearly neededin the art.

SUMMARY OF THE INVENTION

The present invention provides methods and compositions for treatingpsoriasis, e.g., chronic psoriasis, using an antibody, orantigen-binding portion thereof, that binds human IL-12 and/or humanIL-23.

In one aspect, the invention provides a method of treating psoriasis ina subject comprising administering to the subject an antibody, orantigen-binding portion thereof, which is capable of binding to anepitope of the p40 subunit of IL-12 and/or IL-23, wherein the subjectmaintains at least a PASI 75 response for a first extended periodfollowing initial administration of the antibody, or antigen-bindingportion thereof, wherein the subject exhibits a loss of responsefollowing discontinuation of administration of the antibody, orantigen-binding portion thereof, and wherein the subject maintains atleast a PASI 75 response for a second extended period followingre-administration of the antibody, or antigen-binding portion thereof,thereby treating psoriasis in the subject.

In one embodiment, the first extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment, administration of the antibody is discontinued for atleast about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably12 weeks.

In one embodiment, the second extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment the antibody, or antigen-binding portion thereof, isadministered biweekly. In one embodiment, the antibody, orantigen-binding portion thereof, is administered weekly. In oneembodiment, the antibody, or antigen-binding portion thereof, isadministered in a single dose.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered in a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg,150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 or 220 mg.

In one embodiment, the psoriasis is chronic psoriasis. In oneembodiment, the psoriasis is plaque psoriasis, e.g., chronic plaquepsoriasis. In another embodiment, the psoriasis is chronic psoriasis,e.g., chronic plaque psoriasis. In yet another embodiment, the psoriasisis moderate to severe psoriasis, e.g., moderate to severe plaquepsoriasis, moderate to severe chronic psoriasis or moderate to severechronic plaque psoriasis. In one embodiment, the subject has had aclinical diagnosis of psoriasis for at least 6 months. In anotherembodiment, the subject has had stable plaque psoriasis for at least 2months.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject a single dose of anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23, whereinat least one pharmacokinetic characteristic selected from the groupconsisting of a half-life of at least about 3 days, a T_(max) of lessthan or equal to about 4 days, and a bioavailability of at least about40% is achieved following administration of the antibody, orantigen-binding portion thereof.

In various embodiments, a half life of at least about 2 days, 3 days, 4days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days is achieved.

In various embodiments, a T_(max) of less than or equal to about 1 day,2 days, 3 days, 4 days, 5 days, 6 days or more is achieved.

In various embodiments, a bioavailability of at least about 0.1%, 1%,5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more is achieved.

In one embodiment, the antibody is administered via intravenousinjection.

In one embodiment, the antibody is administered via subcutaneousinjection.

In one embodiment, the single dose is between about 0.1 and about 5.0mg/kg (e.g., about 0.1 to about 1.0 mg/kg, about 0.1 to about 2.0 mg/kg,about 0.1 to about 3.0 mg/kg, about 0.1 to about 4.0 mg/kg, about 1.0 toabout 2.0 mg/kg, about 1.0 to about 3.0 mg/kg. about 1.0 to about 4.0mg/kg or about 1.0 to about 5.0 mg/kg) of the antibody, orantigen-binding portion thereof.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject an antibody, orantigen-binding portion thereof, which is capable of binding to anepitope of the p40 subunit of IL-12 and/or IL-23, wherein the subjectmaintains at least a PASI 75 response for a first extended periodfollowing initial administration of the antibody, or antigen-bindingportion thereof, wherein the subject exhibits a loss of responsefollowing discontinuation of administration of the antibody, orantigen-binding portion thereof, and wherein the subject maintains atleast a PASI 50 response for a second extended period followingre-administration of the antibody, or antigen-binding portion thereof,thereby treating psoriasis in the subject.

In one embodiment, the first extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment, administration of the antibody is discontinued for atleast about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably12 weeks.

In one embodiment, the second extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered biweekly. In one embodiment, the antibody, orantigen-binding portion thereof, is administered weekly.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered in a single dose. In one embodiment, the antibody, orantigen-binding portion thereof, is administered in a dose of about 100mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190mg or 200 mg.

In one embodiment, the psoriasis is chronic psoriasis.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject an antibody, orantigen-binding portion thereof, which is capable of binding to anepitope of the p40 subunit of IL-12 and/or IL-23, wherein the subjectmaintains at least a PASI 75 response for a first extended periodfollowing initial administration of the antibody, or antigen-bindingportion thereof, wherein the subject exhibits a loss of responsefollowing discontinuation of administration of the antibody, orantigen-binding portion thereof, and wherein the subject maintains aclear or minimal PGA score for a second extended period followingre-administration of the antibody, or antigen-binding portion thereof,thereby treating psoriasis in the subject.

In one embodiment, the first extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment, administration of the antibody is discontinued for atleast about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably12 weeks.

In one embodiment, the second extended period is at least about 4, 5, 6,7, 8, 9, 10, 11, 12, 13 or 14 weeks, and preferably 12 weeks.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered biweekly. In one embodiment, the antibody, orantigen-binding portion thereof, is administered weekly.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered in a single dose. In one embodiment, the antibody, orantigen-binding portion thereof, is administered in a dose of about 100mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190mg or 200 mg.

In one embodiment, the psoriasis is chronic psoriasis.

In yet another aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject a singledose of an antibody, or antigen-binding portion thereof, which iscapable of binding to an epitope of the p40 subunit of IL-12 and/orIL-23, wherein at least one pharmacokinetic characteristic selected fromthe group consisting of a maximum serum concentration (C_(max)) ofbetween about 0.15 and about 150 μg/mL (e.g., between about 0.2 andabout 140 μg/mL, between about 0.5 and about 125 μg/mL, between about1.0 and about 100 μg/mL, between about 10 and about 90 μg/mL, betweenabout 25 and about 75 μg/mL, between about 35 and about 60 μg/mL andbetween about 40 and about 50 μg/mL) and an area under the serumconcentration-time curve (AUC) of between about 80 and about 13,000μg×hr/mL (e.g., between about 100 and about 12,000 μg×hr/mL, betweenabout 150 and about 10,000 μg×hr/mL, between about 200 and about 8,000μg×hr/mL, between about 400 and about 6,000 μg×hr/mL, between about 800and about 4,000 μg×hr/mL, between about 1000 and about 2,000 μg×hr/mL,between about 145 and about 13,000 μg×hr/mL, and between about 80 andabout 5,000 μg×hr/mL) is achieved following administration of theantibody, or antigen-binding portion thereof.

In one embodiment, the antibody is administered via intravenousinjection.

In a preferred embodiment, the C_(max) is between about 1 and about 150μg/mL (e.g., between about 2 and about 125 μg×hr/mL, about 5 and about100 μg×hr/mL, about 10 and about 80 μg×hr/mL, about 20 and about 60μg×hr/mL, about 30 and about 50 μg×hr/mL, about 1 and about 20 μg×hr/mL,about 20 and about 300 μg×hr/mL, and about 140 and about 150 μg×hr/mL).

In a preferred embodiment, the AUC is between about 145 and about 13,000μg×hr/mL (e.g., between about 200 and about 11,000 μg×hr/mL, about 500and about 10,000 μg×hr/mL, about 1000 and about 5,000 μg×hr/mL, about2000 and about 4000 μg×hr/mL, about 145 and about 165 μg×hr/mL, about500 and about 600 μg×hr/mL, about 2000 and about 3000 μg×hr/mL and about12000 and about 13000 μg×hr/mL).

In one embodiment, the antibody is administered via subcutaneousinjection.

In a preferred embodiment, the C_(max) is between about 0.15 and about20 μg/mL (e.g., between about 0.25 and about 15 μg/mL, about 0.5 andabout 13 μg/mL, about 1 and about 10 μg/mL, about 2 and about 8 μg/mL,about 0.15 and about 0.3 μg/mL, about 0.5 and about 2 μg/mL, about 2 andabout 4 μg/mL, and about 10 and about 15 μg/mL).

In a preferred embodiment, the AUC is between about 80 and about 5000μg×hr/mL (e.g., between about 200 and 3000 μg×hr/mL, between about 400and 2000 μg×hr/mL, between about 500 and 1500 μg×hr/mL, between about4000 and 5000 μg×hr/mL, between about 80 and 90 μg×hr/mL, and betweenabout 200 and 300 μg×hr/mL).

In one embodiment, the single dose is between about 0.1 and about 5.0mg/kg (e.g., about 0.1 to about 1.0 mg/kg, about 0.1 to about 2.0 mg/kg,about 0.1 to about 3.0 mg/kg, about 0.1 to about 4.0 mg/kg, about 1.0 toabout 2.0 mg/kg, about 1.0 to about 3.0 mg/kg. about 1.0 to about 4.0mg/kg or about 1.0 to about 5.0 mg/kg) of the antibody, orantigen-binding portion thereof.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject a single dose of anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23, whereinat least one pharmacokinetic characteristic selected from the groupconsisting of a clearance (CL) of between about 30 and about 600 mL/hr(e.g., between about 50 and about 500 mL/hr, between about 75 and about400 mL/hr, between about 100 and about 300 mL/hr, between about 150 andabout 250 mL/hr, between about 30 and about 40 mL/hr, between about 40and about 60 mL/hr and between about 500 and about 600 mL/hr), and avolume of distribution (Vz) of between about 8 and about 11 L (e.g.,between about 8 and about 10 L, between about 8 and about 9 L, betweenabout 9 and about 10 L, between about 10 and about 11 L and betweenabout 8.5 and 9.5 L) is achieved following intravenous administration ofthe antibody, or antigen-binding portion thereof.

In a related aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject a singledose of an antibody, or antigen-binding portion thereof, which iscapable of binding to an epitope of the p40 subunit of IL-12 and/orIL-23, wherein at least one pharmacokinetic characteristic selected fromthe group consisting of an apparent clearance (CL/F) of between about 90and about 250 mL/hr (e.g., between about 100 and about 225 mL/hr,between about 125 and about 200 mL/hr, between about 140 and about 180mL/hr, between about 90 and about 100 mL/hr, between about 150 and about200 mL/hr, and between about 200 and about 250 mL/hr) and an apparentvolume of distribution (V/F) of between about 23 and about 67 L (e.g.,between about 25 and about 60 L, between about 30 and about 55 L,between about 35 and about 50 L, between about 40 and about 45 L,between about 23 and about 35 L and between about 60 and about 70 L) isachieved following subcutaneous administration of the antibody, orantigen-binding portion thereof.

In one embodiment, the single dose is between about 0.1 and about 5.0mg/kg (e.g., about 0.1 to about 1.0 mg/kg, about 0.1 to about 2.0 mg/kg,about 0.1 to about 3.0 mg/kg, about 0.1 to about 4.0 mg/kg, about 1.0 toabout 2.0 mg/kg, about 1.0 to about 3.0 mg/kg. about 1.0 to about 4.0mg/kg or about 1.0 to about 5.0 mg/kg) of the antibody, orantigen-binding portion thereof.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject an antibody, orantigen-binding portion thereof, which is capable of binding to anepitope of the p40 subunit of IL-12 and/or IL-23, wherein the subjectexhibits a PASI 75 response following initial administration of theantibody, or antigen-binding portion thereof, wherein the subjectexhibits a loss of response following discontinuation of administrationof the antibody, or antigen-binding portion thereof, and wherein thesubject exhibits at least a PASI 75 response by about 25 days followingre-administration of the antibody, or antigen-binding portion thereof,thereby treating psoriasis in the subject.

In one embodiment, the subject exhibits at least a PASI 75 response byabout 50 days following re-administration of the antibody, orantigen-binding portion thereof. In one embodiment, the subject exhibitsat least a PASI 75 response by about 60 days following re-administrationof the antibody, or antigen-binding portion thereof. In one embodiment,the subject exhibits at least a PASI 75 response by about 30, 35, 40,45, 50, 60, 65, 70, 75, 80, 85, 90 or more days followingre-administration of the antibody, or antigen-binding portion thereof.

In one embodiment, initial administration of the antibody is for atleast about 12 weeks.

In one embodiment, administration of the antibody is discontinued for atleast about 4, 5, 6, 7, 8, 9, 10, 11 or 12 weeks.

In one embodiment the antibody, or antigen-binding portion thereof, isadministered biweekly. In one embodiment, the antibody, orantigen-binding portion thereof, is administered weekly. In oneembodiment, the antibody, or antigen-binding portion thereof, isadministered in a single dose.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered in a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg,150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 200 mg.

In one embodiment, the psoriasis is chronic psoriasis.

In yet another aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23, whereinthe subject exhibits a PASI 75 response following initial administrationof the antibody, or antigen-binding portion thereof, wherein the subjectexhibits a loss of response by about 60 days following discontinuationof administration of the antibody, or antigen-binding portion thereof,and wherein the subject achieves a PASI 75 response followingre-administration of the antibody, or antigen-binding portion thereof,thereby treating psoriasis in the subject.

In one embodiment, the subject exhibits a loss of response by about 120days following discontinuation of administration of the antibody, orantigen-binding portion thereof. In one embodiment, the subject exhibitsa loss of response by about 180 days following discontinuation ofadministration of the antibody, or antigen-binding portion thereof. Inone embodiment, the subject exhibits a loss of response by about 50, 55,60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170,180, 190, 200 or more days following discontinuation of administrationof the antibody, or antigen-binding portion thereof.

In one embodiment, initial administration of the antibody is for atleast about 12 weeks.

In one embodiment the antibody, or antigen-binding portion thereof, isadministered biweekly. In one embodiment, the antibody, orantigen-binding portion thereof, is administered weekly. In oneembodiment, the antibody, or antigen-binding portion thereof, isadministered in a single dose.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered in a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg,150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 200 mg.

In one embodiment, the psoriasis is chronic psoriasis.

In another aspect, the invention provides a method of treating psoriasisin a subject comprising administering to a subject a biweekly weekly orsingle dose of an antibody, or antigen-binding portion thereof, directedagainst human an IL-12 and/or human IL-23. In a related aspect, theinvention provides a method of treating psoriasis in a subjectcomprising the steps of: (i) selecting a subject who is suffering fromchronic psoriasis; and (ii) administering to the subject an antibody, orantigen-binding portion thereof, which is capable of binding to anepitope of the p40 subunit of IL-12 and/or IL-23; thereby treatingchronic psoriasis in the subject.

In another related aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23, whereinthe subject maintains at least a PASI 50 response, at least a PASI 75response or at least a PASI 90 response for an extended period followingdiscontinuation of administration of the antibody, or antigen-bindingportion thereof, thereby treating psoriasis in the subject.

In yet another aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23 to thesubject, wherein the subject maintains a clear or minimal PGA rating foran extended period following initial administration of the antibody, orantigen-binding portion thereof, thereby treating psoriasis in thesubject.

In a still further aspect, the invention provides a method of treatingpsoriasis in a subject comprising administering to the subject anantibody, or antigen-binding portion thereof, which is capable ofbinding to an epitope of the p40 subunit of IL-12 and/or IL-23 to thesubject, wherein the subject exhibits an improved PASI score by about 8weeks following initial administration of the antibody, orantigen-binding portion thereof, thereby treating psoriasis in thesubject. In one embodiment, the subject exhibits an improved PASI scoreby about 7 weeks, about 6 weeks, about 5 weeks, about 4 weeks, about 3weeks, about 2 weeks or about 1 week following initial administration ofthe antibody, or antigen binding portion thereof.

In one embodiment, the extended period following discontinuation ofadministration of the antibody is at least about 12 weeks. In oneembodiment, the extended period is at least about 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23 or 24 weeks. In one embodiment, the antibodyis administered for at least about 12 weeks.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention is capable of binding to an epitopeof the p40 subunit of IL-12.

In another embodiment, the antibody, or antigen-binding portion thereof,is capable of binding to the epitope of the p40 subunit when the p40subunit is bound to the p35 subunit of IL-12. In yet another embodiment,the antibody, or antigen-binding portion thereof, is capable of bindingto the epitope of the p40 subunit when the p40 subunit is bound to a p19subunit. In one embodiment, the antibody, or antigen-binding portionthereof, is capable of binding to the epitope of the p40 subunit whenthe p40 subunit is bound to the p35 subunit of IL-12 and when the p40subunit is bound to a p19 subunit.

In one embodiment, the antibody, or antigen binding portion thereof,binds to an epitope of the p40 subunit of IL-12 to which an antibodyselected from the group consisting of Y61 and J695 binds.

In another embodiment, the antibody is further capable of binding to afirst heterodimer and is also capable of binding to a secondheterodimer, wherein the first heterodimer comprises the p40 subunit ofIl-12 and the p35 subunit of Il-12, and wherein the second heterodimercomprises the p40 subunit of IL-12 and a p19 subunit.

In a further embodiment, the antibody neutralizes the activity of thefirst heterodimer. In another embodiment, the antibody neutralizes theactivity of the second heterodimer. In yet another embodiment, theantibody neutralizes the activity of the first heterodimer and thesecond heterodimer.

In a further embodiment, the antibody, or antigen binding portionthereof, used in the methods of the invention inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻⁹ M or less, or which inhibits human IFNγ production withan IC₅₀ of 1×10⁻¹⁰ M or less.

In one embodiment, the antibody, or antigen binding portion thereof,used in the methods of the invention dissociates from the p40 subunit ofIL-12 with a K_(d) of 1×10⁻¹⁰ M or less or a k_(off) rate constant of1×10⁻³ s⁻¹ or less, as determined by surface plasmon resonance.

In one embodiment, the isolated antibody, or antigen binding portionthereof, used in the methods of the invention is a chimeric antibody, ahumanized antibody or a human antibody.

In another embodiment, the antibody, or antigen binding portion thereof,used in the methods of the invention has a heavy chain CDR3 comprisingthe amino acid sequence of SEQ ID NO: 25 and a light chain CDR3comprising the amino acid sequence of SEQ ID NO: 26;

In a further embodiment, the antibody, or antigen binding portionthereof, used in the methods of the invention has a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 27 and a light chainCDR2 comprising the amino acid sequence of SEQ ID NO: 28.

In one embodiment, the antibody, or antigen binding portion thereof,used in the methods of the invention has a heavy chain CDR1 comprisingthe amino acid sequence of SEQ ID NO: 29 and a light chain CDR1comprising the amino acid sequence of SEQ ID NO: 30.

In another embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention is capable of binding to aninterleukin comprising a p40 subunit. In one embodiment, the interleukincomprises a p40 subunit and a p35 subunit, e.g., the interleukin isIL-12. In another embodiment, the interleukin comprises a p40 subunitand a p19 subunit. In yet another embodiment, the antibody, or antigenbinding portion thereof, neutralizes the activity of the interleukin.

In one embodiment, the antibody, or antigen binding portion thereof,binds to an epitope of the p40 subunit.

In one embodiment, the antibody, or antigen-binding portion thereof, isadministered to a subject in a pharmaceutical composition comprising theantibody, or antigen binding portion thereof, and a pharmaceuticallyacceptable carrier. The pharmaceutical composition may also comprise anadditional agent, such as a therapeutic agent, e.g., budenoside,epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine,aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole,lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide,antioxidants, thromboxane inhibitors, IL-1 receptor antagonists,anti-IL-1β monoclonal antibodies, anti-IL-6 monoclonal antibodies,growth factors, elastase inhibitors, pyridinyl-imidazole compounds,antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15,IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3,CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands,methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil,leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone,phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents,complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAPkinase inhibitors, IL-1β converting enzyme inhibitors, TNFα convertingenzyme inhibitors, T-cell signalling inhibitors, metalloproteinaseinhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensinconverting enzyme inhibitors, soluble cytokine receptors, soluble p55TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R,antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13 and TGFβ.

In another embodiment, the therapeutic agent in the pharmaceuticalcomposition administered to the subject may be selected from the groupconsisting of anti-TNF antibodies and antibody fragments thereof,TNFR-Ig constructs, TACE inhibitors, PDE4 inhibitors, cortico steroids,budeno side, dexamethasone, sulfasalazine, 5-aminosalicylic acid,olsalazine, IL-1β converting enzyme inhibitors, IL-1ra, tyrosine kinaseinhibitors, 6-mercaptopurines and IL-11.

In another embodiment, the therapeutic agent may be selected from thegroup consisting of corticosteroids, prednisolone, methylprednisolone,azathioprine, cyclophosphamide, cyclosporine, methotrexate,4-aminopyridine, tizanidine, interferon-β1a, interferon-β1b, Copolymer1, hyperbaric oxygen, intravenous immunoglobulin, clabribine, antibodiesor agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16,IL-18, EMAP-II, GM-CSF, FGF, PDGF, antibodies to CD2, CD3, CD4, CD8,CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands,methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil,leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone,phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents,complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38 or MAPkinase inhibitors, IL-1β converting enzyme inhibitors, TACE inhibitors,T-cell signalling inhibitors, kinase inhibitors, metalloproteinaseinhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensinconverting enzyme inhibitors, soluble cytokine receptors, soluble p55TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R,sIL-13R, anti-P7s, p-selectin glycoprotein ligand (PSGL),antiinflammatory cytokines, IL-4, IL-10, IL-13 and TGFβ.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention binds to human IL-12 and/or humanIL-23 and dissociates from human IL-12 and/or human IL-23, respectively,with a K_(d) of 1×10⁻¹⁰ M or less and a k_(off) rate constant of 1×10⁻³s⁻¹ or less, as determined by surface plasmon resonance. In oneembodiment, the antibody, or antigen-binding portion thereof,dissociates from human IL-12 and/or human IL-23 with a k_(off) rateconstant of 1×10⁻⁴ s⁻¹ or less. In another embodiment, the antibody, orantigen-binding portion thereof, dissociates from human IL-12 and/orhuman IL-23 with a k_(off) rate constant of 1×10⁻⁵s⁻¹ or less.

In another embodiment, the antibody, or antigen-binding portion thereof,binds to human IL-12 and/or human IL-23 and dissociates from human IL-12and/or human Il-23, respectively, with a k_(off) rate constant of 1×10⁻²s⁻¹ or less, as determined by surface plasmon resonance. In yet anotherembodiment, the antibody, or antigen-binding portion thereof,dissociates from human IL-12 and/or human IL-23 with a k_(off) rateconstant of 1×10⁻³ s⁻¹ or less. In a still further another embodiment,the antibody, or antigen-binding portion thereof, dissociates from humanIL-12 and/or human IL-23 with a k_(off) rate constant of 1×10⁻⁴ s⁻¹ orless. In another embodiment, the antibody, or antigen-binding portionthereof, dissociates from human IL-12 and/or human IL-23 with a k_(off)rate constant of 1×10⁻⁵ s⁻¹ or less.

In still another embodiment, the antibody, or antigen-binding portionthereof, binds to human IL-12 and/or human IL-23 and dissociates fromhuman IL-12 and/or human IL-23, respectively, with a K_(d) of 1.34×10⁻¹⁰M or less. In yet another embodiment, the antibody, or antigen-bindingportion thereof, binds to human IL-12 and/or human IL-23 and dissociatesfrom human IL-12 and/or human IL-23, respectively, with a K_(d) of9.74×10⁻¹¹ M or less. In one embodiment, the antibody, orantigen-binding portion thereof, is a recombinant antibody, orantigen-binding portion thereof.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention is a neutralizing antibody, e.g.,neutralizes the activity of human IL-12 and/or human IL-23. In oneembodiment, the neutralizing antibody, or antigen-binding portionthereof, inhibits phytohemagglutinin blast proliferation in an in vitroPHA assay with an IC₅₀ of 1×10⁻⁹ M or less. In another embodiment, theneutralizing antibody, or antigen-binding portion thereof, inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻¹⁰⁻M or less. In still another embodiment, the neutralizingantibody of, or antigen-binding portion thereof, inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻¹¹⁻M or less. In yet another embodiment, the neutralizingantibody, or antigen-binding portion thereof, inhibitsphytohemagglutinin blast proliferation in an in vitro phytohemagglutininblast proliferation assay (PHA assay) with an IC₅₀ of 1×10⁻⁷ M or less.In still another embodiment, the neutralizing antibody, orantigen-binding portion thereof, inhibits phytohemagglutinin blastproliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻⁸ M or less.In one embodiment, the neutralizing antibody, or antigen-binding portionthereof, inhibits human IFNγ production with an IC₅₀ of 1×10⁻¹⁰ M orless. In still another embodiment, the neutralizing antibody, orantigen-binding portion thereof, inhibits human IFNγ production with anIC₅₀ of 1×10⁻¹¹ M or less. In yet a further embodiment, the neutralizingantibody, or antigen-binding portion thereof, inhibits human IFNγproduction with an IC₅₀ of 5×10⁻¹² M or less.

In one embodiment, the antibody, or an antigen-binding portion thereof,used in the methods of the invention

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 26. In one embodiment, the antibody further has a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 27; and a light chainCDR2 comprising the amino acid sequence of SEQ ID NO: 28. In stillanother embodiment, the antibody, or antigen-binding portion thereof,further has a heavy chain CDR1 comprising the amino acid sequence of SEQID NO: 29; and a light chain CDR1 comprising the amino acid sequence ofSEQ ID NO: 30. In still another embodiment, the antibody, orantigen-binding portion thereof, further inhibits phytohemagglutininblast proliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻¹⁰ Mor less. In still another embodiment, the antibody, or antigen-bindingportion thereof, further inhibits phytohemagglutinin blast proliferationin an in vitro PHA assay with an IC₅₀ of 1×10⁻¹¹ M or less.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention has a heavy chain variable regioncomprising the amino acid sequence of SEQ ID NO: 31, and a light chainvariable region comprising the amino acid sequence of SEQ ID NO: 32.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention comprises a heavy chain constantregion selected from the group consisting of IgG1, IgG2, IgG3, IgG4,IgM, IgA and IgE constant regions. In one embodiment, the antibody heavychain constant region is IgG1. In another embodiment, the antibody is aFab fragment, F(ab′)₂ fragment, or a a single chain Fv fragment.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention dissociates from human IL-12 and/orhuman IL-23 with a K_(d) of 1×10⁻¹⁰ M or less and binds to an epitope onthe p40 subunit of human IL-12 and/or human IL-23.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention is a human antibody, orantigen-binding portion thereof, which

a) dissociates from human IL-12 with a k_(off) rate constant of 1×10⁻³s⁻¹ or less, as determined by surface plasmon resonance;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 26.

In another embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention dissociates from human IL-12 with ak_(off) rate constant of 1×10⁻⁴ s⁻¹ or less. In a further embodiment,the human antibody, or antigen-binding portion thereof, dissociates fromhuman IL-12 with a k_(off) rate constant of 1×10⁻⁵ s⁻¹ or less.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention is a human antibody, orantigen-binding portion thereof, that binds to human IL-12 andcomprises:

a light chain CDR3 domain comprising the amino acid sequence of SEQ IDNO: 26; and

a heavy chain CDR3 domain comprising the amino acid sequence of SEQ IDNO: 25.

In one embodiment, the antibody, or antigen-binding portion thereof, hasa light chain variable region (LCVR) having a CDR3 domain comprising theamino acid sequence of SEQ ID NO: 26, and has a heavy chain variableregion (HCVR) having a CDR3 domain comprising the amino acid sequence ofSEQ ID NO: 25. In another embodiment, the antibody, or antigen-bindingportion thereof, comprises an LCVR further having a CDR2 domaincomprising the amino acid sequence of SEQ ID NO: 28 and an HCVR furthercomprising a CDR2 domain comprising the amino acid sequence of SEQ IDNO: 27. In yet another embodiment, the LCVR further has CDR1 domaincomprising the amino acid sequence of SEQ ID NO: 30 and the HCVR has aCDR1 domain comprising the amino acid sequence of SEQ ID NO: 29.

In one embodiment, the antibody, or antigen-binding portion thereof,binds human IL-12 and/or human IL-23 and is the antibody J695 (alsoreferred to as ABT-874), or an antigen binding portion thereof.

In one embodiment, the antibody, or antigen-binding portion thereof,binds to human IL-12 and/or human IL-23 and dissociates from human IL-12with a K_(d) of 1.34×10⁻¹⁰ M or less, and neutralizes human IL-12 and/orhuman IL-23. In one embodiment, the antibody, or antigen-binding portionthereof, dissociates from human IL-12 and/or human IL-23 with a K_(d) of9.74×10⁻¹¹ M or less. In one embodiment, the antibody, orantigen-binding portion thereof, inhibits phytohemagglutinin blastproliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻⁷ M or less.In one embodiment, the antibody, or antigen-binding portion thereof,inhibits phytohemagglutinin blast proliferation in an in vitro PHA assaywith an IC₅₀ of 1×10⁻⁸ M or less. In one embodiment, the antibody, orantigen-binding portion thereof, inhibits phytohemagglutinin blastproliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻⁹ M or less.In one embodiment, the antibody, or antigen-binding portion thereof,inhibits phytohemagglutinin blast proliferation in an in vitro PHA assaywith an IC₅₀ of 1×10⁻¹⁰⁻M or less. In one embodiment, the antibody, orantigen-binding portion thereof, inhibits phytohemagglutinin blastproliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻¹¹⁻M orless. In one embodiment, the antibody, or antigen-binding portionthereof, inhibits human IFNγ production with an IC₅₀ of 1×10⁻¹⁰ M orless. In one embodiment, the antibody, or antigen-binding portionthereof, inhibits human IFNγ production with an IC₅₀ of 1×10⁻¹¹ M orless. In one embodiment, the antibody, or antigen-binding portionthereof, inhibits human IFNγ production with an IC₅₀ of 5×10⁻¹² M orless.

In one embodiment, the antibody, or antigen-binding portion thereof,used in the methods of the invention inhibits IL-12 and/or IL-23 bindingto its receptor in an IL-12 or IL-23 receptor binding assay (RBA),respectively, with an IC₅₀ of 1×10⁻⁹ M or less.

In one embodiment, the antibody, or antigen-binding portion thereof,inhibits IL-12 and/or IL-23 binding to its receptor in an IL-12 or IL-23receptor binding assay (RBA), respectively, with an IC₅₀ of 1×10⁻¹⁰ M orless. In one embodiment, the antibody, or antigen-binding portionthereof, inhibits IL-12 and/or IL-23 binding to its receptor in an IL-12or IL-23 receptor binding assay (RBA), respectively, with an IC₅₀ of1×10⁻¹¹ M or less.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the patient disposition of the trial. (The term “eow”refers to every other week dosing.)

FIG. 2 shows the percentage of patients with at least a 75% improvementin the psoriasis area and severity index (PASI 75) during the 12-weekportion of the trial By week 8, with the exception of the 200 mg×1group, the percentage of patients who had a PASI 75 response wasstatistically significantly greater (p<0.001) in each ABT-874 treatmentgroup for each comparison with placebo based on an analysis of varianceof observed data for the intention-to-treat population. (The term “eow”refers to every other week dosing.)

FIG. 3 shows the mean percentage improvement in psoriasis area andseverity index (PASI) scores from baseline. The data show that *p<0.001for each ABT-874 treatment group compared with placebo at all timepoints (except 100 mg eow at week 1, p=0.023) based on an analysis ofvariance of observed data for the intention-to-treat population. (Theterm “eow” refers to every other week dosing.)

FIGS. 4A-C show the percentage of patients who maintained a PASI 50,PASI 75 and PASI 90 response, respectively, at week 24 of the trial,i.e., at 12 weeks following discontinuation of administration of theantibody.

FIG. 4D shows the percentage of patients maintaining a PASI 75 responseover time during the 24 week period of the trial.

FIG. 5A displays the mean percentage improvement from baseline in PASIscores from Week 4 to Week 12.

FIG. 5B displays the mean percentage improvement from baseline in PASIscores from Week 4 to Week 12 post retreatment.

FIG. 6A displays the serum concentration-time curve for IV dosing ofABT-874.

FIG. 6B displays the serum concentration-time curve for SC dosing ofABT-874.

FIG. 7A displays the percentage of patients re-achieving a PASI 75response following retreatment.

FIG. 7B displays the median time to achieve a PASI 75 response acrossall ABT-874 dosage groups during retreatment.

FIG. 7C displays the median time to loss of a PASI 75 response followingthe initial 12 weeks of treatment.

FIG. 7D displays the percentage of patients achieving a PGA score of 0or 1 following retreatment.

FIGS. 8A-8B show the heavy chain variable region amino acid sequencealignments of a series of human antibodies that bind human IL-12compared to germline sequences Cos-3/JH3 and Dpl18 Lv1042. Kabatnumbering is used to identify amino acid positions. For the Joe 9 wildtype, the full sequence is shown. For the other antibodies, only thoseamino acids positions that differ from Joe 9 wild type are shown.

FIGS. 8C-8D show the light chain variable region amino acid sequencealignments of a series of human antibodies that bind human IL-12. Kabatnumbering is used to identify amino acid positions. For the Joe 9 wildtype, the full sequence is shown. For the other antibodies, only thoseamino acids positions that differ from Joe 9 wild type are shown.

FIGS. 9A-9E show the CDR positions in the heavy chain of the Y61antibody that were mutated by site-directed mutagenesis and therespective amino acid substitutions at each position. The graphs at theright of the figures show the off-rates for the substituted antibodies(black bars) as compared to unmutated Y61 (open bar).

FIGS. 9F-9H show the CDR positions in the light chain of the Y61antibody that were mutated by site-directed mutagenesis and therespective amino acid substitutions at each position. The graphs at theright of the figures show the off-rates for the substituted antibodies(black bars) as compared to unmutated Y61 (open bar).

DETAILED DESCRIPTION OF THE INVENTION

In order that the present invention may be more readily understood,certain terms are first defined.

The term “activity enhancing amino acid residue” includes an amino acidresidue which improves the activity of the antibody. It should beunderstood that the activity enhancing amino acid residue may replace anamino acid residue at a contact, hypermutation or preferred selectivemutagenesis position and, further, more than one activity enhancingamino acid residue can be present within one or more CDRs. An activityenchancing amino acid residue include, an amino acid residue thatimproves the binding specificity/affinity of an antibody, for exampleanti-human IL-12 antibody binding to human IL-12. The activity enhancingamino acid residue is also intended to include an amino acid residuethat improves the neutralization potency of an antibody, for example,the human IL-12 antibody which inhibits human IL-12.

The term “antibody” includes an immunoglobulin molecule comprised offour polypeptide chains, two heavy (H) chains and two light (L) chainsinter-connected by disulfide bonds. Each heavy chain is comprised of aheavy chain variable region (abbreviated herein as HCVR or VH) and aheavy chain constant region. The heavy chain constant region iscomprised of three domains, CH1, CH2 and CH3. Each light chain iscomprised of a light chain variable region (abbreviated herein as LCVRor VL) and a light chain constant region. The light chain constantregion is comprised of one domain, CL. The VH and VL regions can befurther subdivided into regions of hypervariability, termedcomplementarity determining regions (CDRs), interspersed with regionsthat are more conserved, termed framework regions (FR). Each VH and VLis composed of three CDRs and four FRs, arranged from amino-terminus tocarboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,CDR3, FR4. In one embodiment, the antibody used in the compositions andmethods of the invention is the antibody described in U.S. Pat. No.6,914,128, incorporated by reference herein. In another embodiment, theantibody used in the compositions and methods of the invention is theantibody ABT-874 (also referred to as J695; Abbott Laboratories).

The term “antigen-binding portion” of an antibody (or “antibodyportion”) includes fragments of an antibody that retain the ability tospecifically bind to an antigen (e.g., hIL-12). It has been shown thatthe antigen-binding function of an antibody can be performed byfragments of a full-length antibody. Examples of binding fragmentsencompassed within the term “antigen-binding portion” of an antibodyinclude (i) a Fab fragment, a monovalent fragment consisting of the VL,VH, CL and CH1 domains; (ii) a F(ab′)₂ fragment, a bivalent fragmentcomprising two Fab fragments linked by a disulfide bridge at the hingeregion; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) aFv fragment consisting of the VL and VH domains of a single arm of anantibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546),which consists of a VH domain; and (vi) an isolated complementaritydetermining region (CDR). Furthermore, although the two domains of theFv fragment, VL and VH, are coded for by separate genes, they can bejoined, using recombinant methods, by a synthetic linker that enablesthem to be made as a single protein chain in which the VL and VH regionspair to form monovalent molecules (known as single chain Fv (scFv); seee.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988)Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodiesare also intended to be encompassed within the term “antigen-bindingportion” of an antibody. Other forms of single chain antibodies, such asdiabodies are also encompassed. Diabodies are bivalent, bispecificantibodies in which VH and VL domains are expressed on a singlepolypeptide chain, but using a linker that is too short to allow forpairing between the two domains on the same chain, thereby forcing thedomains to pair with complementary domains of another chain and creatingtwo antigen binding sites (see e.g., Holliger, P., et al. (1993) Proc.Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994)Structure 2:1121-1123). Still further, an antibody or antigen-bindingportion thereof may be part of a larger immunoadhesion molecules, formedby covalent or non-covalent association of the antibody or antibodyportion with one or more other proteins or peptides. Examples of suchimmunoadhesion molecules include use of the streptavidin core region tomake a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) HumanAntibodies and Hybridomas 6:93-101) and use of a cysteine residue, amarker peptide and a C-terminal polyhistidine tag to make bivalent andbiotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol.Immunol. 31:1047-1058). Antibody portions, such as Fab and F(ab′)₂fragments, can be prepared from whole antibodies using conventionaltechniques, such as papain or pepsin digestion, respectively, of wholeantibodies. Moreover, antibodies, antibody portions and immunoadhesionmolecules can be obtained using standard recombinant DNA techniques, asdescribed herein. Preferred antigen binding portions are completedomains or pairs of complete domains.

The term “backmutation” refers to a process in which some or all of thesomatically mutated amino acids of a human antibody are replaced withthe corresponding germline residues from a homologous germline antibodysequence. The heavy and light chain sequences of the human antibody ofthe invention are aligned separately with the germline sequences in theVBASE database to identify the sequences with the highest homology.Differences in the human antibody of the invention are returned to thegermline sequence by mutating defined nucleotide positions encoding suchdifferent amino acid. The role of each amino acid thus identified ascandidate for backmutation should be investigated for a direct orindirect role in antigen binding and any amino acid found after mutationto affect any desirable characteristic of the human antibody should notbe included in the final human antibody; as an example, activityenhancing amino acids identified by the selective mutagenesis approachwill not be subject to backmutation. To minimize the number of aminoacids subject to backmutation those amino acid positions found to bedifferent from the closest germline sequence but identical to thecorresponding amino acid in a second germline sequence can remain,provided that the second germline sequence is identical and colinear tothe sequence of the human antibody of the invention for at least 10,preferably 12 amino acids, on both sides of the amino acid in question.Backmuation may occur at any stage of antibody optimization; preferably,backmutation occurs directly before or after the selective mutagenesisapproach. More preferably, backmutation occurs directly before theselective mutagenesis approach.

The phrase “human interleukin 12” (abbreviated herein as hIL-12, orIL-12), as used herein, includes a human cytokine that is secretedprimarily by macrophages and dendritic cells. The term includes aheterodimeric protein comprising a 35 kD subunit (p35) and a 40 kDsubunit (p40) which are both linked together with a disulfide bridge.The heterodimeric protein is referred to as a “p70 subunit”. Thestructure of human IL-12 is described further in, for example,Kobayashi, et al. (1989) J. Exp Med. 170:827-845; Seder, et al. (1993)Proc. Nat. Acad. Sci. 90:10188-10192; Ling, et al. (1995) J. Exp Med.154:116-127; Podlaski, et al. (1992) Arch. Biochem. Biophys.294:230-237. The term human IL-12 is intended to include recombinanthuman IL-12 (rh IL-12), which can be prepared by standard recombinantexpression methods.

The terms “Kabat numbering”, “Kabat definitions and “Kabat labeling” areused interchangeably herein. These terms, which are recognized in theart, refer to a system of numbering amino acid residues which are morevariable (i.e. hypervariable) than other amino acid residues in theheavy and light chain variable regions of an antibody, or an antigenbinding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci.190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins ofImmunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242). For the heavy chainvariable region, the hypervariable region ranges from amino acidpositions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, andamino acid positions 95 to 102 for CDR3. For the light chain variableregion, the hypervariable region ranges from amino acid positions 24 to34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acidpositions 89 to 97 for CDR3.

The Kabat numbering is used herein to indicate the positions of aminoacid modifications made in antibodies of the invention. For example, theY61 anti-IL-12 antibody can be mutated from serine (S) to glutamic acid(E) at position 31 of the heavy chain CDR1 (H31S→E), or glycine (G) canbe mutated to tyrosine (Y) at position 94 of the light chain CDR3(L94G→Y).

The term “human antibody” includes antibodies having variable andconstant regions corresponding to human germline immunoglobulinsequences as described by Kabat et al. (See Kabat, et al. (1991)Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-3242).The human antibodies of the invention may include amino acid residuesnot encoded by human germline immunoglobulin sequences (e.g., mutationsintroduced by random or site-specific mutagenesis in vitro or by somaticmutation in vivo), for example in the CDRs and in particular CDR3. Themutations preferably are introduced using the “selective mutagenesisapproach” described herein. The human antibody can have at least oneposition replaced with an amino acid residue, e.g., an activityenhancing amino acid residue which is not encoded by the human germlineimmunoglobulin sequence. The human antibody can have up to twentypositions replaced with amino acid residues which are not part of thehuman germline immunoglobulin sequence. In other embodiments, up to ten,up to five, up to three or up to two positions are replaced. In apreferred embodiment, these replacements are within the CDR regions asdescribed in detail below. However, the term “human antibody”, as usedherein, is not intended to include antibodies in which CDR sequencesderived from the germline of another mammalian species, such as a mouse,have been grafted onto human framework sequences.

The phrase “recombinant human antibody” includes human antibodies thatare prepared, expressed, created or isolated by recombinant means, suchas antibodies expressed using a recombinant expression vectortransfected into a host cell (described further in Section II, below),antibodies isolated from a recombinant, combinatorial human antibodylibrary (described further in Section III, below), antibodies isolatedfrom an animal (e.g., a mouse) that is transgenic for humanimmunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. AcidsRes. 20:6287-6295) or antibodies prepared, expressed, created orisolated by any other means that involves splicing of humanimmunoglobulin gene sequences to other DNA sequences. Such recombinanthuman antibodies have variable and constant regions derived from humangermline immunoglobulin sequences (See Kabat, E. A., et al. (1991)Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-3242).In certain embodiments, however, such recombinant human antibodies aresubjected to in vitro mutagenesis (or, when an animal transgenic forhuman Ig sequences is used, in vivo somatic mutagenesis) and thus theamino acid sequences of the VH and VL regions of the recombinantantibodies are sequences that, while derived from and related to humangermline VH and VL sequences, may not naturally exist within the humanantibody germline repertoire in vivo. In certain embodiments, however,such recombinant antibodies are the result of selective mutagenesisapproach or backmutation or both.

An “isolated antibody” includes an antibody that is substantially freeof other antibodies having different antigenic specificities (e.g., anisolated antibody that specifically binds hIL-12 is substantially freeof antibodies that specifically bind antigens other than hIL-12). Anisolated antibody that specifically binds hIL-12 may bind IL-12molecules from other species (discussed in further detail below).Moreover, an isolated antibody may be substantially free of othercellular material and/or chemicals.

A “neutralizing antibody” (or an “antibody that neutralized hIL-12activity”) includes an antibody whose binding to hIL-12 results ininhibition of the biological activity of hIL-12. This inhibition of thebiological activity of hIL-12 can be assessed by measuring one or moreindicators of hIL-12 biological activity, such as inhibition of humanphytohemagglutinin blast proliferation in a phytohemagglutinin blastproliferation assay (PHA), or inhibition of receptor binding in a humanIL-12 receptor binding assay (see Example 3-Interferon-gamma InductionAssay of U.S. Pat. No. 6,914,128). These indicators of hIL-12 biologicalactivity can be assessed by one or more of several standard in vitro orin vivo assays known in the art (see Example 3 of U.S. Pat. No.6,914,128).

The term “activity” includes activities such as the bindingspecificity/affinity of an antibody for an antigen, for example, ananti-hIL-12 antibody that binds to an IL-12 antigen and/or theneutralizing potency of an antibody, for example, an anti-hIL-12antibody whose binding to hIL-12 inhibits the biological activity ofhIL-12, e.g. inhibition of PHA blast proliferation or inhibition ofreceptor binding in a human IL-12 receptor binding assay (see Example 3of U.S. Pat. No. 6,914,128).

The phrase “surface plasmon resonance” includes an optical phenomenonthat allows for the analysis of real-time biospecific interactions bydetection of alterations in protein concentrations within a biosensormatrix, for example using the BIAcore system (Pharmacia Biosensor AB,Uppsala, Sweden and Piscataway, N.J.). For further descriptions, seeExample 5 of U.S. Pat. No. 6,914,128 and Jönsson, U., et al. (1993) Ann.Biol. Clin. 51:19-26; Jönsson, U., et al. (1991) Biotechniques11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131; andJohnnson, B., et al. (1991) Anal. Biochem. 198:268-277.

The term “K_(off)”, as used herein, is intended to refer to the off rateconstant for dissociation of an antibody from the antibody/antigencomplex.

The term “K_(d)”, as used herein, is intended to refer to thedissociation constant of a particular antibody-antigen interaction.

The phrase “nucleic acid molecule” includes DNA molecules and RNAmolecules. A nucleic acid molecule may be single-stranded ordouble-stranded, but preferably is double-stranded DNA.

The phrase “isolated nucleic acid molecule”, as used herein in referenceto nucleic acids encoding antibodies or antibody portions (e.g., VH, VL,CDR3) that bind hIL-12 including “isolated antibodies”), includes anucleic acid molecule in which the nucleotide sequences encoding theantibody or antibody portion are free of other nucleotide sequencesencoding antibodies or antibody portions that bind antigens other thanhIL-12, which other sequences may naturally flank the nucleic acid inhuman genomic DNA. Thus, for example, an isolated nucleic acid of theinvention encoding a VH region of an anti-IL-12 antibody contains noother sequences encoding other VH regions that bind antigens other thanIL-12. The phrase “isolated nucleic acid molecule” is also intended toinclude sequences encoding bivalent, bispecific antibodies, such asdiabodies in which VH and VL regions contain no other sequences otherthan the sequences of the diabody.

The term “vector” includes a nucleic acid molecule capable oftransporting another nucleic acid to which it has been linked. One typeof vector is a “plasmid”, which refers to a circular double stranded DNAloop into which additional DNA segments may be ligated. Another type ofvector is a viral vector, wherein additional DNA segments may be ligatedinto the viral genome. Certain vectors are capable of autonomousreplication in a host cell into which they are introduced (e.g.,bacterial vectors having a bacterial origin of replication and episomalmammalian vectors). Other vectors (e.g., non-episomal mammalian vectors)can be integrated into the genome of a host cell upon introduction intothe host cell, and thereby are replicated along with the host genome.Moreover, certain vectors are capable of directing the expression ofgenes to which they are operatively linked. Such vectors are referred toherein as “recombinant expression vectors” (or simply, “expressionvectors”). In general, expression vectors of utility in recombinant DNAtechniques are often in the form of plasmids. In the presentspecification, “plasmid” and “vector” may be used interchangeably as theplasmid is the most commonly used form of vector. However, the inventionis intended to include such other forms of expression vectors, such asviral vectors (e.g., replication defective retroviruses, adenovirusesand adeno-associated viruses), which serve equivalent functions.

The phrase “recombinant host cell” (or simply “host cell”) includes acell into which a recombinant expression vector has been introduced. Itshould be understood that such terms are intended to refer not only tothe particular subject cell but to the progeny of such a cell. Becausecertain modifications may occur in succeeding generations due to eithermutation or environmental influences, such progeny may not, in fact, beidentical to the parent cell, but are still included within the scope ofthe term “host cell” as used herein.

The term “modifying”, as used herein, is intended to refer to changingone or more amino acids in the antibodies or antigen-binding portionsthereof. The change can be produced by adding, substituting or deletingan amino acid at one or more positions. The change can be produced usingknown techniques, such as PCR mutagenesis.

The phrase “contact position” includes an amino acid position of in theCDR1, CDR2 or CDR3 of the heavy chain variable region or the light chainvariable region of an antibody which is occupied by an amino acid thatcontacts antigen in one of the twenty-six known antibody-antigenstructures. If a CDR amino acid in any of the 26 known solved structuresof antibody-antigen complexes contacts the antigen, then that amino acidcan be considered to occupy a contact position. Contact positions have ahigher probability of being occupied by an amino acid which contactantigen than non-contact positions. Preferably a contact position is aCDR position which contains an amino acid that contacts antigen ingreater than 3 of the 26 structures (>11.5%). Most preferably a contactposition is a CDR position which contains an amino acid that contactsantigen in greater than 8 of the 25 structures (>32%).

The term “hypermutation position” includes an amino acid residue thatoccupies position in the CDR1, CDR2 or CDR3 region of the heavy chainvariable region or the light chain variable region of an antibody thatis considered to have a high frequency or probability for somatichypermutation during in vivo affinity maturation of the antibody. “Highfrequency or probability for somatic hypermutation” includes frequenciesor probabilities of a 5 to about 40% chance that the residue willundergo somatic hypermutation during in vivo affinity maturation of theantibody. It should be understood that all ranges within this statedrange are also intended to be part of this invention, e.g., 5 to about30%, e.g., 5 to about 15%, e.g., 15 to about 30%.

The term “preferred selective mutagenesis position” includes an aminoacid residue that occupies a position in the CDR1, CDR2 or CDR3 regionof the heavy chain variable region or the light chain variable regionwhich can be considered to be both a contact and a hypermutationposition.

The phrase “selective mutagenesis approach” includes a method ofimproving the activity of an antibody by selecting and individuallymutating CDR amino acids at least one preferred selective mutagenesisposition, hypermutation, and/or contact position. A “selectivelymutated” human antibody is an antibody which contains a mutation at aposition selected using a selective mutagenesis approach. In anotherembodiment, the selective mutagenesis approach is intended to provide amethod of preferentially mutating selected individual amino acidresidues in the CDR1, CDR2 or CDR3 of the heavy chain variable region(hereinafter H1, H2, and H3, respectively), or the CDR1, CDR2 or CDR3 ofthe light chain variable region (hereinafter referred to as L1, L2, andL3, respectively) of an antibody. Amino acid residues may be selectedfrom preferred selective mutagenesis positions, contact positions., orhypermutation positions. Individual amino acids are selected based ontheir position in the light or heavy chain variable region. It should beunderstood that a hypermutation position can also be a contact position.In an embodiment, the selective mutagenesis approach is a “targetedapproach”. The language “targeted approach” is intended to include amethod of preferentially mutating selected individual amino acidresidues in the CDR1, CDR2 or CDR3 of the heavy chain variable region orthe CDR1, CDR2 or CDR3 of the light chain variable region of an antibodyin a targeted manner, e.g., a “Group-wise targeted approach” or“CDR-wise targeted approach”. In the “Group-wise targeted approach”,individual amino acid residues in particular groups are targeted forselective mutations including groups I (including L3 and H3), II(including H2 and L1) and III (including L2 and H1), the groups beinglisted in order of preference for targeting. In the “CDR-wise targetedapproach”, individual amino acid residues in particular CDRs aretargeted for selective mutations with the order of preference fortargeting as follows: H3, L3, H2, L1, H1 and L2. The selected amino acidresidue is mutated, e.g., to at least two other amino acid residues, andthe effect of the mutation on the activity of the antibody isdetermined. Activity is measured as a change in the bindingspecificity/affinity of the antibody, and/or neutralization potency ofthe antibody. It should be understood that the selective mutagenesisapproach can be used for the optimization of any antibody derived fromany source including phage display, transgenic animals with human IgGgermline genes, human antibodies isolated from human B-cells.Preferably, the selective mutagenesis approach is used on antibodieswhich can not be optimized further using phage display technology. Itshould be understood that antibodies from any source including phagedisplay, transgenic animals with human IgG germline genes, humanantibodies isolated from human B-cells can be subject to backmutationprior to or after the selective mutagenesis approach.

The term “activity enhancing amino acid residue” includes an amino acidresidue which improves the activity of the antibody. It should beunderstood that the activity enhancing amino acid residue may replace anamino acid residue at a preferred selective mutagenesis position,contact position, or a hypermutation position and, further, more thanone activity enhancing amino acid residue can be present within one ormore CDRs. An activity enchancing amino acid residue include, an aminoacid residue that improves the binding specificity/affinity of anantibody, for example anti-human IL-12 antibody binding to human IL-12.The activity enhancing amino acid residue is also intended to include anamino acid residue that improves the neutralization potency of anantibody, for example, the human IL-12 antibody which inhibits humanIL-12.

The term “C_(max)” refers to the maximum or peak serum or plasmaconcentration of an agent observed in a subject after itsadministration.

The term “T_(max)” refers to the time at which C_(max) occurred.

The term “bioavailability” or “F %” refers to a fraction or percent of adose which is absorbed and enters the systemic circulation afteradministration of a given dosage form. The dose of the agent may beadministered through any route, and, preferably, via intravenous orsubcutaneous injection.

The term “dosing”, as used herein, refers to the administration of asubstance (e.g., an anti-IL-12, anti-IL-23 antibody) to achieve atherapeutic objective (e.g., the treatment of rheumatoid arthritis).

The terms “biweekly dosing regimen”, “biweekly dosing”, and “biweeklyadministration”, as used herein, refer to the time course ofadministering a substance (e.g., an anti-IL-12, anti-IL-23 antibody) toa subject to achieve a therapeutic objective, wherein the time course isevery other week (eow). The biweekly dosing regimen is not intended toinclude a weekly dosing regimen. Preferably, the substance isadministered every 9-19 days, more preferably, every 11-17 days, evenmore preferably, every 13-15 days, and most preferably, every 14 days.

The term “combination” as in the phrase “a first agent in combinationwith a second agent” includes co-administration of a first agent and asecond agent, which for example may be dissolved or intermixed in thesame pharmaceutically acceptable carrier, or administration of a firstagent, followed by the second agent, or administration of the secondagent, followed by the first agent. The present invention, therefore,includes methods of combination therapeutic treatment and combinationpharmaceutical compositions.

The term “concomitant” as in the phrase “concomitant therapeutictreatment” includes administering an agent in the presence of a secondagent. A concomitant therapeutic treatment method includes methods inwhich the first, second, third, or additional agents areco-administered. A concomitant therapeutic treatment method alsoincludes methods in which the first or additional agents areadministered in the presence of a second or additional agents, whereinthe second or additional agents, for example, may have been previouslyadministered. A concomitant therapeutic treatment method may be executedstep-wise by different actors. For example, one actor may administer toa subject a first agent and a second actor may to administer to thesubject a second agent, and the administering steps may be executed atthe same time, or nearly the same time, or at distant times, so long asthe first agent (and additional agents) are after administration in thepresence of the second agent (and additional agents). The actor and thesubject may be the same entity (e.g., human).

The term “combination therapy”, as used herein, refers to theadministration of two or more therapeutic substances, e.g., an ananti-IL-12, anti-IL-23 antibody and another drug. The other drug(s) maybe administered concomitant with, prior to, or following theadministration of an an anti-IL-12, anti-IL-23 antibody.

The term “kit” as used herein refers to a packaged product comprisingcomponents with which to administer the anti-IL-12, anti-IL-23 antibodyof the invention for treatment of a IL-12 related disorder. The kitpreferably comprises a box or container that holds the components of thekit. The box or container is affixed with a label or a Food and DrugAdministration approved protocol. The box or container holds componentsof the invention which are preferably contained within plastic,polyethylene, polypropylene, ethylene, or propylene vessels. The vesselscan be capped-tubes or bottles. The kit can also include instructionsfor administering an anti-IL-12, anti-IL-23 antibody.

Various aspects of the invention are described in further detail in thefollowing subsections.

I. Human Antibodies that Bind Human IL-12

This invention provides methods and compositions for using humanantibodies, or antigen-binding portions thereof, that bind to humanIL-12 for the treatment of psoriasis. The invention also includesmethods and compositions for using an antibody which binds both IL-12and IL-23. Preferably, the human antibodies used in the invention arerecombinant, neutralizing human anti-hIL-12 antibodies.

In one embodiment, the antibody used in the invention is the antibodyABT-874 (see U.S. Pat. No. 6,914,128). ABT-874 is a fully human antibodyagainst interleukin 12 (IL-12) and IL-23. It binds with great affinityto the p40 subunit common to both IL-12 and IL-23, validated targets inthe treatment of psoriasis (Ps).

Antibodies that bind to human IL-12 can be selected, for example, byscreening one or more human V_(L) and V_(H) cDNA libraries with hIL-12,such as by phage display techniques as described in Example 1 of U.S.Pat. No. 6,914,128. Screening of human V_(L) and V_(H) cDNA librariesinitially identified a series of anti-IL-12 antibodies of which oneantibody, referred to herein as “Joe 9” (or “Joe 9 wild type”), wasselected for further development. Joe 9 is a relatively low affinityhuman IL-12 antibody (e.g., a K_(off) of about 0.1 sec⁻¹), yet is usefulfor specifically binding and detecting hIL-12. The affinity of the Joe 9antibody was improved by conducting mutagenesis of the heavy and lightchain CDRs, producing a panel of light and heavy chain variable regionsthat were “mixed and matched” and further mutated, leading to numerousadditional anti-hIL-12 antibodies with increased affinity for hIL-12(see Example 1, table 2 of U.S. Pat. No. 6,914,128 (see table 2 ofAppendix A attached hereto)) and the sequence alignments of FIGS. 1A-Dof U.S. Pat. No. 6,914,128 (see FIG. 8A-D herein).

Of these antibodies, the human anti-hIL-12 antibody referred to hereinas Y61 demonstrated a significant improvement in binding affinity (e.g.,a K_(off) of about 2×10⁻⁴ sec⁻¹). The Y61 anti-hIL-12 antibody wasselected for further affinity maturation by individually mutatingspecific amino acids residues within the heavy and light chain CDRs.Amino acids residues of Y61 were selected for site-specific mutation(selective mutagenesis approach) based on the amino acid residueoccupying a preferred selective mutagenesis position, contact and/or ahypermutation position. A summary of the substitutions at selectedpositions in the heavy and light chain CDRs is shown in FIGS. 2A-2H ofU.S. Pat. No. 6,914,128 (FIGS. 9A-H herein). A preferred recombinantneutralizing antibody of the invention, referred to herein as J695 (alsoreferred to as ABT-874 (Abbott Laboratories), resulted from a Gly to Tyrsubstitution at position 50 of the light chain CDR2 of Y61, and a Gly toTyr substitution at position 94 of the light chain CDR3 of Y61.

Amino acid sequence alignments of the heavy and light chain variableregions of a panel of anti-IL-12 antibodies used in the invention, onthe lineage from Joe 9 wild type to J695, are shown in FIGS. 1A-1D ofU.S. Pat. No. 6,914,128 (FIGS. 8A-D herein). These sequence alignmentsallowed for the identification of consensus sequences for preferredheavy and light chain variable regions of antibodies of the inventionthat bind hIL-12, as well as consensus sequences for the CDR3, CDR2, andCDR1, on the lineage from Joe 9 to J695. Moreover, the Y61 mutagenesisanalysis summarized in FIGS. 2A-2H of U.S. Pat. No. 6,914,128 (FIGS.9A-H herein) allowed for the identification of consensus sequences forheavy and light chain variable regions that bind hIL-12, as well asconsensus sequences for the CDR3, CDR2, and CDR1 that bind hIL-12 on thelineage from Y61 to J695 that encompasses sequences with modificationsfrom Y61 yet that retain good hIL-12 binding characteristics. PreferredCDR, VH and VL sequences of the invention (including consensussequences) as identified by sequence identifiers in the attachedSequence Listing, are summarized below.

SEQ ID ANTIBODY NO: CHAIN REGION SEQUENCE 1 Consensus CDR H3(H/S)-G-S-(H/Y)-D-(N/T/Y) Joe 9 to J695 2 Consensus CDR L3Q-(S/T)-Y-(D/E)-(S/R/K)- Joe 9 to J695 (S/G/Y)-(L/F/T/S)-(R/S/T/W/H)-(G/P)-(S/T/A/L) (R/S/M/T/L)-(V/I/T/M/L) 3 Consensus CDR H2F-I-R-Y-D-G-S-N-K-Y-Y-A-D- Joe 9 to J695 S-V-K-G 4 Consensus CDR L2(G/Y)-N-(D/S)-(Q/N)-R-P-S Joe 9 to J695 5 Consensus CDR H1F-T-F-S-(S/E)-Y-G-M-H Joe 9 to J695 6 Consensus CDR L1(S/T)-G-(G/S)-(R/S)-S-N-I Joe 9 to J695 (G/V)-(S/A)-(N/G/Y)-(T/D)-V-(K/H) 7 Consensus VH (full VH sequence; see Joe 9 to J695 sequencelisting) 8 Consensus VL (full VL sequence; see Joe 9 to J695 sequencelisting) 9 Consensus CDR H3 H-(G/V/C/H)-(S/T) Y61 to J695(H/T/V/R/I)-(D/S)- (N/K/A/T/S/F/W/H) 10 Consensus CDR L3Q-S-Y-(D/S)-(Xaa)- Y61 to J695 (G/D/Q/L/F/R/H/N/Y)-T-H- P-A-L-L 11Consensus CDR H2 (F/T/Y)-I-(R/A)-Y- Y61 to J695(D/S/E/A)-(G/R)-S-(Xaa)-K- (Y/E)-Y-A-DS-V-K-G 12 Consensus CDR L2(G/Y/S/T/N/Q)-N-D-Q-R-P-S Y61 to J695 13 Consensus CDR H1F-T-F-(Xaa)-(Xaa)-(Y/H)- Y61 to J695 (G/M/A/N/S)-M-H 14 Consensus CDR L1S-G-G-R-S-N-I-G Y61 to J695 (S/C/R/N/D/T)-(N/M/I)- (T/Y/D/H/K/P)-V-K 15Consensus VH (full VH sequence; see Y61 to J695 sequence listing) 16Consensus VL (full VL sequence; see Y61 to J695 sequence listing) 17 Y61CDR H3 H-G-S-H-D-N 18 Y61 CDR L3 Q-S-Y-D-R-G-T-H-P-A-L-L 19 Y61 CDR H2F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S V-K-G 20 Y61 CDR L2 G-N-D-Q-R-P-S 21 Y61 CDRH1 F-T-F-S-S-Y-G-M-H 22 Y61 CDR L1 S-G-G-R-S-N-I-G-S-N-T-V-K 23 Y61 VH(full VH sequence; see sequence listing) 24 Y61 VL (full VL sequence;see sequence listing) 25 J695 CDR H3 H-G-S-H-D-N 26 J695 CDR L3Q-S-Y-D-R-Y-T-H-P-A-L-L 27 J695 CDR H2 F-I-R-Y-D-S-S-N-K-Y-Y-A-D-S V-K-S28 J695 CDR L2 Y-N-D-Q-R-P-S 29 J695 CDR H1 F-T-F-S-S-Y-S-M-H 30 J695CDR L1 S-G-S-R-S-N-I-G-S-N-T-V-K 31 J695 VH (full VH sequence; seesequence listing) 32 J695 VL (full VL sequence; see sequence listing)

Antibodies produced from affinity maturation of Joe 9 wild type werefunctionally characterized by surface plasmon resonance analysis todetermine the K_(d) and K_(off) rate. A series of antibodies wereproduced having a K_(off) rate within the range of about 0.1 s⁻¹ toabout 1×10⁻⁵ s⁻¹, and more preferably a K_(off) of about 1×10⁻⁴ S⁻¹ to1×10⁻⁵ s⁻¹ or less. Antibodies were also characterized in vitro fortheir ability to inhibit phytohemagglutinin (PHA) blast proliferation,as described in Example 3 of U.S. Pat. No. 6,914,128. A series ofantibodies were produced having an IC₅₀ value in the range of about1×10⁻⁶ M to about 1×10⁻¹¹ M, more preferably about 1×10⁻¹⁰ M to 1×10⁻¹¹M or less.

Accordingly, in one aspect, the invention provides methods andcompositions for using an isolated human antibody, or antigen-bindingportion thereof, that binds to human IL-12 and dissociates from humanIL-12 with a K_(off) rate constant of 0.1 s⁻¹ or less, as determined bysurface plasmon resonance, or which inhibits phytohemagglutinin blastproliferation in an in vitro phytohemagglutinin blast proliferationassay (PHA assay) with an IC₅₀ of 1×10⁻⁶ M or less. In preferredembodiments, the isolated human IL-12 antibody, or an antigen-bindingportion thereof, dissociates from human IL-12 with a K_(off) rateconstant of 1×10⁻² s⁻¹ or less, or inhibits phytohemagglutinin blastproliferation in an in vitro PHA assay with an IC₅₀ of 1×10⁻⁷ M or less.In more preferred embodiments, the isolated human IL-12 antibody, or anantigen-binding portion thereof, dissociates from human IL-12 with aK_(off) rate constant of 1×10⁻³ s⁻¹ or less, or inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻⁸ M or less. In more preferred embodiments, the isolatedhuman IL-12 antibody, or an antigen-binding portion thereof, dissociatesfrom human IL-12 with a K_(off) rate constant of 1×10⁻⁴ s⁻¹ or less, orinhibits phytohemagglutinin blast proliferation in an in vitro PHA assaywith an IC₅₀ of 1×10⁻⁹ M or less. In more preferred embodiments, theisolated human IL-12 antibody, or an antigen-binding portion thereof,dissociates from human IL-12 with a K_(off) rate constant of 1×10⁻⁵ s⁻¹or less, or inhibits phytohemagglutinin blast proliferation in an invitro PHA assay with an IC₅₀ of 1×10⁻¹⁰ M or less. In even morepreferred embodiments, the isolated human IL-12 antibody, or anantigen-binding portion thereof, dissociates from human IL-12 with aK_(off) rate constant of 1×10⁻⁵ s⁻¹ or less, or inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻¹¹ M or less.

The dissociation rate constant (K_(off)) of an IL-12 antibody can bedetermined by surface plasmon resonance (see Example 5 of U.S. Pat. No.6,914,128). Generally, surface plasmon resonance analysis measuresreal-time binding interactions between ligand (recombinant human IL-12immobilized on a biosensor matrix) and analyte (antibodies in solution)by surface plasmon resonance (SPR) using the BIAcore system (PharmaciaBiosensor, Piscataway, N.J.). Surface plasmon analysis can also beperformed by immobilizing the analyte (antibodies on a biosensor matrix)and presenting the ligand (recombinant IL-12 in solution).Neutralization activity of IL-12 antibodies, or antigen binding portionsthereof, can be assessed using one or more of several suitable in vitroassays (see Example 3 of U.S. Pat. No. 6,914,128).

It is well known in the art that antibody heavy and light chain CDRsplay an important role in the binding specificity/affinity of anantibody for an antigen. Accordingly, the invention encompasses humanantibodies having light and heavy chain CDRs of Joe 9, as well as otherantibodies having CDRs that have been modified to improve the bindingspecificity/affinity of the antibody. As demonstrated in Example 1 ofU.S. Pat. No. 6,914,128, a series of modifications to the light andheavy chain CDRs results in affinity maturation of human anti-hIL-12antibodies. The heavy and light chain variable region amino acidsequence alignments of a series of human antibodies ranging from Joe 9wild type to J695 that bind human IL-12 is shown in FIGS. 1A-1D of U.S.Pat. No. 6,914,128 (FIGS. 8A-D herein). Consensus sequence motifs forthe CDRs of antibodies can be determined from the sequence alignment.For example, a consensus motif for the VH CDR3 of the lineage from Joe 9to J695 comprises the amino acid sequence: (H/S)-G-S-(H/Y)-D-(N/T/Y)(SEQ ID NO: 1), which encompasses amino acids from position 95 to 102 ofthe consensus HCVR shown in SEQ ID NO: 7. A consensus motif for the VLCDR3 comprises the amino acid sequence:Q-(S/T)-Y-(D/E)-(S/R/K)-(S/G/Y)-(L/F/T/S)-(R/S/T/W/H)-(G/P)-(S/T/A/L)-(R/S/M/T/L-V/I/T/M/L)(SEQ ID NO: 2), which encompasses amino acids from position 89 to 97 ofthe consensus LCVR shown in SEQ ID NO: 8.

Accordingly, in another aspect, the invention provides methods andcompositions comprising an isolated human antibody, or anantigen-binding portion thereof, which has the followingcharacteristics:

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁶ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 1; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 2.

In a preferred embodiment, the antibody further comprises a VH CDR2comprising the amino acid sequence: F-I-R-Y-D-G-S-N-K-Y-Y-A-D-S-V-K-G(SEQ ID NO: 3) (which encompasses amino acids from position 50 to 65 ofthe consensus HCVR comprising the amino acid sequence SEQ ID NO: 7) andfurther comprises a VL CDR2 comprising the amino acid sequence:(G/Y)-N-(D/S)-(Q/N)-R-P-S (SEQ ID NO: 4) (which encompasses amino acidsfrom position 50 to 56 of the consensus LCVR comprising the amino acidsequence SEQ ID NO: 8).

In another preferred embodiment, the antibody further comprises a VHCDR1 comprising the amino acid sequence: F-T-F-S-(S/E)-Y-G-M-H (SEQ IDNO: 5) (which encompasses amino acids from position 27 to 35 of theconsensus HCVR comprising the amino acid sequence SEQ ID NO: 7) andfurther comprises a VL CDR1 comprising the amino acid sequence:(S/T)-G-(G/S)-(R/S)-S-N-I-(G/V)-(S/A)-(N/G/Y)-(T/D)-V-(K/H) (SEQ ID NO:6) (which encompasses amino acids from position 24 to 34 of theconsensus LCVR comprising the amino acid sequence SEQ ID NO: 8).

In yet another preferred embodiment, the antibody used in the inventioncomprises a HCVR comprising the amino acid sequence of SEQ ID NO: 7 anda LCVR comprising the amino acid sequence of SEQ ID NO: 8.

Additional consensus motifs can be determined based on the mutationalanalysis performed on Y61 that led to the J695 antibody (summarized inFIGS. 2A-2H of U.S. Pat. No. 6,914,128; FIGS. 9A-H herein). Asdemonstrated by the graphs shown in FIGS. 2A-2H of U.S. Pat. No.6,914,128 (FIGS. 9A-H herein), certain residues of the heavy and lightchain CDRs of Y61 were amenable to substitution without significantlyimpairing the hIL-12 binding properties of the antibody. For example,individual substitutions at position 30 in CDR H1 with twelve differentamino acid residues did not significantly reduce the K_(off) rate of theantibody, indicating that is position is amenable to substitution with avariety of different amino acid residues. Thus, based on the mutationalanalysis (i.e., positions within Y61 that were amenable to substitutionby other amino acid residues) consensus motifs were determined. Theconsensus motifs for the heavy and light chain CDR3s are shown in SEQ IDNOs: 9 and 10, respectively, consensus motifs for the heavy and lightchain CDR2s are shown in SEQ ID NOs: 11 and 12, respectively, andconsensus motifs for the heavy and light chain CDR1s are shown in SEQ IDNOs: 13 and 14, respectively. Consensus motifs for the VH and VL regionsare shown in SEQ ID NOs: 15 and 16, respectively.

Accordingly, in one aspect, the invention includes an isolated humanantibody, or an antigen-binding portion thereof, which has the followingcharacteristics:

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 9; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 10.

In a preferred embodiment, the antibody further comprises a VH CDR2comprising the amino acid sequence of SEQ ID NO: 11 and furthercomprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 12.

In another preferred embodiment, the antibody further comprises a VHCDR1 comprising the amino acid sequence of SEQ ID NO: 13 and furthercomprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

In yet another preferred embodiment, the antibody used in the inventioncomprises a HCVR comprising the amino acid sequence of SEQ ID NO: 15 anda LCVR comprising the amino acid sequence of SEQ ID NO: 16.

A preferred antibody used in the invention, the human anti-hIL-12antibody Y61, can be produced by affinity maturation of Joe 9 wild typeby PCR mutagenesis of the CDR3 (as described in Example 1 of U.S. Pat.No. 6,914,128). Y61 had an improved specificity/binding affinitydetermined by surface plasmon resonance and by in vitro neutralizationassays. The heavy and light chain CDR3s of Y61 are shown in SEQ ID NOs:17 and 18, respectively, the heavy and light chain CDR2s of Y61 areshown in SEQ ID NOs: 19 and 20, respectively, and the heavy and lightchain CDR1s of Y61 are shown in SEQ ID NOs: 21 and 22, respectively. TheVH of Y61 has the amino acid sequence of SEQ ID NO: 23 and the VL of Y61has the amino acid sequence of SEQ ID NO: 24 (these sequences are alsoshown in FIGS. 1A-1D of U.S. Pat. No. 6,914,128 (FIGS. 8A-D herein)aligned with Joe9).

Accordingly, in another aspect, the invention features use of anisolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 17; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 18.

In a preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the methods and compositions ofthe invention has a heavy chain CDR2 comprising the amino acid sequenceof SEQ ID NO: 19 and a light chain CDR2 comprising the amino acidsequence of SEQ ID NO: 20.

In another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the methods and compositions ofthe invention, has a heavy chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 21 and a light chain CDR1 comprising the amino acidsequence of SEQ ID NO: 22.

In yet another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the methods and compositions ofthe invention comprising a the heavy chain variable region comprisingthe amino acid sequence of SEQ ID NO: 23, and a light chain variableregion comprising the amino acid sequence of SEQ ID NO: 24.

In certain embodiments, the full length antibody comprises a heavy chainconstant region, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgEconstant regions, and any allotypic variant therein as described inKabat (Kabat, E. A., et al. (1991) Sequences of Proteins ofImmunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242). Preferably, the antibodyheavy chain constant region is an IgG1 heavy chain constant region.Alternatively, the antibody portion can be an Fab fragment, an F(ab′₂)fragment or a single chain Fv fragment.

Modifications of individual residues of Y61 led to the production of apanel of antibodies shown in FIGS. 2A-2H of U.S. Pat. No. 6,914,128(FIGS. 9A-H herein). The specificity/binding affinity of each antibodywas determined by surface plasmon resonance and/or by in vitroneutralization assays.

Accordingly, in another aspect, the invention features an isolated humanantibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence selectedfrom the group consisting of SEQ ID NO: 404-SEQ ID NO: 469; and

c) has a light chain CDR3 comprising the amino acid sequence selectedfrom the group consisting of SEQ ID NO: 534-SEQ ID NO: 579.

In preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the methods and compositions ofthe invention has a heavy chain CDR2 comprising the amino acid sequenceselected from the group consisting of SEQ ID NO:335-SEQ ID NO: 403; anda light chain CDR2 comprising the amino acid sequence selected from thegroup consisting of SEQ ID NO: 506-SEQ ID NO: 533.

In another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, has a heavy chain CDR1 comprising theamino acid sequence selected from the group consisting of SEQ ID NO:288-SEQ ID NO: 334; and a light chain CDR1 comprising the amino acidsequence selected from the group consisting of SEQ ID NO: 470-SEQ ID NO:505.

In yet another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, comprising a the heavy chain variableregion comprising the amino acid sequence of SEQ ID NO: 23, and a lightchain variable region comprising the amino acid sequence of SEQ ID NO:24.

In certain embodiments, the full length antibody comprising a heavychain constant region such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgEconstant regions and any allotypic variant therein as described in Kabat(, Kabat, E. A., et al. (1991) Sequences of Proteins of ImmunologicalInterest, Fifth Edition, U.S. Department of Health and Human Services,NIH Publication No. 91-3242). Preferably, the antibody heavy chainconstant region is an IgG1 heavy chain constant region. Alternatively,the antibody portion can be a Fab fragment, an F(ab′₂) fragment or asingle chain Fv fragment.

A particularly preferred recombinant, neutralizing antibody, J695, whichmay be used in the invention was produced by site-directed mutagenesisof contact and hypermutation amino acids residues of antibody Y61 (seeExample 2 of U.S. Pat. No. 6,914,128 and section III below). J695differs from Y61 by a Gly to Tyr substitution in Y61 at position 50 ofthe light chain CDR2 and by a Gly to Tyr substitution at position 94 ofthe light chain CDR3. The heavy and light chain CDR3s of J695 are shownin SEQ ID NOs: 25 and 26, respectively, the heavy and light chain CDR2sof J695 are shown in SEQ ID NOs: 27 and 28, respectively, and the heavyand light chain CDR1s of J695 are shown in SEQ ID NOs: 29 and 30,respectively. The VH of J695 has the amino acid sequence of SEQ ID NO:31 and the VL of J695 has the amino acid sequence of SEQ ID NO: 32(these sequences are also shown in FIGS. 1A-1D of U.S. Pat. No.6,914,128 (FIGS. 8A-D herein), aligned with Joe9).

Accordingly, in another aspect, the invention features an isolated humanantibody, or an antigen-binding portion thereof, which a) inhibitsphytohemagglutinin blast proliferation in an in vitro PHA assay with anIC₅₀ of 1×10⁻⁹ M or less; b) has a heavy chain CDR3 comprising the aminoacid sequence of SEQ ID NO: 25; and c) has a light chain CDR3 comprisingthe amino acid sequence of SEQ ID NO: 26.

In preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the invention has a heavy chainCDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a lightchain CDR2 comprising the amino acid sequence of SEQ ID NO: 28.

In another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the invention has a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 29, and a lightchain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

In yet another preferred embodiment, the isolated human antibody, or anantigen-binding portion thereof, used in the invention has a heavy chainvariable region comprising the amino acid sequence of SEQ ID NO: 31, anda light chain variable region comprising the amino acid sequence of SEQID NO: 32.

In certain embodiments, the full length antibody comprises a heavy chainconstant region, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgEconstant regions and any allotypic variant therein as described in Kabat(, Kabat, E. A., et al. (1991) Sequences of Proteins of ImmunologicalInterest, Fifth Edition, U.S. Department of Health and Human Services,NIH Publication No. 91-3242). Preferably, the antibody heavy chainconstant region is an IgG1 heavy chain constant region. Alternatively,the antibody portion can be an Fab fragment, an F(ab′₂) fragment or asingle chain Fv fragment.

Additional mutations in the preferred consensus sequences for CDR3,CDR2, and CDR1 of antibodies on the lineage from Joe 9 to J695, or fromthe lineage Y61 to J695, can be made to provide additional anti-IL-12antibodies of the invention. Such methods of modification can beperformed using standard molecular biology techniques, such as by PCRmutagenesis, targeting individual contact or hypermutation amino acidresidues in the light chain and/or heavy chain CDRs-, followed bykinetic and functional analysis of the modified antibodies as describedherein (e.g., neutralization assays described in Example 3 of U.S. Pat.No. 6,914,128, and by BIAcore analysis, as described in Example 5 ofU.S. Pat. No. 6,914,128).

Accordingly, in another aspect the invention features use of an isolatedhuman antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁶ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 3 and a heavy chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 5, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 5; and

c) comprises a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 2, a light chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 4, and a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 6, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a light chain CDR3comprising the amino acid sequence of SEQ ID NO: 2, a light chain CDR2comprising the amino acid sequence of SEQ ID NO: 4, and a light chainCDR1 comprising the amino acid sequence of SEQ ID NO: 6.

In another aspect the invention features use of an isolated humanantibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 9, a heavy chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 11 and a heavy chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 13, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position, contactposition or a hypermutation position, wherein said mutant has a k_(off)rate no more than 10-fold higher than the antibody comprising a heavychain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a heavychain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and aheavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13;and

c) comprises a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 14, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position, contactposition or a hypermutation position, wherein said mutant has a k_(off)rate no more than 10-fold higher than the antibody comprising a lightchain CDR3 comprising the amino acid sequence of SEQ ID NO: 10, a lightchain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and alight chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14.

An ordinarily skilled artisan will also appreciate that additionalmutations to the CDR regions of an antibody, for example in Y61 or inJ695, can be made to provide additional anti-IL-12 antibodies of theinvention. Such methods of modification can be performed using standardmolecular biology techniques, as described above. The functional andkinetic analysis of the modified antibodies can be performed asdescribed in Example 3 of U.S. Pat. No. 6,914,128 and Example 5 of U.S.Pat. No. 6,914,128, respectively. Modifications of individual residuesof Y61 that led to the identification of J695 are shown in FIGS. 2A-2Hof U.S. Pat. No. 6,914,128 (FIGS. 9A-H herein) and are described inExample 2 of U.S. Pat. No. 6,914,128.

Accordingly, in another aspect the invention features use of an isolatedhuman antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 17, a heavy chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 19 and a heavy chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 21, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 17, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 19, and a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 21; and

c) comprises a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 18, a light chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 20, and a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 22, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a light chain CDR3comprising the amino acid sequence of SEQ ID NO: 18, a light chain CDR2comprising the amino acid sequence of SEQ ID NO: 20, and a light chainCDR1 comprising the amino acid sequence of SEQ ID NO: 22.

In another aspect the invention features use of an isolated humanantibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an in vitro PHAassay with an IC₅₀ of 1×10⁻⁹ M or less;

b) comprises a heavy chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 25, a heavy chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 27 and a heavy chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 29, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 25, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 27, and a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 29; and

c) comprises a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 26, a light chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 30, or a mutant thereof having one or more amino acidsubstitutions at a preferred selective mutagenesis position or ahypermutation position, wherein said mutant has a k_(off) rate no morethan 10-fold higher than the antibody comprising a light chain CDR3comprising the amino acid sequence of SEQ ID NO: 26, a light chain CDR2comprising the amino acid sequence of SEQ ID NO: 28, and a light chainCDR1 comprising the amino acid sequence of SEQ ID NO: 30.

In yet another embodiment, the invention provides use of an isolatedhuman antibodies, or antigen-binding portions thereof, that neutralizethe activity of human IL-12, and at least one additional primate IL-12selected from the group consisting of baboon IL-12, marmoset IL-12,chimpanzee IL-12, cynomolgus IL-12 and rhesus IL-12, but which do notneutralize the activity of the mouse IL-12.

II Selection of Recombinant Human Antibodies

Recombinant human antibodies which may be used in the invention can beisolated by screening of a recombinant combinatorial antibody library,preferably a scFv phage display library, prepared using human VL and VHcDNAs prepared from mRNA derived from human lymphocytes. Methods foridentifying antibodies which may be used in the methods and compositionsof the invention are described in U.S. Pat. No. 6,914,128, incorporatedby reference herein. Methodologies for preparing and screening suchlibraries are known in the art. In addition to commercially availablekits for generating phage display libraries (e.g., the PharmaciaRecombinant Phage Antibody System, catalog no. 27-9400-01; and theStratagene SurfZAP™ phage display kit, catalog no. 240612), examples ofmethods and reagents particularly amenable for use in generating andscreening antibody display libraries can be found in, for example, Kanget al. PCT Publication No. WO 92/18619; Winter et al. PCT PublicationNo. WO 92/20791; Breitling et al. PCT Publication No. WO 93/01288;McCafferty et al. PCT Publication No. WO 92/01047; Garrard et al. PCTPublication No. WO 92/09690; Fuchs et al. (1991) Bio/Technology2:1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse etal. (1989) Science 246:1275-1281; McCafferty et al., Nature (1990)348:552-554; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al.(1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991)Bio/Technology 2:1373-1377; Hoogenboom et al (1991) Nuc Acid Res19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982.

The antibody libraries used in this method are preferably scFv librariesprepared from human VL and VH cDNAs. The scFv antibody libraries arepreferably screened using recombinant human IL-12 as the antigen toselect human heavy and light chain sequences having a binding activitytoward IL-12. To select for antibodies specific for the p35 subunit ofIL-12 or the p70 heterodimer, screening assays were performed in thepresence of excess free p40 subunit. Subunit preferences can bedetermined, for example by, micro-Friguet titration, as described inExample 1 of U.S. Pat. No. 6,914,128.

Once initial human VL and VH segments are selected, “mix and match”experiments, in which different pairs of the selected VL and VH segmentsare screened for IL-12 binding, are performed to select preferred VL/VHpair combinations (see Example 1 of U.S. Pat. No. 6,914,128).Additionally, to further improve the affinity and/or lower the off rateconstant for hIL-12 binding, the VL and VH segments of the preferredVL/VH pair(s) can be randomly mutated, preferably within the CDR3 regionof VH and/or VL, in a process analogous to the in vivo somatic mutationprocess responsible for affinity maturation of antibodies during anatural immune response. This in vitro affinity maturation can beaccomplished by amplifying VH and VL regions using PCR primerscomplimentary to the VH CDR3 or VL CDR3, respectively, which primershave been “spiked” with a random mixture of the four nucleotide bases atcertain positions such that the resultant PCR products encode VH and VLsegments into which random mutations have been introduced into the VHand/or VL CDR3 regions. These randomly mutated VH and VL segments can bereselected and rescreened for binding to hIL-12 and sequences thatexhibit high affinity and a low off rate for IL-12 binding can beselected. Table 2 of Appendix A of U.S. Pat. No. 6,914,128 (see table 2of Appendix A attached hereto) shows antibodies that displayed alteredbinding specificity/affinity produced as a result of in vitro affinitymaturation.

Following selection, isolation and screening of an anti-hIL-12 antibodyof the invention from a recombinant immunoglobulin display library,nucleic acid encoding the selected antibody can be recovered from thephage particle(s) (e.g., from the phage genome) and subcloned into otherexpression vectors by standard recombinant DNA techniques. If desired,the nucleic acid can be further manipulated to create other antibodyforms of the invention (e.g., linked to nucleic acid encoding additionalimmunoglobulin domains, such as additional constant regions). To expressa recombinant human antibody isolated by screening of a combinatoriallibrary, the DNA encoding the antibody is cloned into a recombinantexpression vector and introduced into a mammalian host cells, asdescribed in further detail in Section IV below.

Methods for selecting human IL-12 binding antibodies by phage displaytechnology, and affinity maturation of selected antibodies by random orsite-directed mutagenesis of CDR regions are described in further detailin Example 1 of U.S. Pat. No. 6,914,128.

As described in Example 1 of U.S. Pat. No. 6,914,128, screening of humanVL and VH cDNA libraries identified a series of anti-IL-12 antibodies,of which the Joe 9 antibody was selected for further development. Acomparison of the heavy chain variable region of Joe 9 with the heavychain germline sequences selected from the VBASE database, revealed thatJoe 9 was similar to the COS-3 germline sequence. COS-3 belongs to theV_(H)3 family of germline sequences.

The V_(H)3 family is part of the human VH germline repertoire which isgrouped into seven families, V_(H)1-V_(H)7, based on nucleotide sequencehomology (Tomlinson et al. (1992) J. Mol. Biol., 227, 776-798 and Cooket al. (1995) Immunology Today, 16, 237-242). The V_(H)3 family containsthe highest number of members and makes the largest contribution to thegermline repertoire. For any given human V_(H)3-germline antibodysequence, the amino acid sequence identity within the entire V_(H)3family is high (See e.g., Tomlinson et al. (1992) J. Mol. Biol., 227,776-798 and Cook et al. (1995) Immunology Today, 16, 237-242). The rangeof amino acid sequence identity between any two germline VH sequences ofthe V_(H)3 family varies from 69-98 residues out of approximately 100 VHresidues, (i.e., 69-98% amino acid sequence homology between any twogermline VH sequences). For most pairs of germline sequences there is atleast 80 or more identical amino acid residues, (i.e., at least 80%amino acid sequence homology). The high degree of amino acid sequencehomology between the V_(H)3 family members results in certain amino acidresidues being present at key sites in the CDR and framework regions ofthe VH chain. These amino acid residues confer structural features uponthe CDRs.

Studies of antibody structures have shown that CDR conformations can begrouped into families of canonical CDR structures based on the key aminoacid residues that occupy certain positions in the CDR and frameworkregions. Consequently, there are similar local CDR conformations indifferent antibodies that have canonical structures with identical keyamino acid residues (Chothia et al. (1987) J. Mol. Biol., 196, 901-917and Chothia et al. (1989) Nature, 342, 877-883). Within the V_(H)3family there is a conservation of amino acid residue identity at the keysites for the CDR1 and CDR2 canonical structures (Chothia et al. (1992)J. Mol. Biol., 227, 799-817).

The COS-3 germline VH gene, is a member of the V_(H)3 family and is avariant of the 3-30 (DP-49) germline VH allele. COS-3, differs from Joe9VH amino acid sequences at only 5 positions. The high degree of aminoacid sequence homology between Joe9 VH and COS-3, and between Joe9 VHand the other V_(H)3 family members also confers a high degree of CDRstructural homology (Chothia et al. (1992) J. Mol. Biol., 227, 799-817;Chothia et al. (1987) J. Mol. Biol., 196, 901-917 and Chothia et al.(1989) Nature, 342, 877-883).

The skilled artisan will appreciate that based on the high amino acidsequence and canonical structural similarity to Joe 9, other V_(H)3family members could also be used to generate antibodies that bind tohuman IL-12. This can be performed, for example, by selecting anappropriate VL by chain-shuffling techniques (Winter et al. (1994)Annual Rev. Immunol., 12, 433-55), or by the grafting of CDRs from arodent or other human antibody including CDRs from antibodies of thisinvention onto a V_(H)3 family framework.

The human V lambda germline repertoire is grouped into 10 families basedon nucleotide sequence homology (Williams et al. (1996) J. Mol. Biol.,264, 220-232). A comparison of the light chain variable region of Joe 9with the light chain germline sequences selected from the VBASEdatabase, revealed that Joe 9 was similar to the DPL8 lambda germline.The Joe9 VL differs from DPL8 sequence at only four framework positions,and is highly homologous to the framework sequences of the other V_(λ)1family members. Based on the high amino acid sequence homology andcanonical structural similarity to Joe 9, other V_(λ)1 family membersmay also be used to generate antibodies that bind to human IL-12. Thiscan be performed, for example, by selecting an appropriate VH bychain-shuffling techniques (Winter et al. Supra, or by the grafting ofCDRs from a rodent or other human antibody including CDRs fromantibodies of this invention onto a V_(λ)1 family framework.

The methods of the invention are intended to include recombinantantibodies that bind to hIL-12, comprising a heavy chain variable regionderived from a member of the V_(H)3 family of germline sequences, and alight chain variable region derived from a member of the V_(λ)1 familyof germline sequences. Moreover, the skilled artisan will appreciatethat any member of the V_(H)3 family heavy chain sequence can becombined with any member of the V_(λ)1 family light chain sequence.

Those skilled in the art will also appreciate that DNA sequencepolymorphisms that lead to changes in the amino acid sequences of thegermline may exist within a population (e.g., the human population).Such genetic polymorphism in the germline sequences may exist amongindividuals within a population due to natural allelic variation. Suchnatural allelic variations can typically result in 1-5% variance in thenucleotide sequence of the a gene. Any and all such nucleotidevariations and resulting amino acid polymorphisms in germline sequencesthat are the result of natural allelic variation are intended to bewithin the scope of the invention.

Accordingly, in one aspect, the invention features an isolated humanantibody, or an antigen-binding portion thereof, which has the followingcharacteristics:

-   -   a) that binds to human IL-12 and dissociates from human IL-12        with a k_(off) rate constant of 0.1 s⁻¹ or less, as determined        by surface plasmon resonance, or which inhibits        phytohemagglutinin blast proliferation in an in vitro        phytohemagglutinin blast proliferation assay (PHA assay) with an        IC₅₀ of 1×10⁻⁶ M or less.    -   b) has a heavy chain variable region comprising an amino acid        sequence selected from a member of the V_(H)3 germline family,        wherein the heavy chain variable region has a mutation at a        contact or hypermutation position with an activity enhancing        amino acid residue.    -   c) has a light chain variable region comprising an amino acid        sequence selected from a member of the V_(λ)1 germline family,        wherein the light chain variable region has a mutation at a        preferred selective mutagenesis position, contact or        hypermutation position with an activity enhancing amino acid        residue.

In a preferred embodiment, the isolated human antibody, or antigenbinding has mutation in the heavy chain CDR3. In another preferredembodiment, the isolated human antibody, or antigen binding has mutationin the light chain CDR3. In another preferred embodiment, the isolatedhuman antibody, or antigen binding has mutation in the heavy chain CDR2.In another preferred embodiment, the isolated human antibody, or antigenbinding has mutation in the light chain CDR2. In another preferredembodiment, the isolated human antibody, or antigen binding has mutationin the heavy chain CDR1. In another preferred embodiment, the isolatedhuman antibody, or antigen binding has mutation in the light chain CDR1.

An ordinarily skilled artisan will appreciate that based on the highamino acid sequence similarity between members of the V_(H)3 germlinefamily, or between members of the light chain V_(λ)1 germline family,that mutations to the germlines sequences can provide additionalantibodies that bind to human IL-12. Table 1 of U.S. Pat. No. 6,914,128(see Table 1 of Appendix A attached hereto) shows the germline sequencesof the V_(H)3 family members and demonstrates the significant sequencehomology within the family members. Also shown in table 1 of U.S. Pat.No. 6,914,128 (see table 1 of Appendix A, attached hereto) are thegermline sequences for V_(λ)1 family members. The heavy and light chainsequences of Joe 9 are provided as a comparison. Mutations to thegermline sequences of V_(H)3 or V_(λ)1 family members may be made, forexample, at the same amino acid positions as those made in theantibodies of the invention (e.g. mutations in Joe 9). The modificationscan be performed using standard molecular biology techniques, such as byPCR mutagenesis, targeting individual amino acid residues in thegermline sequences, followed by kinetic and functional analysis of themodified antibodies as described herein (e.g., neutralization assaysdescribed in Example 3 of U.S. Pat. No. 6,914,128, and by BIAcoreanalysis, as described in Example 5 of U.S. Pat. No. 6,914,128).

Accordingly, in one aspect, the invention features use of an isolatedhuman antibody, or an antigen-binding portion thereof, which has thefollowing characteristics:

-   -   a) has a heavy chain variable region comprising an amino acid        sequence selected from the group consisting of SEQ ID NOs:        595-667, wherein the heavy chain variable region has a mutation        at a preferred selective mutagenesis position, contact or        hypermutation position with an activity enhancing amino acid        residue.    -   b) has a light chain variable region comprising an amino acid        sequence selected from the group consisting of SEQ ID NOs:        669-675, wherein the light chain variable region has a mutation        at a preferred selective mutagenesis position, contact or        hypermutation position with an activity enhancing amino acid        residue.

An ordinarily skilled artisan will appreciate that based on the highamino acid sequence similarity between Joe 9 and COS-3 heavy chaingermline sequence, and between Joe 9 and DPL8 lambda germline sequence,that other mutations to the CDR regions of these germlines sequences canprovide additional antibodies that bind to human IL-12. Such methods ofmodification can be performed using standard molecular biologytechniques as described above.

Accordingly, in one aspect, the invention features use of an isolatedhuman antibody, or an antigen-binding portion thereof, which has thefollowing characteristics:

-   -   a) that binds to human IL-12 and dissociates from human IL-12        with a k_(off) rate constant of 0.1 s⁻¹ or less, as determined        by surface plasmon resonance, or which inhibits        phytohemagglutinin blast proliferation in an in vitro        phytohemagglutinin blast proliferation assay (PHA assay) with an        IC₅₀ of 1×10⁻⁶ M or less.    -   b) has a heavy chain variable region comprising the COS-3        germline amino acid sequence, wherein the heavy chain variable        region has a mutation at a preferred selective mutagenesis        position, contact or hypermutation position with an activity        enhancing amino acid residue.    -   c) has a light chain variable region comprising the DPL8        germline amino acid sequence, wherein the light chain variable        region has a mutation at a preferred selective mutagenesis        position, contact or hypermutation position with an activity        enhancing amino acid residue.

Due to certain amino acid residues occupying key sites in the CDR andframework regions in the light and heavy chain variable region,structural features are conferred at these regions. In particular, theCDR2 and CDR1 regions are subject to canonical structuralclassifications. Since there is a high degree of amino acids sequencehomology between family members, these canonical features are presentbetween family members. The skilled artisan will appreciate thatmodifications at the amino acid residues that confer these canonicalstructures would produce additional antibodies that bind to IL-12. Themodifications can be performed using standard molecular biologytechniques as described above.

Accordingly, in another aspect, the invention features use of anisolated human antibody, or an antigen-binding portion thereof, whichhas the following characteristics:

-   -   a) that binds to human IL-12 and dissociates from human IL-12        with a k_(off) rate constant of 0.1 s⁻¹ or less, as determined        by surface plasmon resonance, or which inhibits        phytohemagglutinin blast proliferation in an in vitro        phytohemagglutinin blast proliferation assay (PHA assay) with an        IC₅₀ of 1×10⁻⁶ M or less.    -   b) has a heavy chain variable region comprising an amino acid        sequence selected from a member of the V_(H)3 germline family,        wherein the heavy chain variable region comprises a CDR2 that is        structurally similar to CDR2s from other V_(H)3 germline family        members, and a CDR1 that is structurally similar to CDR1s from        other V_(H)3 germline family members, and wherein the heavy        chain variable region has a mutation at a preferred selective        mutagenesis position, contact or hypermutation position with an        activity enhancing amino acid residue;    -   c) has a light chain variable region comprising an amino acid        sequence selected from a member of the V_(λ)1 germline family,        wherein the light chain variable region comprises a CDR2 that is        structurally similar to CDR2s from other V_(λ)1 germline family        members, and a CDR1 that is structurally similar to CDR1s from        other V_(λ)1 germline family members, and wherein the light        chain variable region has a mutation at a preferred selective        mutagenesis position, contact or hypermutation position with an        activity enhancing amino acid residue.

Recombinant human antibodies used in the invention have variable andconstant regions which are homologous to human germline immunoglobulinsequences selected from the VBASE database. Mutations to the recombinanthuman antibodies (e.g., by random mutagenesis or PCR mutagenesis) resultin amino acids that are not encoded by human germline immunoglobulinsequences. Also, libraries of recombinant antibodies which were derivedfrom human donors will contain antibody sequences that differ from theircorresponding germline sequences due to the normal process of somaticmutation that occurs during B-cell development. It should be noted thatif the “germline” sequences obtained by PCR amplification encode aminoacid differences in the framework regions from the true germlineconfiguration (i.e., differences in the amplified sequence as comparedto the true germline sequence), it may be desirable to change theseamino acid differences back to the true germline sequences (i.e.,“backmutation” of framework residues to the germline configuration).Thus, the present invention can optionally include a backmutation step.To do this, the amino acid sequences of heavy and light chain encoded bythe germline (as found as example in VBASE database) are first comparedto the mutated immunoglobulin heavy and light chain framework amino acidsequences to identify amino acid residues in the mutated immunoglobulinframework sequence that differ from the closest germline sequences.Then, the appropriate nucleotides of the mutated immunoglobulin sequenceare mutated back to correspond to the germline sequence, using thegenetic code to determine which nucleotide changes should be made.Mutagenesis of the mutated immunoglobulin framework sequence is carriedout by standard methods, such as PCR-mediated mutagenesis (in which themutated nucleotides are incorporated into the PCR primers such that thePCR product contains the mutations) or site-directed mutagenesis. Therole of each amino acid identified as candidate for backmutation shouldbe investigated for a direct or indirect role in antigen binding and anyamino acid found after mutation to affect any desirable characteristicof the human antibody should not be included in the final humanantibody; as an example, activity enhancing amino acids identified bythe selective mutagenesis approach will not be subject to backmutation.Assays to determine the characteristics of the antibody resulting frommutagenesis can include ELISA, competitive ELISA, in vitro and in vivoneutralization assays and/or (see e.g. Example 3 of U.S. Pat. No.6,914,128) immunohistochemistry with tissue sections from varioussources (including human, primate and/or other species).

To minimize the number of amino acids subject to backmutation thoseamino acid positions found to be different from the closest germlinesequence but identical to the corresponding amino acid in a secondgermline sequence can remain, provided that the second germline sequenceis identical and colinear to the sequence of the human antibody of theinvention for at least 10, preferably 12 amino acids, on both sides ofthe amino acid in question. This would assure that any peptide epitopepresented to the immune system by professional antigen presenting cellsin a subject treated with the human antibody of the invention would notbe foreign but identical to a self-antigen, i.e. the immunoglobulinencoded by that second germline sequence. Backmutation may occur at anystage of antibody optimization; preferably, backmutation occurs directlybefore or after the selective mutagenesis approach. More preferably,backmutation occurs directly before the selective mutagenesis approach.

III. Modifications to Preferred Selective Mutagenesis Positions, Contactand/or Hypermutation Positions

Typically, selection of antibodies with improved affinities can becarried out using phage display methods, as described in section IIabove and in U.S. Pat. No. 6,914,128, incorporated by reference herein.This can be accomplished by randomly mutating combinations of CDRresidues and generating large libraries containing antibodies ofdifferent sequences. However, for these selection methods to work, theantibody-antigen reaction must tend to equilibrium to allow, over time,preferential binding of higher affinity antibodies to the antigen.Selection conditions that would allow equilibrium to be establishedcould not be determined (presumably due to additional non-specificinteractions between the antigen and phage particle) when phage displaymethods were used to improve the affinity of selected anti-IL-12antibodies, upon attaining a certain level of affinity achieved (i.e.,that of antibody Y61). Accordingly, antibodies with even higheraffinities could not be selected by phage display methods. Thus, for atleast certain antibodies or antigens, phage display methods are limitingin their ability to select antibodies with a highly improved bindingspecificity/affinity. Accordingly, a method termed Selective MutagenesisApproach which does not require phage display affinity maturation ofantibodies, was established to overcome this limitation and is providedby the invention. Although this Selective Mutagenesis Approach wasdeveloped to overcome limitations using the phage display system, itshould be noted that this method can also be used with the phage displaysystem. Moreover, the selective mutagenesis approach can be used toimprove the activity of any antibody.

To improve the activity (e.g., affinity or neutralizing activity) of anantibody, ideally one would like to mutate every CDR position in boththe heavy and light chains to every other possible amino acid residue.However, since there are, on average, 70 CDR positions within anantibody, such an approach would be very time consuming and laborintensive. Accordingly, the method of the invention allows one toimprove the activity of the antibody by mutating only certain selectedresidues within the heavy and/or light chain CDRs. Furthermore, themethod of the invention allows improvement in activity of the antibodywithout affecting other desirable properties of the antibody.

Determining which amino acid residues of an antibody variable region arein contact with an antigen cannot be accurately predicted based onprimary sequence or their positions within the variable region.Nevertheless, alignments of sequences from antibodies with differentspecificities conducted by Kabat et al. have identified the CDRs aslocal regions within the variable regions which differ significantlyamong antibodies (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-393,Kabat, E. A., et al (1991) Sequences of Proteins of ImmunologicalInterest, Fifth Edition, U.S. Department of Health and Human Services,NIH Publication No. 91-3242). Structural studies have shown that theantigen binding surface is formed by amino acid residues present in theCDRs. Other amino acid residues outside the CDR are also known to playstructural roles or be directly involved in antigen binding. Therefore,for each antigen-antibody pair, amino acid residues within and outsideof the CDRs may be important.

The sequence alignment studies by Tomlison et al identified a number ofpositions in the heavy and light chain CDR1 and CDR2, and in a portionof the kappa chain CDR3 which are frequent sites of somatic mutation.(Tomlison et al (1996) J. Mol. Biol. 256: 813-817). In particular,positions H31, H31B, H33, H33B, H52B, H56, H58, L30, L31, L31A, L50,L53, L91, L92, L93 and L94 were identified as frequent sites for somaticmutation. However, this analysis excludes the important heavy chain CDR3regions, and sections of the light chain CDR3 which are known to lie inthe center of an antibody binding site, and potentially provideimportant interactions with an antigen. Furthermore, Tomlison et al.propose that somatic diversity alone does not necessarily predict a roleof a specific amino acid in antigen binding, and suggest conserved aminoacid residues that contact the antigen, and diverse amino acid residueswhich do not contact the antigen. This conclusion is further supportedby mutational studies on the role of somatic mutations to antibodyaffinity (Sharon, (1990), PNAS, 87:4814-7). Nineteen somatic mutationsin a high-affinity anti-p-azophenylarsonate (Ars) antibody weresimultaneously replaced with their corresponding germline residues,generating a germline version of the anti-Ars antibody which had atwo-hundred fold loss in activity. The full affinity of the anti-Arsantibody could be recovered by restoring only three of the nineteensomatic mutations, demonstrating that many somatic mutations may bepermitted that do not contribute to antigen binding activity.

The result can be explained in part by the nature of antibody diversityitself. Immature B-cells may produce initially low affinity antibodiesthat recognize a number of self or non-self antigens. Moreover,antibodies may undergo in the course of affinity maturation sequencevariations that may cause self-reactivity. Hypermutation of such lowaffinity antibodies may serve to abolish self-reactivity (“negativeselection”) and increase affinity for the foreign antigen. Therefore,the analysis of primary and structural data of a large number ofantibodies does not provide a method of predicting either (1) the roleof somatic hyper-mutation sites in the affinity maturation processversus the process of decreasing affinity towards unwanted antigens, or(2) how a given amino acid contributes to the properties of a specificantigen-antibody pair.

Other attempts to address the role of specific amino acid residues inantigen recognition were made by analyzing a number of crystalstructures of antigen-antibody complexes (MacCallum et al. (1996) J.Mol. Biol. 262: 732-745). The potential role of positions located withinand outside the CDRs was indicated. Positions in CDRs involved inantigen binding in more than 10 of 26 analyzed structures included H31,H33, H50, H52, H53, H54, H56, H58, H95, H96, H97, H98 and H100 in theheavy chain and L30A, L32, L91, L92, L93, L94, L96 in the light chain.However, the authors noted that prediction of antigen contacts usingthese and other structural data may over and under predict contactpositions, leading to the speculation that a different strategy may haveto be applied to different antigens.

Pini et al. describe randomizing multiple residues in antibody CDRsequences in a large phage display library to rapidly increase antibodyaffinity (Pini et al. (1998) J. Biol Chem. 273: 21769-21776). However,the high affinity antibodies discussed by Pini et al. had mutations in atotal of eight positions, and a reductionary analysis of which changesare absolutely required to improve affinity of the antibody becomesimpractical because of the large number of possible combinations to betested for the smallest number of amino acids required.

Furthermore, randomizing multiple residues may not necessarily preserveother desired properties of the antibody. Desirable properties orcharacteristics of an antibody are art-recognized and include forexample, preservation of non-cross reactivity, e.g., with other proteinsor human tissues and preservation of antibody sequences that are closeto human germline immunoglobulin sequences improvement of neutralizationpotency. Other desirable properties or characteristics include abilityto preserve species cross reactivity, ability to preserve epitopespecificity and ability to preserve high expression levels of protein inmammalian cells. The desirable properties or characteristics can beobserved or measured using art-recognized techniques including but notlimited to ELISA, competitive ELISA, in vitro and in vivo neutralizationassays (see e.g. Example 3 of U.S. Pat. No. 6,914,128),immunohistochemistry with tissue sections from different sourcesincluding human, primate or other sources as the need may be, andstudies to expression in mammalian cells using transient expression orstable expression.

In addition, the method of Pini et al may introduce more changes thanthe minimal number actually required to improve affinity and may lead tothe antibodies triggering anti-human-antibody (HAMA) formation in humansubjects. Further, as discussed elsewhere, the phage display asdemonstrated here, or other related method including ribosome displaymay not work appropriately upon reaching certain affinities betweenantibody and antigen and the conditions required to reach equilibriummay not be established in a reasonable time frame because of additionalinteractions including interactions with other phage or ribosomecomponents and the antigen.

The ordinarily skilled artisan may glean interesting scientificinformation on the origin of antibody diversity from the teachings ofthe references discussed above. The present invention, however, providesa method for increasing antibody affinity of a specific antigen-antibodypair while preserving other relevant features or desirablecharacteristics of the antibody. This is especially important whenconsidering the desirability of imparting a multitude of differentcharacteristics on a specific antibody including antigen binding.

If the starting antibody has desirable properties or characteristicswhich need to be retained, a selective mutagenesis approach can be thebest strategy for preserving these desirable properties while improvingthe activity of the antibody. For example, in the mutagenesis of Y61,the aim was to increase affinity for hIL-12, and to improve theneutralization potency of the antibody while preserving desiredproperties. Desired properties of Y61 included (1) preservation ofnon-cross reactivity with other proteins or human tissues, (2)preservation of fine epitope specificity, i.e. recognizing a p40 epitopepreferably in the context of the p70 (p40/p35) heterodimer, therebypreventing binding interference from free soluble p40; and (3)generation of an antibody with heavy and light chain amino acidsequences that were as close as possible to their respective germlineimmunoglobulin sequences.

In one embodiment, the method of the invention provides a selectivemutagenesis approach as a strategy for preserving the desirableproperties or characteristics of the antibody while improving theaffinity and/or neutralization potency. The term “selective mutagenesisapproach” is as defined above and includes a method of individuallymutating selected amino acid residues. The amino acid residues to bemutated may first be selected from preferred selective mutagenesispositions, then from contact positions, and then from hypermutationpositions. The individual selected position can be mutated to at leasttwo other amino acid residue and the effect of the mutation both on thedesired properties of the antibody, and improvement in antibody activityis determined.

The Selective Mutagenesis approach comprises the steps of:

selecting candidate positions in the order 1) preferred selectivemutagenesis positions; 2) contact positions; 3) hypermutation positionsand ranking the positions based on the location of the position withinthe heavy and light chain variable regions of an antibody (CDR3preferred over CDR2 preferred over CDR1);

individually mutating candidate preferred selective mutagenesispositions, hypermutation and/or contact positions in the order ofranking, to all possible other amino acid residues and analyzing theeffect of the individual mutations on the activity of the antibody inorder to determine activity enhancing amino acid residues;

if necessary, making stepwise combinations of the individual activityenhancing amino acid residues and analyzing the effect of the variouscombinations on the activity of the antibodies; selecting mutantantibodies with activity enhancing amino acid residues and ranking themutant antibodies based on the location and identity of the amino acidsubstitutions with regard to their immunogenic potential. Highestranking is given to mutant antibodies that comprise an amino acidsequence which nearly identical to a variable region sequence that isdescribed in a germline database, or has an amino acid sequence that iscomparable to other human antibodies. Lower ranking is given to mutantantibodies containing an amino acid substitution that is rarelyencountered in either germline sequences or the sequences of other humanantibodies. The lowest ranking is given to mutant antibodies with anamino acid substitution that has not been encountered in a germlinesequence or the sequence of another human antibody. As set forth above,mutant antibodies comprising at least one activity enhancing amino acidresidue located in CDR3 is preferred over CDR2 which is preferred overCDR1. The CDRs of the heavy chain variable regions are preferred overthose of the light chain variable region.

The mutant antibodies can also be studied for improvement in activity,e.g. when compared to their corresponding parental antibody. Theimprovement in activity of the mutant antibody can be determined forexample, by neutralization assays, or binding specificity/affinity bysurface plasmon resonance analysis (see Example 3 of U.S. Pat. No.6,914,128). Preferably, the improvement in activity can be at least 2-20fold higher than the parental antibody. The improvement in activity canbe at least “x₁” to “x₂” fold higher than the parental antibody wherein“x₁” and “x₂” are integers between and including 2 to 20, includingranges within the state range, e.g. 2-15, e.g. 5-10.

The mutant antibodies with the activity enhancing amino acid residuealso can be studied to determine whether at least one other desirableproperty has been retained after mutation. For example, with anti-hIL-12antibodies testing for, (1) preservation of non-cross reactivity withother proteins or human tissues, (2) preservation of epitoperecognition, i.e. recognizing a p40 epitope preferably in the context ofthe p70 (p40/p35) heterodimer, thereby preventing binding interferencefrom free soluble p40; and (3) generation of antibodies with heavy andlight chain amino acid sequences that were as close as possible to theirrespective germline immunoglobulin sequences, and determining whichwould be least likely to elicit a human immune response based on thenumber of differences from the germline sequence. The same observationscan be made on an antibody having more than one activity enhancing aminoacid residues, e.g. at least two or at least three activity enhancingamino acid residues, to determine whether retention of the desirableproperty or characteristic has occurred.

An example of the use of a “selective mutagenesis approach”, in themutagenesis of Y61 is described below. The individual mutations H31S→E,L50→Y, or L94G→Y each improved neutralization activity of the antibody.However, when combination clones were tested, the activity of thecombined clone H31S→E+L50→Y+L94G→Y was no better than L50→Y+L94G→Y(J695). Therefore, changing the germline amino acid residue Ser to Gluat position 31 of CDR1 was unnecessary for the improved activity of J695over Y61. The selective mutagenesis approach therefore, identified theminimal number of changes that contributed to the final activity,thereby reducing the immunogenic potential of the final antibody andpreserving other desired properties of the antibody.

Isolated DNA encoding the VH and VL produced by the selected mutagenesisapproach can be converted into full length antibody chain genes, to Fabfragment genes as to a scFV gene, as described in section IV. Forexpression of VH and VL regions produced by the selected mutagenesisapproach, expression vectors encoding the heavy and light chain can betransfected into variety host cells as described in detail in sectionIV. Preferred host cells include either prokaryotic host cells, forexample, E coli, or eukaryotic host cells, for example, yeast cells,e.g., S. cerevisae. Most preferred eukaryotic host cells are mammalianhost cells, described in detail in section IV.

The selective mutagenesis approach provides a method of producingantibodies with improved activities without prior affinity maturation ofthe antibody by other means. The selective mutagenesis approach providesa method of producing antibodies with improved affinities which havebeen subject to back mutations. The selective mutagenesis approach alsoprovides a method of improving the activity of affinity maturedantibodies.

The skilled artisan will recognize that the selective mutagenesisapproach can be used in standard antibody manipulation techniques knownin the art. Examples include, but are not limited to, CDR graftedantibodies, chimeric antibodies, scFV fragments, Fab fragments of a fulllength antibodies and human antibodies from other sources, e.g.,transgenic mice.

Rapid large scale mutational analysis of antibodies include in vitrotranscription and translation using ribosome display technology (seee.g., Hanes et al., (1997) Proc. Natl. Acad. Sci. 94: 4937-4942; DallAcqua et al., (1998) Curr. Opin. Struc. Biol. 8: 443-450; He et al,(1997) Nucleic Acid Res. 25:5132-5134), and U.S. Pat. Nos. 5,643,768 and5,658,754 issued to Kawasaki. The selective mutagenesis approach alsoprovides a method of producing antibodies with improved activities thatcan be selected using ribosomal display techniques.

In the methods of the invention, antibodies or antigen binding portionsthereof are further modified by altering individual positions in theCDRs of the HCVR and/or LCVR. Although these modifications can be madein phage-displayed antibodies, the method is advantageous in that it canbe performed with antibodies that are expressed in other types of hostsystems, such as bacterial, yeast or mammalian cell expression systems.The individual positions within the CDRs selected for modification arebased on the positions being a contact and/or hypermutation position.

Preferred contact positions and hypermutation positions as definedherein are shown in Table 3 of U.S. Pat. No. 6,914,128 (see Appendix Aof U.S. Pat. No. 6,914,128 and Table 3 of Appendix A attached herto) andtheir modification in accordance with the method of the invention isdescribed in detail in Example 2 of U.S. Pat. No. 6,914,128. Preferredcontact positions are selected from the group consisting of H30, H31,H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97,H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94and L96. Preferred hypermutation positions are selected from the groupconsisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31, L32, L53 andL93. More preferred amino acid residues (referred to as “preferredselective mutagenesis positions”) are both contact and hypermutationpositions and are selected from the group consisting of H30, H31, H31B,H32, H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93, L94.Particularly preferred contact positions are selected from the groupconsisting of L50 and L94. Preferred activity enhancing amino acidresidues replace amino acid residues located at positions selected fromthe group consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A,H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50,L52, L53, L55, L91, L92, L93, L94, and L96. More preferred activityenhancing amino acid residues replace amino acid residues located atpositions H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32, L50,L91, L92, L93, L94. Particularly, preferred activity enhancing aminoacid residues replace amino acid residues located at positions selectedfrom the group consisting of L50 and L94.

In general, the method of the invention involves selecting a particularpreferred selective mutagenesis position, contact and/or hypermutationposition within a CDR of the heavy or light chain of a parent antibodyof interest, or antigen binding portion thereof, randomly mutagenizingthat individual position (e.g., by genetic means using a mutagenicoligonucleotide to generate a “mini-library” of modified antibodies), ormutating a position to specific desired amino acids, to identifyactivity enhancing amino acid residues expressing, and purifying themodified antibodies (e.g., in a non-phage display host system),measuring the activity of the modified antibodies for antigen (e.g., bymeasuring k_(off) rates by BIAcore analysis), repeating these steps forother CDR positions, as necessary, and combining individual mutationsshown to have improved activity and testing whether the combination(s)generate an antibody with even greater activity (e.g., affinity orneutralizing potency) than the parent antibody, or antigen-bindingportion thereof.

Accordingly, in one embodiment, the invention provides a method forimproving the activity of an antibody, or antigen-binding portionthereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting in order a 1) preferred selective mutagenesis position, 2)contact position, or 3) hypermutation position within a complementaritydetermining region (CDR) for mutation, thereby identifying a selectedpreferred selective mutagenesis position, contact or hypermutationposition;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof;

e) optionally, repeating steps a) through d) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

f) combining, in the parent antibody, or antigen-binding portionthereof, individual mutations shown to have improved activity, to formcombination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof; until an antibody, or antigen-bindingportion thereof, with an improved activity, relative to the parentantibody, or antigen-binding portion thereof, is obtained. Preferably,the selected antibody or antibodies have an improved activity withoutloss or with retention of at least one desirable characteristic orproperty of the parental antibody as described above. The desirablecharacteristic or property can be measured or observed by the ordinarilyskilled artisan using art-recognized techniques.

Preferred contact positions are selected from the group consisting ofH30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95,H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92,L93, L94 and L96. Preferred hypermutation positions are selected fromthe group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31,L32, L53 and L93. More preferred preferred selective mutagenesispositions are selected from the group consisting of H30, H31, H31B, H32,H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94.Particularly preferred contact positions are selected from the groupconsisting of L50 and L94.

In another embodiment, the invention provides a method for improving theactivity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, thereby identifying an activityenhancing amino acid residue;

e) optionally, repeating steps a) through d) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

f) combining, in the parent antibody, or antigen-binding portionthereof, two individual activity enhancing amino acid residues shown tohave improved activity, to form combination antibodies, orantigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, orantigen-binding portions thereof with two activity enhancing amino acidresidues, relative to the parent antibody or antigen-binding portionthereof;

until an antibody, or antigen-binding portion thereof, with an improvedactivity, relative to the parent antibody, or antigen-binding portionthereof, is obtained.

Preferred contact positions are selected from the group consisting ofH30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95,H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92,L93, L94 and L96. Preferred hypermutation positions are selected fromthe group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31,L32, L53 and L93. More preferred preferred selective mutagenesispositions are selected from the group consisting of H30, H31, H31B, H32,H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94.Particularly preferred contact positions are selected from the groupconsisting of L50 and L94.

In another embodiment, the invention provides a method for improving theactivity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, thereby identifying an activityenhancing amino acid residue;

e) optionally, repeating steps a) through d) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

f) combining, in the parent antibody, or antigen-binding portionthereof, three individual activity enhancing amino acid residues shownto have improved activity, to form combination antibodies, orantigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, orantigen-binding portions thereof with two activity enhancing amino acidresidues, relative to the parent antibody or antigen-binding portionthereof;

until an antibody, or antigen-binding portion thereof, with an improvedactivity, relative to the parent antibody, or antigen-binding portionthereof, is obtained.

Preferably, the activity enhancing amino acid residue replaces aminoacid residues located at positions selected from the group consisting ofH30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95,H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92,L93, L94 and L96.

Following mutagenesis of individual selected positions, mutated clonescan be sequenced to identify which amino acid residues have beenintroduced into the selected position in each clone. A small number ofclones (e.g., about 24) can be selected for sequencing, whichstatistically should yield 10-15 unique antibodies, whereas largernumbers of clones (e.g., greater than 60) can be sequenced to ensurethat antibodies with every possible substitution at the selectedposition are identified.

In one embodiment, contact and/or hypermutation positions within theCDR3 regions of the heavy and/or light chains are first selected formutagenesis. However, for antibodies that have already been affinitymatured in vitro by random mutagenesis of the CDR3 regions via phagedisplay selection, it may be preferably to first select contact and/orhypermutation positions within CDR1 or CDR2 of the heavy and/or lightchain.

In a more preferred embodiment, preferred selective mutagenesispositions within the CDR3 regions of the heavy and/or light chains arefirst selected for mutagenesis. However, for antibodies that havealready been affinity matured in vitro by random mutagenesis of the CDR3regions via phage display selection, it may be preferably to firstselect preferred selective mutagenesis positions within CDR1 or CDR2 ofthe heavy and/or light chain.

In another preferred embodiment, the optimization of a selected antibodyby the selective mutagenesis approach is done sequentially as follows:preferred selective mutagenesis positions selected from the groupconsisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31, L32,L50, L91, L92, L93, L94 are mutated first to at least 2 other aminoacids each (preferably 5-14 other amino acids) and the resultingantibodies are characterized for increased affinity, neutralizationpotency (and possibly also for at least one other retainedcharacteristic or property discussed elsewhere). If a mutation of asingle preferred selective mutagenesis position does not increase theaffinity or neutralization potency at all or sufficiently and if eventhe combination of multiple activity enhancing amino acids replacingamino acids in preferred selective mutagenesis positions does not resultin an combination antibody which meets the target activity (includingaffinity and/or neutralization potency), additional amino acid residueswill be selected for selective mutagenesis from the group consisting ofH35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 are mutated to atleast 2 other amino acids each (preferably 5-14 other amino acids) andthe resulting antibodies are characterized for increased affinity,neutralization potency (and possibly also for at least one otherretained characteristic or property discussed elsewhere).

If a mutation of a single amino acid residue selected from the groupconsisting of H35, H50, H53, H54, H95, H96, H97, H98, L30A and L96 doesnot increase the activity (including affinity and/or neutralizationpotency) at all or not sufficiently and if even the combination ofmultiple activity enhancing amino acids replacing amino acids in thosepositions does not result in an combination antibody which meets thetargeted activity (including affinity and/or target neutralizationpotency), additional amino acid residues will be selected for selectivemutagenesis from the group consisting of H33B, H52B, L31A and aremutated to at least 2 other amino acids each (preferably 5-14 otheramino acids) and the resulting antibodies are characterized forincreased affinity, neutralization potency (and possibly also for atleast one other retained characteristic or property discussedelsewhere).

It should be understood that the sequential selective mutagenesisapproach may end at any of the steps outline above as soon as anantibody with the desired activity (including affinity andneutralization potency) has been identified. If mutagenesis of thepreselected positions has identified activity enhancing amino acidsresidues but the combination antibody still do not meet the targets setfor activity (including affinity and neutralization potency) and/or ifthe identified activity enhancing amino acids also affect other desiredcharacteristics and are therefore not acceptable, the remaining CDRresidues may be subjected to mutagenesis (see section IV).

The method of the invention can be used to improve activity of anantibody, or antigen binding portion thereof, to reach a predeterminedtarget activity (e.g. a predetermined affinity and/or neutralizationpotency, and/or a desired property or characteristic).

Accordingly, the invention provides a method of improving the activityof an antibody, or antigen-binding portion thereof, to attain apredetermined target activity, comprising:

a) providing a parent antibody a antigen-binding portion thereof;

b) selecting a preferred selective mutagenesis position selected fromgroup consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31,L32, L50, L91, L92, L93, L94.

c) individually mutating the selected preferred selective mutagenesisposition to at least two other amino acid residues to hereby create afirst panel of mutated antibodies, or antigen binding portions thereof;

d) evaluating the activity of the first panel of mutated antibodies, orantigen binding portions thereof to determined if mutation of a singleselective mutagenesis position produces an antibody or antigen bindingportion thereof with the predetermined target activity or a partialtarget activity;

e) combining in a stepwise fashion, in the parent antibody, or antigenbinding portion thereof, individual mutations shown to have an improvedactivity, to form combination antibodies, or antigen binding portionsthereof.

f) evaluating the activity of the combination antibodies, or antigenbinding portions thereof to determined if the combination antibodies, orantigen binding portions thereof have the predetermined target activityor a partial target activity.

g) if steps d) or f) do not result in an antibody or antigen bindingportion thereof having the predetermined target activity, or result anantibody with only a partial activity, additional amino acid residuesselected from the group consisting of H35, H50, H53, H54, H95, H96, H97,H98, L30A and L96 are mutated to at least two other amino acid residuesto thereby create a second panel of mutated antibodies orantigen-binding portions thereof;

h) evaluating the activity of the second panel of mutated antibodies orantigen binding portions thereof, to determined if mutation of a singleamino acid residue selected from the group consisting of H35, H50, H53,H54, H95, H96, H97, H98, L30A and L96 results an antibody or antigenbinding portion thereof, having the predetermined target activity or apartial activity;

i) combining in stepwise fashion in the parent antibody, orantigen-binding portion thereof, individual mutations of step g) shownto have an improved activity, to form combination antibodies, or antigenbinding portions thereof;

j) evaluating the activity of the combination antibodies or antigenbinding portions thereof, to determined if the combination antibodies,or antigen binding portions thereof have the predetermined targetactivity or a partial target activity;

k) if steps h) or j) do not result in an antibody or antigen bindingportion thereof having the predetermined target activity, or result inan antibody with only a partial activity, additional amino acid residuesselected from the group consisting of H33B, H52B and L31A are mutated toat least two other amino acid residues to thereby create a third panelof mutated antibodies or antigen binding portions thereof;

l) evaluating the activity of the third panel of mutated antibodies orantigen binding portions thereof, to determine if a mutation of a singleamino acid residue selected from the group consisting of H33B, H52B andL31A resulted in an antibody or antigen binding portion thereof, havingthe predetermined target activity or a partial activity;

m) combining in a stepwise fashion in the parent antibody, or antigenbinding portion thereof, individual mutation of step k) shown to have animproved activity, to form combination antibodies, or antigen bindingportions, thereof;

n) evaluating the activity of the combination antibodies orantigen-binding portions thereof, to determine if the combinationantibodies, or antigen binding portions thereof have the predeterminedtarget activity to thereby produce an antibody or antigen bindingportion thereof with a predetermined target activity.

A number of mutagenesis methods can be used, including PCR assembly,Kunkel (dut-ung-) and thiophosphate (Amersham Sculptor kit)oligonucleotide-directed mutagenesis.

A wide variety of host expression systems can be used to express themutated antibodies, including bacterial, yeast, baculoviral andmammalian expression systems (as well as phage display expressionsystems). An example of a suitable bacterial expression vector ispUC119(Sfi). Other antibody expression systems are known in the artand/or are described below in section IV.

The modified antibodies, or antigen binding portions thereof, producedby the method of the invention can be identified without the reliance onphage display methods for selection. Accordingly, the method of theinvention is particularly advantageous for improving the activity of arecombinant parent antibody or antigen-binding portion thereof, that wasobtained by selection in a phage-display system but whose activitycannot be further improved by mutagenesis in the phage-display system.

Accordingly, in another embodiment, the invention provides a method forimproving the affinity of an antibody, or antigen-binding portionthereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof; that was obtained by selection in a phage-display system butwhose activity cannot be further improved by mutagenesis in saidphage-display system;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation, thereby identifying a selected contact or hypermutationposition;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof, and expressing said panel in anon-phage display system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof;

e) optionally repeating steps b) through d) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

f) combining, in the parent antibody, or antigen-binding portionthereof, individual mutations shown to have improved activity, to formcombination antibodies, or antigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof; until an antibody, or antigen-bindingportion thereof, with an improved activity, relative to the parentantibody, or antigen-binding portion thereof, is obtained.

Preferred contact positions are selected from the group consisting ofH30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95,H96, H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92,L93, L94 and L96. Preferred hypermutation positions are selected fromthe group consisting of H30, H31, H31B, H32, H52, H56, H58, L30, L31,L32, L53 and L93. More preferred preferred selective mutagenesispositions are selected from the group consisting of H30, H31, H31B, H32,H33, H52, H56, H58, L30, L31, L32, L50, L91, L92, L93 and L94.Particularly preferred contact positions are selected from the groupconsisting of L50 and L94.

With available methods it is not possible or it is extremely laboriousto derive an antibody with increased binding affinity and neutralizationpotency while retaining other properties or characteristics of theantibodies as discussed above. The method of this invention, however,can readily identify such antibodies. The antibodies subjected to themethod of this invention can come from any source.

Therefore, in another embodiment, the invention provides a method forimproving the activity of an antibody, or antigen-binding portionthereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation, thereby identifying a selected preferred selectivemutagenesis position, contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof and expressing said panel in anappropriate expression system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof for at least one other property or characteristics,wherein the property or characteristic is one that needs to be retainedin the antibody;

until an antibody, or antigen-binding portion thereof, with an improvedactivity and at least one retained property or characteristic, relativeto the parent antibody, or antigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from thegroup consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53,H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52,L53, L55, L91, L92, L93, L94 and L96 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another preferred embodiment, the hypermutation positions areselected from the group consisting of H30, H31, H31B, H32, H52, H56,H58, L30, L31, L32, L53 and L93 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesisare selected from the preferred selective mutagenesis positions from thegroup consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31,L32, L50, L91, L92, L93, L94 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected fromthe group consisting of L50 and L94 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

If therefore, the affinity of an antibody for a specific antigen shouldbe improved, but where the phage display (or related system includingribosome display) method is no longer applicable, and other desirableproperties or characteristics should be retained, the method of theinvention can be used. Accordingly, in another embodiment, the inventionprovides a method for improving the activity of an antibody, orantigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof; that was obtained by selection in a phage-display system butwhose activity cannot be further improved by mutagenesis in saidphage-display system;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation, thereby identifying a selected preferred selectivemutagenesis position, contact or hypermutation position;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof, and expressing said panel in anon-phage display system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof for at least one other property or characteristic,wherein the property or characteristic is one that needs to be retained,until an antibody, or antigen-binding portion thereof, with an improvedactivity and at least one retained property or characteristic, relativeto the parent antibody, or antigen-binding portion thereof, is obtained.

f) optionally, repeating steps a) through e) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

g) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity and at least one retained property orcharacteristic, to form combination antibodies, or antigen-bindingportions thereof; and

h) evaluating the activity of the combination antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof; until an antibody, or antigen-bindingportion thereof, with an improved activity and at least one retainedother property or characteristic, relative to the parent antibody, orantigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from thegroup consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53,H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52,L53, L55, L91, L92, L93, L94 and L96 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another preferred embodiment, the hypermutation positions areselected from the group consisting of H30, H31, H31B, H32, H52, H56,H58, L30, L31, L32, L53 and L93 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesisare selected from the preferred selective mutagenesis positions from thegroup consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31,L32, L50, L91, L92, L93, L94 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected fromthe group consisting of L50 and L94 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another embodiment, the invention provides a method for improving theactivity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof; that was obtained by selection in a phage-display system butwhose activity cannot be further improved by mutagenesis in saidphage-display system;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation, thereby identifying a selected contact or hypermutationposition;

c) individually mutating said selected preferred selective mutagenesisposition, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof, and expressing said panel in anon-phage display system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof for at least one other property or characteristic,wherein the property or characteristic is one that needs to be retained,until an antibody, or antigen-binding portion thereof, with an improvedactivity and at least one retained property or characteristic, relativeto the parent antibody, or antigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from thegroup consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53,H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52,L53, L55, L91, L92, L93, L94 and L96 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another preferred embodiment, the hypermutation positions areselected from the group consisting of H30, H31, H31B, H32, H52, H56,H58, L30, L31, L32, L53 and L93 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesisare selected from the preferred selective mutagenesis positions from thegroup consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31,L32, L50, L91, L92, L93, L94 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected fromthe group consisting of L50 and L94 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another embodiment, the invention provides a method for improving theactivity of an antibody, or antigen-binding portion thereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof; that was obtained by selection in a phage-display system butwhose activity cannot be further improved by mutagenesis in saidphage-display system;

b) selecting a preferred selective mutagenesis position, contact orhypermutation position within a complementarity determining region (CDR)for mutation, thereby identifying a selected contact or hypermutationposition;

c) individually mutating said selected preferred selective mutagenesispositions, contact or hypermutation position to at least two other aminoacid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof, and expressing said panel in anon-phage display system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof for at least one other property or characteristic,wherein the property or characteristic is one that needs to be retained,until an antibody, or antigen-binding portion thereof, with an improvedactivity and at least one retained characteristic, relative to theparent antibody, or antigen-binding portion thereof, is obtained.

f) optionally, repeating steps a) through e) for at least one otherpreferred selective mutagenesis position, contact or hypermutationposition;

g) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity and at least on retained othercharacteristic, to form combination antibodies, or antigen-bindingportions thereof; and

h) evaluating the activity of the combination antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof; until an antibody, or antigen-bindingportion thereof, with an improved activity and at least one retainedproperty or characteristic, relative to the parent antibody, orantigen-binding portion thereof, is obtained.

In a preferred embodiment, the contact positions are selected from thegroup consisting of H30, H31, H31B, H32, H33, H35, H50, H52, H52A, H53,H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32, L34, L50, L52,L53, L55, L91, L92, L93, L94 and L96 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

In another preferred embodiment, the hypermutation positions areselected from the group consisting of H30, H31, H31B, H32, H52, H56,H58, L30, L31, L32, L53 and L93 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment the residues for selective mutagenesisare selected from the preferred selective mutagenesis positions from thegroup consisting of H30, H31, H31B, H32, H33, H52, H56, H58, L30, L31,L32, L50, L91, L92, L93, L94 and the other characteristic is selectedfrom 1) preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

In a more preferred embodiment, the contact positions are selected fromthe group consisting of L50 and L94 and the other characteristic isselected from 1) preservation of non-crossreactivity with other proteinsor human tissues, 2) preservation of epitope recognition, i.e.recognizing p40 epitope preferably in the context of the p70 p40/p35heterodimer preventing binding interference from free, soluble p40and/or 3) to produce an antibody with a close to germline immunoglobulinsequence.

IV. Modifications of Other CDR Residues

Ultimately, all CDR residues in a given antibody-antigen pair identifiedby any means to be required as activity enhancing amino acid residuesand/or required directly or indirectly for binding to the antigen and/orfor retaining other desirable properties or characteristics of theantibody. Such CDR residues are referred to as “preferred selectivemutagenesis positions”. It should be noted that in specificcircumstances that preferred selective mutagenesis residues can beidentified also by other means including co-crystallization of antibodyand antigen and molecular modeling.

If the preferred attempts to identify activity enhancing amino acidsfocussing on the preferred selective mutagenesis positions, contact orhypermutation positions described above are exhausted, or if additionalimprovements are required, the remaining CDR residues may be modified asdescribed below. It should be understood that the antibody could alreadybe modified in any one or more contact or hypermutation positionsaccording to the embodiments discussed above but may require furtherimprovements. Therefore, in another embodiment, the invention provides amethod for improving the activity of an antibody, or antigen-bindingportion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position e.g., to at least twoother amino acid residues to thereby create a mutated antibody or apanel of mutated antibodies, or antigen-binding portions thereof;

d) evaluating the activity of the mutated antibody or the panel ofmutated antibodies, or antigen-binding portions thereof, relative to theparent antibody or antigen-binding portion thereof thereby identifyingan activity enhancing amino acid residue;

e) evaluating the mutated antibody or the panel of mutated antibodies,or antigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, for changes in at least one otherproperty or characteristic until an antibody, or antigen-binding portionthereof, with an improved activity, relative to the parent antibody, orantigen-binding portion thereof, is obtained.

Preferably, the other characteristic or property is selected from 1)preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence

If mutagenesis of a single residue is not sufficient other residues canbe included; therefore, in another embodiment, the invention provides amethod for improving the activity of an antibody, or antigen-bindingportion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, thereby identifying an activityenhancing amino acid residue;

e) repeating steps b) through d) for at least one other CDR positionwhich is neither the position selected under b) nor a position at H30,H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96,H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93,L94 and L96;

f) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity, to form combination antibodies, orantigen-binding portions thereof; and

g) evaluating the activity of the combination antibodies, orantigen-binding portions thereof with two activity enhancing amino acidresidues, relative to the parent antibody or antigen-binding portionthereof until an antibody, or antigen-binding portion thereof, with animproved activity, relative to the parent antibody, or antigen-bindingportion thereof, is obtained.

If the preferred attempts to identify activity enhancing amino acidsfocussing on the contact or hypermutation positions described above areexhausted, or if additional improvements are required, and the antibodyin question can not further be optimized by mutagenesis and phagedisplay (or related ribosome display) methods the remaining CDR residuesmay be modified as described below. It should be understood that theantibody could already be modified in any one or more preferredselective mutagenesis position, contact or hypermutation positionsaccording to the embodiments discussed above but may require furtherimprovements.

Therefore, in another embodiment, the invention provides a method forimproving the activity of an antibody, or antigen-binding portionthereof, comprising:

a) providing a recombinant parent antibody or antigen-binding portionthereof; that was obtained by selection in a phage-display system butwhose activity cannot be further improved by mutagenesis in saidphage-display system;

b) selecting a selecting an amino acid residue within a complementaritydetermining region (CDR) for mutation other than H30, H31, H31B, H32,H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101,L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94 and;

c) individually mutating said selected contact or hypermutation positionto at least two other amino acid residues to thereby create a panel ofmutated antibodies, or antigen-binding portions thereof, and expressingsaid panel in a non-phage display system;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof, for changes in at least one other property orcharacteristic, until an antibody, or antigen-binding portion thereof,with an improved activity, relative to the parent antibody, orantigen-binding portion thereof, is obtained.

Preferably, the other characteristic or property is selected from 1)preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence.

If a single mutagenesis is not sufficient to increase the affinity ofthe antibody other residues may be included in the mutagenesis.Therefore, in another embodiment, the invention provides a method forimproving the activity of an antibody, or antigen-binding portionthereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof thatwas obtained by selection in a phage-display system but whose activitycannot be further improved by mutagenesis in said phage-display system;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof and expression in a non-phage displaysystem;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) repeating steps b) through d) for at least one other position whichis neither the position selected under b) nor a position at H30, H31,H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96, H97,H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93, L94;

g) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity, to form combination antibodies, orantigen-binding portions thereof; and

h) evaluating the activity and other property or characteristic of thecombination antibodies, or antigen-binding portions thereof with twoactivity enhancing amino acid residues, relative to the parent antibodyor antigen-binding portion thereof; until an antibody, orantigen-binding portion thereof, with an improved activity, relative tothe parent antibody, or antigen-binding portion thereof, is obtained.

Preferably, the other characteristic or property is selected from 1)preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence

The preferred attempts to identify activity enhancing amino acidsfocussing on the preferred selective mutagenesis positions, contact orhypermutation positions described may be exhausted, or additionalimprovements may be required, and it is important to retain otherproperties or characteristics of the antibody.

Therefore, in another embodiment, the invention provides a method forimproving the activity of an antibody, or antigen-binding portionthereof, without affecting other characteristics, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof, for changes in at least one other property orcharacteristic until an antibody, or antigen-binding portion thereof,with an improved activity and retained other property or characteristic,relative to the parent antibody, or antigen-binding portion thereof, isobtained.

Preferably, the other characteristic or property is selected from 1)preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence

If mutagenesis of a single residue is not sufficient other residues canbe included; therefore, in another embodiment, the invention provides amethod for improving the activity of an antibody, or antigen-bindingportion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof, thereby identifying an activityenhancing amino acid residue;

e.) evaluating the panel of mutated antibodies or antigen-bindingportions thereof, relative to the parent antibody or antigen-portionthereof, for changes in at least one other characteristic or property;

e) repeating steps b) through e) for at least one other CDR positionwhich is neither the position selected under b) nor a position at H30,H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96,H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93,L94 and L96;

f) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity and not affecting at least one otherproperty or characteristic, to form combination antibodies, orantigen-binding portions thereof; and

g) evaluating the activity and the retention of at least one otherproperty or characteristic of the combination antibodies, orantigen-binding portions thereof with two activity enhancing amino acidresidues, relative to the parent antibody or antigen-binding portionthereof until an antibody, or antigen-binding portion thereof, with animproved activity and at least one retained other property orcharacteristic, relative to the parent antibody, or antigen-bindingportion thereof, is obtained.

Mutagenesis of the preferred selective mutagenesis position, contact andhypermutation residues may not have increased the affinity of theantibody sufficiently, and mutagenesis and the phage display method (orrelated ribosome display method) may no longer be useful and at leastone other characteristic or property of the antibody should be retained.

Therefore, in another embodiment the invention provides a method toimprove the affinity of an antibody or antigen-binding portion thereof,comprising:

a) providing a parent antibody or antigen-binding portion thereof thatwas obtained by selection in a phage-display system but whose activitycannot be further improved by mutagenesis in said phage-display system;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof and expression in a non-phage displaysystem;

d) evaluating the activity of the panel of mutated antibodies, orantigen-binding portions thereof, relative to the parent antibody orantigen-binding portion thereof thereby identifying an activityenhancing amino acid residue;

e) evaluating the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof, for changes in at least one other property orcharacteristic until an antibody, or antigen-binding portion thereof,with an improved activity, relative to the parent antibody, orantigen-binding portion thereof, is obtained.

Preferably, the other characteristic or property is selected from 1)preservation of non-crossreactivity with other proteins or humantissues, 2) preservation of epitope recognition, i.e. recognizing p40epitope preferably in the context of the p70 p40/p35 heterodimerpreventing binding interference from free, soluble p40 and/or 3) toproduce an antibody with a close to germline immunoglobulin sequence

If mutagenesis of a single residue is not sufficient other residues canbe included; therefore, in another embodiment, the invention provides amethod for improving the activity of an antibody, or antigen-bindingportion thereof, comprising:

a) providing a parent antibody or antigen-binding portion thereof thatwas obtained by selection in a phage-display system but whose activitycannot be further improved by mutagenesis in said phage-display system;

b) selecting an amino acid residue within a complementarity determiningregion (CDR) for mutation other than H30, H31, H31B, H32, H33, H35, H50,H52, H52A, H53, H54, H56, H58, H95, H96, H97, H98, H101, L30, L31, L32,L34, L50, L52, L53, L55, L91, L92, L93, L94 and L96;

c) individually mutating said selected position to at least two otheramino acid residues to thereby create a panel of mutated antibodies, orantigen-binding portions thereof and expression in a non-phage displaysystem;

d) evaluating the activity and retention of at least one other propertyor characteristic of the panel of mutated antibodies, or antigen-bindingportions thereof, relative to the parent antibody or antigen-bindingportion thereof, thereby identifying an activity enhancing amino acidresidue;

e) repeating steps b) through d) for at least one other CDR positionwhich is neither the position selected under b) nor a position at H30,H31, H31B, H32, H33, H35, H50, H52, H52A, H53, H54, H56, H58, H95, H96,H97, H98, H101, L30, L31, L32, L34, L50, L52, L53, L55, L91, L92, L93,L94 and L96;

f) combining, in the parent antibody, or antigen-binding portionthereof, at least two individual activity enhancing amino acid residuesshown to have improved activity and not to affect at least one otherproperty or characteristic, to form combination antibodies, orantigen-binding portions thereof; and

g) evaluating the activity and retention of at least one property orcharacteristic of the combination antibodies, or antigen-bindingportions thereof with two activity enhancing amino acid residues,relative to the parent antibody or antigen-binding portion thereof untilan antibody, or antigen-binding portion thereof, with an improvedactivity and at least one other retained characteristic or property,relative to the parent antibody, or antigen-binding portion thereof, isobtained.

V. Expression of Antibodies

An antibody, or antibody portion, of the invention can be prepared byrecombinant expression of immunoglobulin light and heavy chain genes ina host cell. To express an antibody recombinantly, a host cell istransfected with one or more recombinant expression vectors carrying DNAfragments encoding the immunoglobulin light and heavy chains of theantibody such that the light and heavy chains are expressed in the hostcell and, preferably, secreted into the medium in which the host cellsare cultured, from which medium the antibodies can be recovered.Standard recombinant DNA methodologies are used to obtain antibody heavyand light chain genes, incorporate these genes into recombinantexpression vectors and introduce the vectors into host cells, such asthose described in Sambrook, Fritsch and Maniatis (eds), MolecularCloning; A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y.,(1989), Ausubel, F. M. et al. (eds.) Current Protocols in MolecularBiology, Greene Publishing Associates, (1989) and in U.S. Pat. No.4,816,397 by Boss et al.

To obtain a DNA fragment encoding the heavy chain variable region of Joe9 wt or a Joe 9 wt-related antibody, antibodies specific for human IL-12were screened from human libraries and mutated, as described in sectionII. Once DNA fragments encoding Joe 9 wt or Joe 9 wt-related VH and VLsegments are obtained, mutagenesis of these sequences is carried out bystandard methods, such as PCR site directed mutagenesis (PCR-mediatedmutagenesis in which the mutated nucleotides are incorporated into thePCR primers such that the PCR product contains the mutations) or othersite-directed mutagenesis methods. Human IL-12 antibodies that displayeda level of activity and binding specificity/affinity that was desirable,for example J695, were further manipulated by standard recombinant DNAtechniques, for example to convert the variable region genes tofull-length antibody chain genes, to Fab fragment genes or to a scFvgene. In these manipulations, a VL- or VH-encoding DNA fragment isoperatively linked to another DNA fragment encoding another protein,such as an antibody constant region or a flexible linker. The term“operatively linked”, as used in this context, is intended to mean thatthe two DNA fragments are joined such that the amino acid sequencesencoded by the two DNA fragments remain in-frame.

The isolated DNA encoding the VH region can be converted to afull-length heavy chain gene by operatively linking the VH-encoding DNAto another DNA molecule encoding heavy chain constant regions (CH1, CH2and CH3). The sequences of human heavy chain constant region genes areknown in the art (see e.g., Kabat, E. A., et al. (1991) Sequences ofProteins of Immunological Interest, Fifth Edition, U.S. Department ofHealth and Human Services, NIH Publication No. 91-3242) and DNAfragments encompassing these regions can be obtained by standard PCRamplification. The heavy chain constant region can be an IgG1, IgG2,IgG3, IgG4, IgA, IgE, IgM or IgD constant region and any allotypicvariant therein as described in Kabat (, Kabat, E. A., et al. (1991)Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.Department of Health and Human Services, NIH Publication No. 91-3242),but most preferably is an IgG1 or IgG4 constant region. For a Fabfragment heavy chain gene, the VH-encoding DNA can be operatively linkedto another DNA molecule encoding only the heavy chain CH1 constantregion.

The isolated DNA encoding the VL region can be converted to afull-length light chain gene (as well as a Fab light chain gene) byoperatively linking the VL-encoding DNA to another DNA molecule encodingthe light chain constant region, CL. The sequences of human light chainconstant region genes are known in the art (see e.g., Kabat, E. A., etal. (1991) Sequences of Proteins of Immunological Interest, FifthEdition, U.S. Department of Health and Human Services, NIH PublicationNo. 91-3242) and DNA fragments encompassing these regions can beobtained by standard PCR amplification. The light chain constant regioncan be a kappa or lambda constant region, but most preferably is alambda constant region.

To create a scFv gene, the VH- and VL-encoding DNA fragments areoperatively linked to another fragment encoding a flexible linker, e.g.,encoding the amino acid sequence (Gly₄-Ser)₃, such that the VH and VLsequences can be expressed as a contiguous single-chain protein, withthe VL and VH regions joined by the flexible linker (see e.g., Bird etal. (1988) Science 242:423-426; Huston et al. (1988) Proc. Natl. Acad.Sci. USA 85:5879-5883; McCafferty et al., Nature (1990) 348:552-554).

To express the antibodies, or antibody portions of the invention, DNAsencoding partial or full-length light and heavy chains, obtained asdescribed above, are inserted into expression vectors such that thegenes are operatively linked to transcriptional and translationalcontrol sequences. In this context, the term “operatively linked” isintended to mean that an antibody gene is ligated into a vector suchthat transcriptional and translational control sequences within thevector serve their intended function of regulating the transcription andtranslation of the antibody gene. The expression vector and expressioncontrol sequences are chosen to be compatible with the expression hostcell used. The antibody light chain gene and the antibody heavy chaingene can be inserted into separate vector or, more typically, both genesare inserted into the same expression vector. The antibody genes areinserted into the expression vector by standard methods (e.g., ligationof complementary restriction sites on the antibody gene fragment andvector, or blunt end ligation if no restriction sites are present).Prior to insertion of the J695 or J695-related light or heavy chainsequences, the expression vector may already carry antibody constantregion sequences. For example, one approach to converting the J695 orJ695-related VH and VL sequences to full-length antibody genes is toinsert them into expression vectors already encoding heavy chainconstant and light chain constant regions, respectively, such that theVH segment is operatively linked to the CH segment(s) within the vectorand the VL segment is operatively linked to the CL segment within thevector. Additionally or alternatively, the recombinant expression vectorcan encode a signal peptide that facilitates secretion of the antibodychain from a host cell. The antibody chain gene can be cloned into thevector such that the signal peptide is linked in-frame to the aminoterminus of the antibody chain gene. The signal peptide can be animmunoglobulin signal peptide or a heterologous signal peptide (i.e., asignal peptide from a non-immunoglobulin protein).

In addition to the antibody chain genes, the recombinant expressionvectors of the invention carry regulatory sequences that control theexpression of the antibody chain genes in a host cell. The term“regulatory sequence” is intended to include promoters, enhancers andother expression control elements (e.g., polyadenylation signals) thatcontrol the transcription or translation of the antibody chain genes.Such regulatory sequences are described, for example, in Goeddel; GeneExpression Technology: Methods in Enzymology 185, Academic Press, SanDiego, Calif. (1990). It will be appreciated by those skilled in the artthat the design of the expression vector, including the selection ofregulatory sequences may depend on such factors as the choice of thehost cell to be transformed, the level of expression of protein desired,etc. Preferred regulatory sequences for mammalian host cell expressioninclude viral elements that direct high levels of protein expression inmammalian cells, such as promoters and/or enhancers derived fromcytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., theadenovirus major late promoter (AdMLP)) and polyoma. For furtherdescription of viral regulatory elements, and sequences thereof, seee.g., U.S. Pat. No. 5,168,062 by Stinski, U.S. Pat. No. 4,510,245 byBell et al. and U.S. Pat. No. 4,968,615 by Schaffner et al., U.S. Pat.No. 5,464,758 by Bujard et al. and U.S. Pat. No. 5,654,168 by Bujard etal.

In addition to the antibody chain genes and regulatory sequences, therecombinant expression vectors of the invention may carry additionalsequences, such as sequences that regulate replication of the vector inhost cells (e.g., origins of replication) and selectable marker genes.The selectable marker gene facilitates selection of host cells intowhich the vector has been introduced (see e.g., U.S. Pat. Nos.4,399,216, 4,634,665 and 5,179,017, all by Axel et al.). For example,typically the selectable marker gene confers resistance to drugs, suchas G418, hygromycin or methotrexate, on a host cell into which thevector has been introduced. Preferred selectable marker genes includethe dihydrofolate reductase (DHFR) gene (for use in dhfr⁻ host cellswith methotrexate selection/amplification) and the neo gene (for G418selection).

For expression of the light and heavy chains, the expression vector(s)encoding the heavy and light chains is transfected into a host cell bystandard techniques. The various forms of the term “transfection” areintended to encompass a wide variety of techniques commonly used for theintroduction of exogenous DNA into a prokaryotic or eukaryotic hostcell, e.g., electroporation, calcium-phosphate precipitation,DEAE-dextran transfection and the like. Although it is theoreticallypossible to express the antibodies of the invention in eitherprokaryotic or eukaryotic host cells, expression of antibodies ineukaryotic cells, and most preferably mammalian host cells, is the mostpreferred because such eukaryotic cells, and in particular mammaliancells, are more likely than prokaryotic cells to assemble and secrete aproperly folded and immunologically active antibody. Preferred mammalianhost cells for expressing the recombinant antibodies of the inventioninclude Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells,described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA77:4216-4220, used with a DHFR selectable marker, e.g., as described inR. J. Kaufman and P. A. Sharp (1982) Mol. Biol. 159:601-621), NS0myeloma cells, COS cells and SP2 cells. When recombinant expressionvectors encoding antibody genes are introduced into mammalian hostcells, the antibodies are produced by culturing the host cells for aperiod of time sufficient to allow for expression of the antibody in thehost cells or, more preferably, secretion of the antibody into theculture medium in which the host cells are grown. Antibodies can berecovered from the culture medium using standard protein purificationmethods.

Host cells can also be used to produce portions of intact antibodies,such as Fab fragments or scFv molecules. It will be understood thatvariations on the above procedure are within the scope of the presentinvention. For example, it may be desirable to transfect a host cellwith DNA encoding either the light chain or the heavy chain (but notboth) of an antibody of this invention. Recombinant DNA technology mayalso be used to remove some or all of the DNA encoding either or both ofthe light and heavy chains that is not necessary for binding to hIL-12The molecules expressed from such truncated DNA molecules are alsoencompassed by the antibodies of the invention. In addition,bifunctional antibodies may be produced in which one heavy and one lightchain are an antibody of the invention and the other heavy and lightchain are specific for an antigen other than hIL-12 by crosslinking anantibody of the invention to a second antibody by standard chemicalcrosslinking methods.

In a preferred system for recombinant expression of an antibody, orantigen-binding portion thereof, of the invention, a recombinantexpression vector encoding both the antibody heavy chain and theantibody light chain is introduced into dhfr-CHO cells by calciumphosphate-mediated transfection. Within the recombinant expressionvector, the antibody heavy and light chain genes are each operativelylinked to enhancer/promoter regulatory elements (e.g., derived fromSV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLPpromoter regulatory element or an SV40 enhancer/AdMLP promoterregulatory element) to drive high levels of transcription of the genes.The recombinant expression vector also carries a DHFR gene, which allowsfor selection of CHO cells that have been transfected with the vectorusing methotrexate selection/amplification. The selected transformanthost cells are culture to allow for expression of the antibody heavy andlight chains and intact antibody is recovered from the culture medium.Standard molecular biology techniques are used to prepare therecombinant expression vector, transfect the host cells, select fortransformants, culture the host cells and recover the antibody from theculture medium. Antibodies or antigen-binding portions thereof of theinvention can be expressed in an animal (e.g., a mouse) that istransgenic for human immunoglobulin genes (see e.g., Taylor, L. D. etal. (1992) Nucl. Acids Res. 20: 6287-6295). Plant cells can also bemodified to create transgenic plants that express the antibody orantigen binding portion thereof, of the invention.

In view of the foregoing, another aspect of the invention pertains tonucleic acid, vector and host cell compositions that can be used forrecombinant expression of the antibodies and antibody portions of theinvention. Preferably, the invention features isolated nucleic acidsthat encode CDRs of J695, or the full heavy and/or light chain variableregion of J695. Accordingly, in one embodiment, the invention featuresan isolated nucleic acid encoding an antibody heavy chain variableregion that encodes the J695 heavy chain CDR3 comprising the amino acidsequence of SEQ ID NO: 25. Preferably, the nucleic acid encoding theantibody heavy chain variable region further encodes a J695 heavy chainCDR2 which comprises the amino acid sequence of SEQ ID NO: 27. Morepreferably, the nucleic acid encoding the antibody heavy chain variableregion further encodes a J695 heavy chain CDR1 which comprises the aminoacid sequence of SEQ ID NO: 29. Even more preferably, the isolatednucleic acid encodes an antibody heavy chain variable region comprisingthe amino acid sequence of SEQ ID NO: 31 (the full VH region of J695).

In other embodiments, the invention features an isolated nucleic acidencoding an antibody light chain variable region that encodes the J695light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.Preferably, the nucleic acid encoding the antibody light chain variableregion further encodes a J695 light chain CDR2 which comprises the aminoacid sequence of SEQ ID NO: 28. More preferably, the nucleic acidencoding the antibody light chain variable region further encodes a J695light chain CDR1 which comprises the amino acid sequence of SEQ ID NO:30. Even more preferably, the isolated nucleic acid encodes an antibodylight chain variable region comprising the amino acid sequence of SEQ IDNO: 32 (the full VL region of J695).

The invention also provides recombinant expression vectors encoding bothan antibody heavy chain and an antibody light chain. For example, in oneembodiment, the invention provides a recombinant expression vectorencoding:

-   -   a) an antibody heavy chain having a variable region comprising        the amino acid sequence of SEQ ID NO: 31; and    -   b) an antibody light chain having a variable region comprising        the amino acid sequence of SEQ ID NO: 32.

The invention also provides host cells into which one or more of therecombinant expression vectors of the invention have been introduced.Preferably, the host cell is a mammalian host cell, more preferably thehost cell is a CHO cell, an NS0 cell or a COS cell. Still further theinvention provides a method of synthesizing a recombinant human antibodyof the invention by culturing a host cell of the invention in a suitableculture medium until a recombinant human antibody of the invention issynthesized. The method can further comprise isolating the recombinanthuman antibody from the culture medium.

VI. Pharmaceutical Compositions and Pharmaceutical Administration

The antibodies and antibody-portions of the invention can beincorporated into pharmaceutical compositions suitable foradministration to a subject. Typically, the pharmaceutical compositioncomprises an antibody or antibody portion of the invention and apharmaceutically acceptable carrier. As used herein, “pharmaceuticallyacceptable carrier” includes any and all solvents, dispersion media,coatings, antibacterial and antifungal agents, isotonic and absorptiondelaying agents, and the like that are physiologically compatible.Examples of pharmaceutically acceptable carriers include one or more ofwater, saline, phosphate buffered saline, dextrose, glycerol, ethanoland the like, as well as combinations thereof. In many cases, it will bepreferable to include isotonic agents, for example, sugars, polyalcoholssuch as mannitol, sorbitol, or sodium chloride in the composition.Pharmaceutically acceptable carriers may further comprise minor amountsof auxiliary substances such as wetting or emulsifying agents,preservatives or buffers, which enhance the shelf life or effectivenessof the antibody or antibody portion.

The antibodies and antibody-portions of the invention can beincorporated into a pharmaceutical composition suitable for parenteraladministration. Preferably, the antibody or antibody-portions will beprepared as an injectable solution containing 0.1-250 mg/ml antibody.The injectable solution can be composed of either a liquid orlyophilized dosage form in a flint or amber vial, ampule or pre-filledsyringe. The buffer can be L-histidine (1-50 mM), optimally 5-10 mM, atpH 5.0 to 7.0 (optimally pH 6.0). Other suitable buffers include but arenot limited to, sodium succinate, sodium citrate, sodium phosphate orpotassium phosphate. Sodium chloride can be used to modify the toxicityof the solution at a concentration of 0-300 mM (optimally 150 mM for aliquid dosage form). Cryoprotectants can be included for a lyophilizeddosage form, principally 0-10% sucrose (optimally 0.5-1.0%). Othersuitable cryoprotectants include trehalose and lactose. Bulking agentscan be included for a lyophilized dosage form, principally 1-10%mannitol (optimally 2-4%). Stabilizers can be used in both liquid andlyophilized dosage forms, principally 1-50 mM L-Methionine (optimally5-10 mM). Other suitable bulking agents include glycine, arginine, canbe included as 0-0.05% polysorbate-80 (optimally 0.005-0.01%).Additional surfactants include but are not limited to polysorbate 20 andBRIJ surfactants.

In a preferred embodiment, the pharmaceutical composition includes theantibody at a dosage of about 100 mg-200 mg dose.

The compositions of this invention may be in a variety of forms. Theseinclude, for example, liquid, semi-solid and solid dosage forms, such asliquid solutions (e.g., injectable and infusible solutions), dispersionsor suspensions, tablets, pills, powders, liposomes and suppositories.The preferred form depends on the intended mode of administration andtherapeutic application. Typical preferred compositions are in the formof injectable or infusible solutions, such as compositions similar tothose used for passive immunization of humans with other antibodies. Thepreferred mode of administration is parenteral (e.g., intravenous,subcutaneous, intraperitoneal, intramuscular). In a preferredembodiment, the antibody is administered by subcutaneous injection.

Therapeutic compositions typically must be sterile and stable under theconditions of manufacture and storage. The composition can be formulatedas a solution, microemulsion, dispersion, liposome, or other orderedstructure suitable to high drug concentration. Sterile injectablesolutions can be prepared by incorporating the active compound (i.e.,antibody or antibody portion) in the required amount in an appropriatesolvent with one or a combination of ingredients enumerated above, asrequired, followed by filtered sterilization. Generally, dispersions areprepared by incorporating the active compound into a sterile vehiclethat contains a basic dispersion medium and the required otheringredients from those enumerated above. In the case of sterile,lyophilized powders for the preparation of sterile injectable solutions,the preferred methods of preparation are vacuum drying and spray-dryingthat yields a powder of the active ingredient plus any additionaldesired ingredient from a previously sterile-filtered solution thereof.The proper fluidity of a solution can be maintained, for example, by theuse of a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prolonged absorption of injectable compositions can be brought about byincluding in the composition an agent that delays absorption, forexample, monostearate salts and gelatin.

The antibodies and antibody-portions of the present invention can beadministered by a variety of methods known in the art, although for manytherapeutic applications, the preferred route/mode of administration issubcutaneous injection, intravenous injection or infusion. As will beappreciated by the skilled artisan, the route and/or mode ofadministration will vary depending upon the desired results. In certainembodiments, the active compound may be prepared with a carrier thatwill protect the compound against rapid release, such as a controlledrelease formulation, including implants, transdermal patches, andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Manymethods for the preparation of such formulations are patented orgenerally known to those skilled in the art. See, e.g., Sustained andControlled Release Drug Delivery Systems, J. R. Robinson, ed., MarcelDekker, Inc., New York, 1978.

In certain embodiments, an antibody or antibody portion of the inventionmay be orally administered, for example, with an inert diluent or anassimilable edible carrier. The compound (and other ingredients, ifdesired) may also be enclosed in a hard or soft shell gelatin capsule,compressed into tablets, or incorporated directly into the subject'sdiet. For oral therapeutic administration, the compounds may beincorporated with excipients and used in the form of ingestible tablets,buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers,and the like. To administer a compound of the invention by other thanparenteral administration, it may be necessary to coat the compoundwith, or co-administer the compound with, a material to prevent itsinactivation.

Supplementary active compounds can also be incorporated into thecompositions. In certain embodiments, an antibody or antibody portion ofthe invention is coformulated with and/or coadministered with one ormore additional therapeutic agents that are useful for treatingdisorders in which IL-12 activity is detrimental. For example, ananti-hIL-12 antibody or antibody portion of the invention may becoformulated and/or coadministered with one or more additionalantibodies that bind other targets (e.g., antibodies that bind othercytokines or that bind cell surface molecules). Furthermore, one or moreantibodies of the invention may be used in combination with two or moreof the foregoing therapeutic agents. Such combination therapies mayadvantageously utilize lower dosages of the administered therapeuticagents, thus avoiding possible toxicities or complications associatedwith the various monotherapies. It will be appreciated by the skilledpractitioner that when the antibodies of the invention are used as partof a combination therapy, a lower dosage of antibody may be desirablethan when the antibody alone is administered to a subject (e.g., asynergistic therapeutic effect may be achieved through the use ofcombination therapy which, in turn, permits use of a lower dose of theantibody to achieve the desired therapeutic effect).

Interleukin 12 plays a critical role in the pathology associated with avariety of diseases involving immune and inflammatory elements. Thesediseases include, but are not limited to, rheumatoid arthritis,osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriaticarthritis, reactive arthritis, spondyloarthropathy, systemic lupuserythematosus, Crohn's disease, ulcerative colitis, inflammatory boweldisease, insulin dependent diabetes mellitus, thyroiditis, asthma,allergic diseases, psoriasis, dermatitis scleroderma, atopic dermatitis,graft versus host disease, organ transplant rejection, acute or chronicimmune disease associated with organ transplantation, sarcoidosis,atherosclerosis, disseminated intravascular coagulation, Kawasaki'sdisease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome,Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopicvasculitis of the kidneys, chronic active hepatitis, uveitis, septicshock, toxic shock syndrome, sepsis syndrome, cachexia, infectiousdiseases, parasitic diseases, acquired immunodeficiency syndrome, acutetransverse myelitis, Huntington's chorea, Parkinson's disease,Alzheimer's disease, stroke, primary biliary cirrhosis, hemolyticanemia, malignancies, heart failure, myocardial infarction, Addison'sdisease, sporadic, polyglandular deficiency type I and polyglandulardeficiency type II, Schmidt's syndrome, adult (acute) respiratorydistress syndrome, alopecia, alopecia areata, seronegative arthropathy,arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative coliticarthropathy, enteropathic synovitis, chlamydia, yersinia and salmonellaassociated arthropathy, spondyloarthopathy, atheromatousdisease/arteriosclerosis, atopic allergy, autoimmune bullous disease,pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease,autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia,acquired pernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis, primary sclerosing hepatitis, cryptogenicautoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome,Acquired Immunodeficiency Related Diseases, Hepatitis C, common variedimmunodeficiency (common variable hypogammaglobulinaemia), dilatedcardiomyopathy, female infertility, ovarian failure, premature ovarianfailure, fibrotic lung disease, cryptogenic fibrosing alveolitis,post-inflammatory interstitial lung disease, interstitial pneumonitis,connective tissue disease associated interstitial lung disease, mixedconnective tissue disease associated lung disease, systemic sclerosisassociated interstitial lung disease, rheumatoid arthritis associatedinterstitial lung disease, systemic lupus erythematosus associated lungdisease, dermatomyositis/polymyositis associated lung disease, Sjögren'sdisease associated lung disease, ankylosing spondylitis associated lungdisease, vasculitic diffuse lung disease, haemosiderosis associated lungdisease, drug-induced interstitial lung disease, radiation fibrosis,bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocyticinfiltrative lung disease, postinfectious interstitial lung disease,gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis(classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis(anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type Binsulin resistance with acanthosis nigricans, hypoparathyroidism, acuteimmune disease associated with organ transplantation, chronic immunedisease associated with organ transplantation, osteoarthrosis, primarysclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia,renal disease NOS, glomerulonephritides, microscopic vasulitis of thekidneys, lyme disease, discoid lupus erythematosus, male infertilityidiopathic or NOS, sperm autoimmunity, multiple sclerosis (allsubtypes), insulin-dependent diabetes mellitus, sympathetic ophthalmia,pulmonary hypertension secondary to connective tissue disease,Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa,acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia,idiopathic thrombocytopenia, autoimmune thyroid disease,hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto'sdisease), atrophic autoimmune hypothyroidism, primary myxoedema,phacogenic uveitis, primary vasculitis and vitiligo. The humanantibodies, and antibody portions of the invention can be used to treatautoimmune diseases, in particular those associated with inflammation,including, rheumatoid spondylitis, allergy, autoimmune diabetes,autoimmune uveitis.

Preferably, the antibodies of the invention or antigen-binding portionsthereof, are used to treat rheumatoid arthritis, Crohn's disease,multiple sclerosis, insulin dependent diabetes mellitus and psoriasis,as described in more detail in section VII.

A human antibody, or antibody portion, of the invention also can beadministered with one or more additional therapeutic agents useful inthe treatment of autoimmune and inflammatory diseases.

Antibodies of the invention, or antigen binding portions thereof can beused alone or in combination to treat such diseases. It should beunderstood that the IL-12 antibodies of the invention or antigen bindingportion thereof can be used alone or in combination with an additionalagent, e.g., a therapeutic agent, said additional agent being selectedby the skilled artisan for its intended purpose. For example, theadditional agent can be a therapeutic agent art-recognized as beinguseful to treat the disease or condition being treated by the antibodyof the present invention. The additional agent also can be an agentwhich imparts a beneficial attribute to the therapeutic compositione.g., an agent which effects the viscosity of the composition.

It should further be understood that the combinations which are to beincluded within this invention are those combinations useful for theirintended purpose. The agents set forth below are illustrative forpurposes and not intended to be limited. The combinations which are partof this invention can be the antibodies of the present invention and atleast one additional agent selected from the lists below. Thecombination can also include more than one additional agent, e.g., twoor three additional agents if the combination is such that the formedcomposition can perform its intended function. Furthermore, additionalagents described herein used in combination with an IL-12 antibody, arenot limited to the disorder to which they are attributed for treatment.

Preferred combinations are non-steroidal anti-inflammatory drug(s) alsoreferred to as NSAIDS which include drugs like ibuprofen. Otherpreferred combinations are corticosteroids including prednisolone; thewell known side-effects of steroid use can be reduced or even eliminatedby tapering the steroid dose required when treating patients incombination with the anti-IL-12 antibodies of this invention.Non-limiting examples of therapeutic agents for rheumatoid arthritiswith which an antibody, or antibody portion, of the invention can becombined include the following: cytokine suppressive anti-inflammatorydrug(s) (CSAIDs); antibodies to or antagonists of other human cytokinesor growth factors, for example, TNF (including adalimumab/HUMIRA), LT,IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF,and PDGF. Antibodies of the invention, or antigen binding portionsthereof, can be combined with antibodies to cell surface molecules suchas CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1),CD86 (B7.2), CD90, or their ligands including CD154 (gp39 or CD40L).

Preferred combinations of therapeutic agents may interfere at differentpoints in the autoimmune and subsequent inflammatory cascade; preferredexamples include TNF antagonists like chimeric, humanized or human TNFantibodies, D2E7, (U.S. application Ser. No. 08/599,226 filed Feb. 9,1996), cA2 (Remicade™), CDP 571, anti-TNF antibody fragments (e.g.,CDP870), and soluble p55 or p75 TNF receptors, derivatives thereof,(p75TNFR1gG (Enbrel™) or p55TNFR1gG (Lenercept), soluble IL-13 receptor(sIL-13), and also TNFα converting enzyme (TACE) inhibitors; similarlyIL-1 inhibitors (e.g., Interleukin-1-converting enzyme inhibitors, suchas Vx740, or IL-1RA etc.) may be effective for the same reason. Otherpreferred combinations include Interleukin 11, anti-P7s and p-selectinglycoprotein ligand (PSGL). Yet another preferred combination are otherkey players of the autoimmune response which may act parallel to,dependent on or in concert with IL-12 function; especially preferred areIL-18 antagonists including IL-18 antibodies or soluble IL-18 receptors,or IL-18 binding proteins. It has been shown that IL-12 and IL-18 haveoverlapping but distinct functions and a combination of antagonists toboth may be most effective. Yet another preferred combination arenon-depleting anti-CD4 inhibitors. Yet other preferred combinationsinclude antagonists of the co-stimulatory pathway CD80 (B7.1) or CD86(B7.2) including antibodies, soluble receptors or antagonistic ligands.

Anti-IL12 antibodies, or antigen binding portions thereof, may also becombined with agents, such as methotrexate, 6-MP, azathioprinesulphasalazine, mesalazine, olsalazine chloroquinine/hydroxychloroquine,pencillamine, aurothiomalate (intramuscular and oral), azathioprine,cochicine, corticosteroids (oral, inhaled and local injection), beta-2adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines(theophylline, aminophylline), cromoglycate, nedocromil, ketotifen,ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolatemofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroidssuch as prednisolone, phosphodiesterase inhibitors, adensosine agonists,antithrombotic agents, complement inhibitors, adrenergic agents, agentswhich interfere with signalling by proinflammatory cytokines such asTNFα or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1βconverting enzyme inhibitors (e.g., Vx740), anti-P7s, p-selectinglycoprotein ligand (PSGL), TNFα converting enzyme (TACE) inhibitors,T-cell signalling inhibitors such as kinase inhibitors,metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNFreceptors and the derivatives p75TNFRIgG (Enbrel™) and p55TNFRIgG(Lenercept), sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13))and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 andTGFβ). Preferred combinations include methotrexate or leflunomide and inmoderate or severe rheumatoid arthritis cases, cyclosporine.

Non-limiting examples of therapeutic agents for inflammatory boweldisease with which an anti-IL-12 antibody, or antibody portion, can becombined include the following: budenoside; epidermal growth factor;corticosteroids; cyclosporin, sulfasalazine; aminosalicylates;6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors;mesalamine; olsalazine; balsalazide; antioxidants; thromboxaneinhibitors; IL-1 receptor antagonists; anti-IL-1β monoclonal antibodies;anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors;pyridinyl-imidazole compounds; antibodies to or antagonists of otherhuman cytokines or growth factors, for example, TNF (includingadalimumab/HUMIRA), LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16,IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, orantigen binding portions thereof, can be combined with antibodies tocell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30,CD40, CD45, CD69, CD90 or their ligands. The antibodies of theinvention, or antigen binding portions thereof, may also be combinedwith agents, such as methotrexate, cyclosporin, FK506, rapamycin,mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen,corticosteroids such as prednisolone, phosphodiesterase inhibitors,adenosine agonists, antithrombotic agents, complement inhibitors,adrenergic agents, agents which interfere with signalling byproinflammatory cytokines such as TNFα or IL-1 (e.g. IRAK, NIK, IKK, p38or MAP kinase inhibitors), IL-Iβ converting enzyme inhibitors (e.g.,Vx740), anti-P7s, p-selectin glycoprotein ligand (PSGL), TNFα convertingenzyme inhibitors, T-cell signalling inhibitors such as kinaseinhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNFreceptors, sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13))and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 andTGFβ).

Preferred examples of therapeutic agents for Crohn's disease in which anantibody or an antigen binding portion can be combined include thefollowing: TNF antagonists, for example, anti-TNF antibodies, D2E7(adalimumab/HUMIRA), cA2 (Remicade™), CDP 571, anti-TNF antibodyfragments (e.g., CDP870), TNFR-Ig constructs (p75TNFRIgG (Enbrel™) andp55TNFRIgG (Lenercept)), anti-P7s, p-selectin glycoprotein ligand(PSGL), soluble IL-13 receptor (sIL-13), and PDE4 inhibitors. Antibodiesof the invention or antigen binding portions thereof, can be combinedwith corticosteroids, for example, budenoside and dexamethasone.Antibodies may also be combined with agents such as sulfasalazine,5-aminosalicylic acid and olsalazine, and agents which interfere withsynthesis or action of proinflammatory cytokines such as IL-1, forexample, IL-Iβ converting enzyme inhibitors (e.g., Vx740) and IL-1ra.Antibodies or antigen binding portion thereof may also be used with Tcell signaling inhibitors, for example, tyrosine kinase inhibitors6-mercaptopurines. Antibodies or antigen binding portions thereof, canbe combined with IL-11.

Non-limiting examples of therapeutic agents for multiple sclerosis withwhich an antibody, or antibody portion, can be combined include thefollowing: corticosteroids; prednisolone; methylprednisolone;azathioprine; cyclophosphamide; cyclosporine; methotrexate;4-aminopyridine; tizanidine; interferon-β1a (Avonex; Biogen);interferon-β1b (Betaseron; Chiron/Berlex); Copolymer 1 (Cop-1; Copaxone;Teva Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenousimmunoglobulin; clabribine; antibodies to or antagonists of other humancytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6,IL-7, IL-8, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF.Antibodies of the invention, or antigen binding portions thereof, can becombined with antibodies to cell surface molecules such as CD2, CD3,CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or theirligands. The antibodies of the invention, or antigen binding portionsthereof, may also be combined with agents, such as methotrexate,cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide,NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone,phosphodiesterase inhibitors, adensosine agonists, antithromboticagents, complement inhibitors, adrenergic agents, agents which interferewith signalling by proinflammatory cytokines such as TNFα or IL-1 (e.g.IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1β converting enzymeinhibitors (e.g., Vx740), anti-P7s, p-selectin glycoprotein ligand(PSGL), TACE inhibitors, T-cell signalling inhibitors such as kinaseinhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNFreceptors, sIL-1RI, sIL-1RII, sIL-6R, soluble IL-13 receptor (sIL-13))and antiinflammatory cytokines (e.g. IL-4, IL-10, IL-13 and TGFβ).

Preferred examples of therapeutic agents for multiple sclerosis in whichthe antibody or antigen binding portion thereof can be combined toinclude interferon-β, for example, IFNβ1a and IFNβ1b; copaxone,corticosteroids, IL-1 inhibitors, TNF inhibitors, and antibodies to CD40ligand and CD80.

An antibody, antibody portion, may be used in combination with otheragents to treat skin conditions. For example, an antibody, antibodyportion, or other IL-12 inhibitor of the invention is combined with PUVAtherapy. PUVA is a combination of psoralen (P) and long-wave ultravioletradiation (UVA) that is used to treat many different skin conditions.The antibodies, antibody portions, or other IL-12 inhibitors of theinvention can also be combined with pimecrolimus. In another embodiment,the antibodies of the invention are used to treat psoriasis, wherein theantibodies are administered in combination with tacrolimus. In a furtherembodiment, tacrolimus and IL-12 inhibitors are administered incombination with methotrexate and/or cyclosporine. In still anotherembodiment, the IL-12 inhibitor of the invention is administered withexcimer laser treatment for treating psoriasis.

The pharmaceutical compositions of the invention may include a“therapeutically effective amount” or a “prophylactically effectiveamount” of an antibody or antibody portion of the invention. A“therapeutically effective amount” refers to an amount effective, atdosages and for periods of time necessary, to achieve the desiredtherapeutic result. A therapeutically effective amount of the antibodyor antibody portion may vary according to factors such as the diseasestate, age, sex, and weight of the individual, and the ability of theantibody or antibody portion to elicit a desired response in theindividual. A therapeutically effective amount is also one in which anytoxic or detrimental effects of the antibody or antibody portion areoutweighed by the therapeutically beneficial effects. A“prophylactically effective amount” refers to an amount effective, atdosages and for periods of time necessary, to achieve the desiredprophylactic result. Typically, since a prophylactic dose is used insubjects prior to or at an earlier stage of disease, theprophylactically effective amount will be less than the therapeuticallyeffective amount.

Dosage regimens may be adjusted to provide the optimum desired response(e.g., a therapeutic or prophylactic response). For example, a singlebolus may be administered, several divided doses may be administeredover time or the dose may be proportionally reduced or increased asindicated by the exigencies of the therapeutic situation. It isespecially advantageous to formulate parenteral compositions in dosageunit form for ease of administration and uniformity of dosage. Dosageunit form as used herein refers to physically discrete units suited asunitary dosages for the mammalian subjects to be treated; each unitcontaining a predetermined quantity of active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier. The specification for the dosage unit forms ofthe invention are dictated by and directly dependent on (a) the uniquecharacteristics of the active compound and the particular therapeutic orprophylactic effect to be achieved, and (b) the limitations inherent inthe art of compounding such an active compound for the treatment ofsensitivity in individuals.

In one embodiment, the IL-12 antibody, or antigen-binding portionthereof, is administered on a biweekly dosing regimen, including, forexample, a biweekly dosage ranging from about 50 to 300 mg, a dosageranging from about 100 mg to about 200 mg, and a dosage from about 125to about 175 mg. Alternatively, the IL-12 antibody may be administeredas a one time dose, including, for example, a dose of about 200 mg dose,a dose of about 100 mg. In another embodiment, the IL-12 antibody isadministered on a weekly dosing regimen, including, for example, a doseranging from about 50 to 300 mg, a dosage ranging from about 100 mg toabout 200 mg, and a dosage from about 125 to about 175 mg. It should benoted that doses within the specified ranges are also included herein,e.g., 85 mg, 97 mg, etc.

In another embodiment, a human IL-12 antibody, or antigen-bindingportion thereof, is administered as a single dose to a subject having adisorder in which IL-12 activity is detrimental, e.g., psoriasis, whichresults in treatment. A response to the IL-12 antibody, orantigen-binding portion thereof, may be maintained for an extendedperiod in a subject. Maintenance of a response may be monitored inaccordance with the disorder being treated. For example, maintenance ofa response with an IL-12 antibody, or antigen-binding portion thereof,for treating psoriasis may be determined by the subject's PASI 75response over time. Maintenance of a response for treating psoriasis mayalso be determined by the subject's PASI 50 response or PASI 90 responseover time. Maintenance of a response for treating psoriasis mayalternatively be determined by the subject's achieving a PGA score of“clear” or “minimal”, e.g., a PGA score of 0 or 1, over time.

It is to be noted that dosage values may vary with the type and severityof the condition to be alleviated. It is to be further understood thatfor any particular subject, specific dosage regimens should be adjustedover time according to the individual need and the professional judgmentof the person administering or supervising the administration of thecompositions, and that dosage ranges set forth herein are exemplary onlyand are not intended to limit the scope or practice of the claimedcomposition.

VII. Uses of the Invention

The invention provides a method for inhibiting IL-12 activity in asubject suffering from a disorder in which IL-12 activity isdetrimental. In one embodiment, the invention provides a method treatingpsoriasis comprising administering a single dose of an IL-12 antibody,or antigen-binding portion thereof.

IL-12 has been implicated in the pathophysiology of a wide variety ofdisorders (Windhagen et al., (1995) J. Exp. Med. 182: 1985-1996; Moritaet al. (1998) Arthritis and Rheumatism. 41: 306-314; Bucht et al.,(1996) Clin. Exp. Immunol. 103: 347-367; Fais et al. (1994) J.Interferon Res. 14:235-238; Parronchi et al., (1997) Am. J. Path.150:823-832; Monteleone et al., (1997) Gastroenterology. 112:1169-1178,and Berrebi et al., (1998) Am. J. Path 152:667-672; Parronchi et al(1997) Am. J. Path. 150:823-832). The invention provides methods forinhibiting IL-12 activity in a subject suffering from such a disorder,which method comprises administering to the subject an antibody orantibody portion of the invention such that IL-12 activity in thesubject is inhibited. Preferably, the IL-12 is human IL-12 and thesubject is a human subject. Alternatively, the subject can be a mammalexpressing a IL-12 with which an antibody of the invention cross-reacts.Still further the subject can be a mammal into which has been introducedhIL-12 (e.g., by administration of hIL-12 or by expression of an hIL-12transgene). An antibody of the invention can be administered to a humansubject for therapeutic purposes (discussed further below). Moreover, anantibody of the invention can be administered to a non-human mammalexpressing a IL-12 with which the antibody cross-reacts for veterinarypurposes or as an animal model of human disease. Regarding the latter,such animal models may be useful for evaluating the therapeutic efficacyof antibodies of the invention (e.g., testing of dosages and timecourses of administration).

As used herein, the phrase “a disorder in which IL-12 activity isdetrimental” is intended to include diseases and other disorders inwhich the presence of IL-12 in a subject suffering from the disorder hasbeen shown to be or is suspected of being either responsible for thepathophysiology of the disorder or a factor that contributes to aworsening of the disorder. Accordingly, a disorder in which IL-12activity is detrimental is a disorder in which inhibition of IL-12activity is expected to alleviate the symptoms and/or progression of thedisorder. Such disorders may be evidenced, for example, by an increasein the concentration of IL-12 in a biological fluid of a subjectsuffering from the disorder (e.g., an increase in the concentration ofIL-12 in serum, plasma, synovial fluid, etc. of the subject), which canbe detected, for example, using an anti-IL-12 antibody as describedabove. There are numerous examples of disorders in which IL-12 activityis detrimental. In one embodiment, the antibodies or antigen bindingportions thereof, can be used in therapy to treat the diseases ordisorders described herein. In another embodiment, the antibodies orantigen binding portions thereof, can be used for the manufacture of amedicine for treating the diseases or disorders described herein. Theuse of the antibodies and antibody portions of the invention in thetreatment of a few non-limiting specific disorders is discussed furtherbelow:

A. Rheumatoid Arthritis:

Interleukin-12 has been implicated in playing a role in inflammatorydiseases such as rheumatoid arthritis. Inducible IL-12p40 message hasbeen detected in synovia from rheumatoid arthritis patients and IL-12has been shown to be present in the synovial fluids from patients withrheumatoid arthritis (see e.g., Morita et al., (1998) Arthritis andRheumatism 41: 306-314). IL-12 positive cells have been found to bepresent in the sublining layer of the rheumatoid arthritis synovium. Thehuman antibodies, and antibody portions of the invention can be used totreat, for example, rheumatoid arthritis, juvenile rheumatoid arthritis,Lyme arthritis, rheumatoid spondylitis, osteoarthritis and goutyarthritis. Typically, the antibody, or antibody portion, is administeredsystemically, although for certain disorders, local administration ofthe antibody or antibody portion may be beneficial. An antibody, orantibody portion, of the invention also can be administered with one ormore additional therapeutic agents useful in the treatment of autoimmunediseases.

In the collagen induced arthritis (CIA) murine model for rheumatoidarthritis, treatment of mice with an anti-IL-12 mAb (rat anti-mouseIL-12 monoclonal antibody, C17.15) prior to arthritis profoundlysuppressed the onset, and reduced the incidence and severity of disease.Treatment with the anti-IL-12 mAb early after onset of arthritis reducedseverity, but later treatment of the mice with the anti-IL-12 mAb afterthe onset of disease had minimal effect on disease severity.

B. Crohn's Disease

Interleukin-12 also plays a role in the inflammatory bowel disease,Crohn's disease. Increased expression of IFN-γ and IL-12 occurs in theintestinal mucosa of patients with Crohn's disease (see e.g., Fais etal., (1994) J. Interferon Res. 14: 235-238; Parronchi et al., (1997)Amer. J. Pathol. 150: 823-832; Monteleone et al., (1997)Gastroenterology 112: 1169-1178; Berrebi et al., (1998) Amer. J. Pathol.152: 667-672). Anti-IL-12 antibodies have been shown to suppress diseasein mouse models of colitis, e.g., TNBS induced colitis IL-2 knockoutmice, and recently in IL-10 knock-out mice. Accordingly, the antibodies,and antibody portions, of the invention, can be used in the treatment ofinflammatory bowel diseases.

C. Multiple Sclerosis

Interleukin-12 has been implicated as a key mediator of multiplesclerosis. Expression of the inducible IL-12 p40 message or IL-12 itselfcan be demonstrated in lesions of patients with multiple sclerosis(Windhagen et al., (1995) J. Exp. Med. 182: 1985-1996, Drulovic et al.,(1997) J. Neurol. Sci. 147: 145-150). Chronic progressive patients withmultiple sclerosis have elevated circulating levels of IL-12.Investigations with T-cells and antigen presenting cells (APCs) frompatients with multiple sclerosis revealed a self-perpetuating series ofimmune interactions as the basis of progressive multiple sclerosisleading to a Th1-type immune response. Increased secretion of IFN-γ fromthe T cells led to increased IL-12 production by APCs, which perpetuatedthe cycle leading to a chronic state of a Th1-type immune activation anddisease (Balashov et al., (1997) Proc. Nat. Acad. Sci. 94: 599-603). Therole of IL-12 in multiple sclerosis has been investigated using mouseand rat experimental allergic encephalomyelitis (EAE) models of multiplesclerosis. In a relapsing-remitting EAE model of multiple sclerosis inmice, pretreatment with anti-IL-12 mAb delayed paralysis and reducedclinical scores. Treatment with anti-IL-12 mAb at the peak of paralysisor during the subsequent remission period reduced clinical scores.Accordingly, the antibodies or antigen binding portions thereof of theinvention may serve to alleviate symptoms associated with multiplesclerosis in humans.

D. Insulin-Dependent Diabetes Mellitus

Interleukin-12 has been implicated as an important mediator ofinsulin-dependent diabetes mellitus (IDDM). IDDM was induced in NOD miceby administration of IL-12, and anti-IL-12 antibodies were protective inan adoptive transfer model of IDDM. Early onset IDDM patients oftenexperience a so-called “honeymoon period” during which some residualislet cell function is maintained. These residual islet cells produceinsulin and regulate blood glucose levels better than administeredinsulin. Treatment of these early onset patients with an anti-IL-12antibody may prevent further destruction of islet cells, therebymaintaining an endogenous source of insulin.

E. Psoriasis

Interleukin-12 (IL-12) and the related cytokine IL-23 have beenimplicated as key mediators in psoriasis. Psoriasis involves acute andchronic skin lesions that are associated with a TH1-type cytokineexpression profile (Hamid et al. (1996) J. Allergy Clin. Immunol.1:225-231; Turka et al. (1995) Mol. Med. 1:690-699). Both IL-12 andIL-23 contribute to the development of the type 1T helper cell (Th1)immune response in psoriasis. Moreover, the IL-12 p40 and IL-23 p40messenger RNA is overexpressed in psoriatic skin lesions. Accordingly,the antibodies or antigen binding portions thereof of the invention mayserve to alleviate chronic skin disorders such psoriasis.

In one embodiment, the invention provides a method for treatingpsoriasis. Treatment for psoriasis often includes a topicalcorticosteroids, vitamin D analogs, and topical or oral retinoids, orcombinations thereof. In one embodiment, an IL-12 and/or IL-23 antibodyis administered in combination with or the presence of one of thesecommon treatments. Additional therapeutic agents which can be combinedwith the IL-12 and/or IL-23 antibody for treatment of psoriasis aredescribed in more detail below.

The diagnosis of psoriasis is usually based on the appearance of theskin. Additionally a skin biopsy, or scraping and culture of skinpatches may be needed to rule out other skin disorders. An x-ray may beused to check for psoriatic arthritis if joint pain is present andpersistent.

Improvements in psoriasis in a subject can be monitored by the subject'sPsoriasis Area and Severity Index Score (PASI). The method fordetermining the PASI has been described in Fredriksson and Pettersson(1978) Dermatologica 157:238 and Marks et al. (1989) Arch Dermatol125:235. Briefly, the index is based on evaluation of four anatomicsites, including the head, upper extremities, trunk, and lowerextremities, for erythema, induration, and desquamation using a 5 pointscale (0=no symptoms; 1=slight; 2=moderate; 3=marked; 4=very marked).Based on the extent of lesions in a given anatomic site, the areaaffected is assigned a numerical value (0=0; 1=<10%; 2=10-29%; 3=30-49%;4=50-69%; 5=70=89%; 6=90-100%). The PASI score is then calculated,wherein the possible range of PASI score is 0.0 to 72.0 with the highestscore representing complete erythroderma of the severest degree.

In one embodiment of the invention, an IL-12 and/or IL-23 antibody isused for the treatment of psoriasis, including chronic plaque psoriasis,guttate psoriasis, inverse psoriasis, pustular psoriasis, pemphigusvulgaris, erythrodermic psoriasis, psoriasis associated withinflammatory bowel disease (IBD), and psoriasis associated withrheumatoid arthritis (RA). In another embodiment, an IL-12 and/or IL-23antibody, such as J695/ABT-874, is used to treat subjects who havepsoriasis in combination with PsA. Specific types of psoriasis includedin the treatment methods of the invention are described in detail below:

a. Chronic Plaque Psoriasis

Chronic plaque psoriasis (also referred to as psoriasis vulgaris) is themost common form of psoriasis. Chronic plaque psoriasis is characterizedby raised reddened patches of skin, ranging from coin-sized to muchlarger. In chronic plaque psoriasis, the plaques may be single ormultiple, they may vary in size from a few millimeters to severalcentimeters. The plaques are usually red with a scaly surface, andreflect light when gently scratched, creating a “silvery” effect.Lesions (which are often symmetrical) from chronic plaque psoriasisoccur all over body, but with predilection for extensor surfaces,including the knees, elbows, lumbosacral regions, scalp, and nails.Occasionally chronic plaque psoriasis can occur on the penis, vulva andflexures, but scaling is usually absent. Diagnosis of patients withchronic plaque psoriasis is usually based on the clinical featuresdescribed above. In particular, the distribution, color and typicalsilvery scaling of the lesion in chronic plaque psoriasis arecharacteristic of chronic plaque psoriasis.

b. Guttate Psoriasis

Guttate psoriasis refers to a form of psoriasis with characteristicwater drop shaped scaly plaques. Flares of guttate psoriasis generallyfollow an infection, most notably a streptococcal throat infection.Diagnosis of guttate psoriasis is usually based on the appearance of theskin, and the fact that there is often a history of recent sore throat.

c. Inverse Psoriasis

Inverse psoriasis is a form of psoriasis in which the patient hassmooth, usually moist areas of skin that are red and inflammed, which isunlike the scaling associated with plaque psoriasis. Inverse psoriasisis also referred to as intertiginous psoriasis or flexural psoriasis.Inverse psoriasis occurs mostly in the armpits, groin, under the breastsand in other skin folds around the genitals and buttocks, and, as aresult of the locations of presentation, rubbing and sweating canirritate the affected areas.

d. Pustular Psoriasis

Pustular psoriasis, also referred to as palmar plantar psoriasis, is aform of psoriasis that causes pus-filled blisters that vary in size andlocation, but often occur on the hands and feet. The blisters may belocalized, or spread over large areas of the body. Pustular psoriasiscan be both tender and painful, can cause fevers.

e. Other Psoriasis Disorders

Other examples of psoriatic disorders which can be treated with theIL-12 and/or IL-23 antibody include erythrodermic psoriasis, vulgaris,psoriasis associated with IBD, and psoriasis associated with arthritis,including rheumatoid arthritis.

The present invention is further illustrated by the following exampleswhich should not be construed as limiting in any way. The contents ofall cited references, including literature references, issued patents,and published patent applications, as cited throughout this applicationare hereby expressly incorporated herein by reference. It should furtherbe understood that the contents of all the tables attached hereto (seeAppendix A attached hereto and Appendix A of U.S. Pat. No. 6,914,128) aswell as the entire contents of U.S. Pat. No. 6,914,128 are incorporatedherein by reference.

EXAMPLES Example 1 Efficacy of the Fully Human IL-12/IL-23 MonoclonalAntibody, ABT-874, In the Treatment of Moderate to Severe PlaquePsoriasis

ABT-874 is a fully human antibody against interleukin-12 (IL-12) andIL-23. It binds with great affinity to the p40 subunit common to bothIL-12 and IL-23, both validated targets in the treatment of psoriasis(Ps).

The objective of the following study was to evaluate the efficacy ofsubcutaneous injections of ABT-874 in the treatment of patients withmoderate to severe plaque Ps.

Adult patients with Ps affecting ≧10% body surface area (BSA) and aPsoriasis Area and Severity Index (PASI) score ≧12 at baseline wereeligible for this 12-week, double-blind, placebo-controlled study.Patients were randomized to 1 of 6 arms: 1) 100-mg ABT-874 every otherweek (eow) for 12 weeks; 2) one 200-mg ABT-874 dose at Week 0; 3) 200-mgABT-874 every week for 4 weeks; 4) 200-mg ABT-874 eow for 12 weeks; 5)200-mg ABT-874 every week for 12 weeks; or 6) placebo. Primary endpointwas a ≧PAS175 response at Week 12. Other efficacy assessments includedthe PASI50 and Physician's Global Assessment (PGA). Patients who met theprimary endpoint entered a 36-week blinded/retreatment phase and weremonitored for time to loss of response.

A total of 180 patients enrolled in the study, 30 in each arm. Baselinecharacteristics were similar between arms and indicative of moderate tosevere Ps (all mean values except % male): age, 46 yrs, 74% male; 21 yrsduration of Ps; PASI 19; and 25% BSA affected. At Week 12, thepercentages of patients achieving ≧PAS175 were statisticallysignificantly greater for patients in each of the 5 ABT-874 arms vs.placebo (93%, 63%, 90%, 93%, 90%, vs. 3%, respectively, p<0.001, ITT).In addition, the percentages of patients achieving ≧PASI50 werestatistically significantly greater for patients in each of the 5ABT-874 arms vs. placebo (100%, 77%, 97%, 97%, and 100%, vs. 17%,p<0.001). The mean percentage decreases (improvements) in PASI at Week12 were 90%, 70%, 92%, 92%, and 90%, respectively, in the ABT-874 arms,and 26% for placebo. Similarly, the percentages of patients with a PGAof Clear/Minimal were 83%, 50%, 73%, 87% and 87%, respectively, in theABT-874 arms, and 3% for placebo.

In conclusion, ABT-874 was significantly more efficacious than placeboin the treatment of moderate to severe plaque psoriasis.

Example 2 Safety and Efficacy of the Fully Human IL-12/-23 MonoclonalAntibody, ABT-874, in the Treatment of Moderate to Severe PlaquePsoriasis

ABT-874 is a fully human antibody against interleukin 12 (IL-12) andIL-23. It binds with great affinity to the p40 subunit common to bothIL-12 and IL-23, validated targets in the treatment of psoriasis (Ps).The objective of this Phase II study was to investigate the efficacy andsafety of subcutaneous injections of ABT-874 in the treatment ofmoderate to severe plaque Ps.

Adults with Ps affecting ≧10% body surface area (BSA) and a PASI score≧12 were eligible for this 12-wk, double-blind, placebo-controlledstudy. Patients were randomized to 1 of 6 arms: 1) 100-mg ABT-874 everyother week (eow) for 12 wks; 2) one 200-mg ABT-874 dose at Wk 0; 3)200-mg ABT-874 every wk for 4 wks; 4) 200-mg ABT-874 eow for 12 wks; 5)200-mg ABT-874 every wk for 12 wks; or 6) placebo. The primary endpointwas a ≧PASI75 response at Wk 12. Patients who met the primary endpointentered a 36-wk blinded/retreatment phase and were monitored for time toloss of response. All patients were evaluated for safety through Wk 54.

180 patients enrolled, 30 in each arm. Baseline characteristics weresimilar between arms (mean values presented except % male): age, 46 yrs,74% male; 21 yrs duration of Ps; PASI=19; and 25% BSA affected. At Wk12, the % s of patients with ≧PASI75 were statistically significantlygreater in each of the 5 ABT-874 arms vs. placebo (93%, 63%, 90%, 93%,90%, vs. 3%, respectively, p<0.001, ITT). During the 12-wk, DB phase,infectious AEs for the ABT-874 groups ranged from 23-43% and for theplacebo group was 23%, with the most common being nasopharyngitis (7-17%for ABT-874; 3% for placebo). There were no statistically significantdifferences between arms. No serious infectious AEs were reported, andno deaths occurred.

In conclusion, ABT-874 was significantly more efficacious than placeboin the treatment of moderate to severe plaque Ps, and appears to have afavorable safety profile.

Example 3 Maintenance of Response with the Fully Human IL-12/-23Monoclonal Antibody, ABT-874, in the Treatment of Moderate to SeverePlaque Psoriasis

The efficacy and safety of ABT-874 was evaluated in a 12-week, Phase II,randomized controlled trial and 36-week follow-up phase. The objectiveof the following example was to analyze maintenance of responsefollowing discontinuation of therapy during the second 12 weeks of thisPhase II study of subcutaneous injections of ABT-874 in the treatment ofmoderate to severe plaque Ps.

Adults with Ps affecting ≧10% body surface area (BSA) and a PASI score≧12 were eligible for this 12-week, double-blind, placebo-controlledstudy. Patients were randomized to 1 of 6 arms:

1) 100-mg ABT-874 every other week (eow) for 12 wks;

2) one 200-mg ABT-874 dose at Wk 0;

3) 200-mg ABT-874 every wk for 4 wks;

4) 200-mg ABT-874 eow for 12 wks;

5) 200-mg ABT-874 every wk for 12 wks; or

6) placebo.

The primary endpoint was a ≧PASI75 response at Week 12. Patients who metthe primary endpoint entered a 36-week blinded/retreatment phase.Treatment with study drug was discontinued, and patients were monitoredfor time to loss of response (a decrease in PASI score, any time duringthe 36-week follow-up period, to <PASI 50). Maintenance of PASI responsewas evaluated through Week 24.

A total of 180 patients enrolled, 30 in each arm. Baselinecharacteristics were similar between arms (mean values presented except% male): age, 46 years, 74% male; 21 years duration of Ps; PASI=19; and25% BSA affected.

At Week 12, the percentages of patients with ≧PASI75 were statisticallysignificantly greater in each of the 5 ABT-874 arms vs. placebo (Table1). At Week 24, substantial percentages of PASI 75 responders in theactive treatments arms had maintained at least a PASI 50 response.

TABLE 1 24-Week Efficacy of ABT-874 Maintenance of PASI ≧PASI75 atResponse: Wk 12 Wk 24 vs. Wk 12 100 mg eow for 28/30 (93%)* 24/28 (86%)12 wks 200 mg, one dose 19/30 (63%)* 15/19 (79%) 200-mg every wk for27/30 (90%)* 23/27 (85%) 4 wks 200-mg eow for 28/30 (93%)* 26/28 (93%)12 wks 200-mg every wk for 27/30 (90%)* 26/27 (96%) 12 wks Placebo  1/30(3%) — *p < 0.001 vs. placebo, NRI.

In conclusion, ABT-874 was significantly more efficacious than placeboin the treatment of moderate to severe plaque Ps. Substantialpercentages of PASI 75 responders maintained these responses at Week 24,following discontinuation of active therapy.

Example 4 Safety and Efficacy of ABT-874, a Fully Human IL-12/-23Monoclonal Antibody, in the Treatment of Moderate to Severe ChronicPlaque Psoriasis

The objective of the following example was to demonstrate the efficacyand safety of a range of doses of a human IL-12/23 monoclonal antibody(ABT-874) compared with placebo in the treatment of patients withclinically stable moderate to severe chronic plaque psoriasis.

I. Materials and Methods

A. Study design: The following study was a 12-week, multicentre,randomised, double-blind, phase II, placebo-controlled trial that wasconducted at 24 centres in the United States (16 sites) and Canada (8sites). ABT-874 (Abbott Laboratories, Abbott Park, Ill.) is a humanmonoclonal antibody with genetically engineeredcomplementarity-determining regions that have high affinity for theIL-12/23 p40 subunit protein. Patients were randomised in a 1:1:1:1:1:1ratio to receive 1 of 6 treatments: 200 mg of ABT-874, 1 dose at week 0(200 mg×1); 100 mg of ABT-874 every other week (eow) for 12 weeks (100mg eow); 200 mg of ABT-874 weekly for the first 4 weeks (200 mg×4); 200mg of ABT-874 eow for 12 weeks (200 mg eow); 200 mg of ABT-874 weeklyfor 12 weeks (200 mg weekly); or placebo. After week 12, all patientswho achieved at least a 75% reduction in psoriasis area and severityindex (PASI 75) response continued into a 36-week blindedobservation/retreatment phase.

B. Patients: Patients were ≧18 years of age and had a clinical diagnosisof psoriasis for at least 6 months (determined by patient interview andconfirmation of diagnosis through physical examination by theinvestigator), stable plaque psoriasis for at least 2 months beforescreening and at baseline visits as determined by subject interview,moderate to severe plaque psoriasis defined by ≧10% body surface area(BSA) involvement at the baseline visit, a PASI score of ≧12 at thebaseline visit, and a physician's global assessment (PGA) of at leastmoderate disease at the baseline visit.

Patients were ineligible if they had previous exposure to systemic orbiologic anti-IL-12 therapy; nonplaque psoriasis; inability todiscontinue the following therapies before the baseline visit: topicalpsoriasis therapies at least 2 weeks before, ultraviolet B lightphototherapy at least 2 weeks before, psoralen-ultraviolet-lightphototherapy at least 4 weeks before, systemic therapies at least 4weeks before, and biologic therapies at least 12 weeks before; requiredintake of oral or injectable corticosteroids during the study (inhaledcorticosteroids for stable medical conditions were allowed); anexacerbation of asthma requiring hospitalization in the 10 years priorto screening; an infection or risk factors for severe infection; ahistory of malignancies other than successfully treated basal cellcarcinoma (patients with a history of squamous cell carcinoma wereexcluded) or cervical carcinoma in situ; or a history of majorimmunologic reaction (e.g., serum sickness or anaphylactoid reaction) toan immunoglobulin G-containing agent (e.g., intravenous gamma globulin,a fusion protein, or monoclonal antibody).

Patients were allowed to continue treatment with medicated shampoos thatdid not contain corticosteroids, bland (without beta- or alpha-hydroxyacids) emollients, or Class VI or VII low-potency topicalcorticosteroids on their palms, soles, face, inframammary area, andgroin area during the course of the study. Application of these topicalpsoriasis therapies was not to occur within 24 hours of a study visit.Vaccination with a live viral agent was not allowed within 1 month priorto dosing with ABT-874, during the study, or for 1 month after the lastdose of study drug was administered.

Occurrence of any of the following clinically significant abnormallaboratory results led to immediate withdrawal of a patient from thestudy: aspartate transaminase or alanine transaminase >5 times the upperlimit of normal; serum total bilirubin >3 times the upper limit ofnormal; serum creatinine >3 times the upper limit of normal; creatinephosphokinase >5 times the upper limit of normal; hemoglobin <8 g/dL;white blood cell count <2×10⁹/L; or platelet count <75×10⁹/L.

C. Efficacy assessments: The primary efficacy assessment was thepercentage of patients achieving a PASI 75 response at week 12, definedas at least a 75% reduction in PASI score relative to the baselinescore. PASI is a measure of the severity of psoriatic lesions (in termsof erythema, induration, and desquamation) and the extent of BSAinvolvement. The PASI score ranges from 0 (no psoriasis) to 72 (severedisease) (Fredriksson T, Pettersson U. Dermatologica 1978; 157: 238-44).Other efficacy measures included the percentage of patients who achievedat least PASI 75 at weeks 1, 2, 4, and 8; the percentage of patients whoachieved at least PASI 50 or PASI 90 at weeks 1, 2, 4, 8, and 12; andthe percentage of patients who attained a PGA of clear or minimal atweek 12 and at weeks 1, 2, 4, and 8. The PGA measures the severity ofdisease on a 6-point scale, which ranges from 0 (no disease, or clear)to 5 (very severe) (Ko H-S. Clinical trial design in psoriasis.Presented at: 49th Meeting of the Dermatologic and OpthalmologicAdvisory Committee; Mar. 20, 1998; Bethesda, Md.).

D. Safety assessments: Adverse events, laboratory data, and vital signswere assessed throughout the study. Patients were closely monitored forsigns of infection, malignancy, and immunologic reaction.Treatment-emergent AEs were defined as those events that occurredbetween week 0 and the earlier of 45 days after the last nonmissingstudy drug dose or 1 day prior to the first retreatment dose (for thosepatients continuing on to the 36-week trial).

E. Statistical analysis: The sample size was calculated using nQueryAdvisor® 4.0 (Statistical Solutions, Saugus, Mass.). With the assumptionthat 15% of the patients in the placebo group would achieve a PASI 75response at week 12, the study designers determined that a sample sizeof 26 in each dosage group would be adequate to detect at least a 45%difference from a treated group using the Fisher exact test with 90%power at a 0.05 2-sided significance level. The study was designed toenroll approximately 180 patients, with 30 patients in each group.

The intention-to-treat population included all patients who wererandomised at week 0 and received at least 1 injection of study drug;this population was used for the efficacy analyses. All tests wereperformed at α=0.05. Nonresponder imputation was used for all efficacyanalyses; any patient with a missing PASI or PGA score at any visit wasconsidered a nonresponder at that visit. To assess the impact of themissing data, sensitivity analyses of week-12 data were completed usingthe last-observation-carried-forward method. The primary analysis ofPASI 75 response at week 12 was performed using the following sequentialorder to adjust for multiplicity: 200 mg weekly versus placebo, 200 mgeow versus placebo, 100 mg eow versus placebo, 200 mg×4 versus placebo,and 200 mg×1 versus placebo. The treatment difference between eachABT-874 treatment group and the placebo group for mean percentage changein PASI score was assessed using analysis of variance, with baselinePASI score and treatment group as factors. The safety analyses wereconducted using the safety population, which included all patients whoreceived at least 1 injection of study drug.

II. Results

A. Patients: A total of 180 patients were enrolled and randomised to 1of the 6 treatment groups (FIG. 1). The majority of patients (76.7% ofplacebo-treated patients and 98% of all ABT-874 treatment grouppatients) completed the 12-week portion of the study.

Patients were well balanced across treatment groups with respect todemographic characteristics and disease activity (table 1). Patientswere predominantly male (74.4%) and white (92.2%). Mean BSA involvementwas 25% and mean PASI score was 18.8.

B. Efficacy: The percentage of patients achieving the primary endpointof PASI 75 response at week 12 was statistically significantly greater(p<0.001) in all of the ABT-874 treatment groups (200 mg×1: 63.3%, 19 of30; 100 mg eow: 93.3%, 28 of 30; 200 mg×4:90.0%, 27 of 30; 200 mg eow:93.3%, 28 of 30; 200 mg weekly: 90.0%, 27 of 30) compared with placebo(3.3%, 1 of 30). For the relatively short duration of this trial, PASI75 responses in all ABT-874 treatment groups were similar with theexception of the 200 mg×1 treatment group (FIG. 2).

A subgroup analysis by demographics (gender, age, race, and weight),baseline disease characteristics (history of psoriatic arthritis, BSA,and PASI score), and baseline therapy for psoriasis within 12 months ofreceiving study treatment (systemic biologic and nonbiologic, topical,and phototherapy) demonstrated that ABT-874-treated patients within thevarious subgroups consistently achieved high levels of PASI 75 responseat week 12.

Nearly 100% of the higher ABT-874 dosage groups attained at least a PASI50 response by week 12 (200 mg×1:76.7%, 23 of 30; 100 mg eow: 100.0%, 30of 30; 200 mg×4:96.7%, 29 of 30; 200 mg eow: 96.7%, 29 of 30; 200 mgweekly: 100.0%, 30 of 30; placebo: 16.7%, 5 of 30; p<0.001 for eachcomparison with placebo). The percentage of patients achieving at leasta PASI 90 response at week 12 was statistically significantly greater(p<0.001) in all but 1 (200 mg×1) of the ABT-874 treatment groups whencompared with placebo, as follows: 200 mg×1:16.7%, 5 of 30; 100 mg eow:53.3%, 16 of 30; 200 mg×4:63.3%, 19 of 30; 200 mg eow: 76.6%, 23 of 30;200 mg weekly: 53.3%, 16 of 30; and placebo: 0%, 0 of 30. In addition,by week 12, significantly more (p<0.001) patients in all ABT-874treatment groups had attained a clear or minimal PGA rating comparedwith patients in the placebo group, as follows: 200 mg×1:50.0%, 15 of30; 100 mg eow: 83.3%, 25 of 30; 200 mg×4:73.3%, 22 of 30; 200 mg eow:86.7%, 26 of 30; 200 mg weekly: 86.7%, 26 of 30; versus placebo: 3.3%, 1of 30.

The percentage of patients achieving the primary endpoint of PASI 100response at week 12 was statistically significantly greater (p<0.001) inthe following ABT-874 treatment groups (200 mg eow: 46.7%, 14 of 30; 200mg weekly: 36.7%, 11 of 30) compared with placebo (0%, 0 of 30).

Response to ABT-874 was rapid. The mean percentage improvement in PASIscores from baseline increased over time for all ABT-874 treatmentgroups (FIG. 3) and were statistically significantly greater for eachABT-874 treatment group compared with placebo at each time point(p<0.001, except for the 100 mg eow group at week 1, p=0.023).

C. Safety: ABT-874 therapy was generally well tolerated (table 2). One(0.7%) patient treated with ABT-874 discontinued the study owing to alocalised skin discoloration; 2 (6.7%) patients treated with placebodiscontinued the study, 1 for psoriatic arthropathy and 1 for ovariancancer. Two (1.1%) patients experienced serious adverse effects (AEs); 1placebo-treated patient was diagnosed with ovarian cancer on day 37, and1 ABT-874-treated patient (200 mg×1) was diagnosed with costochondritison day 10. No patients experienced myocardial or cerebral infarctions,and there were no deaths.

Patients receiving any dose of ABT-874 were significantly (p=0.033) morelikely than patients receiving placebo to experience an AE at leastpossibly related to study drug (ABT-874:36.0%, 54 of 150; placebo:10.0%, 3 of 30; table 2); most of these AEs were related to theinjection site (injection-site reaction, erythema, pruritus, orirritation).

Most AEs were mild (mild AEs occurred in 46.0% [69 of 150] ofABT-874-treated patients and 30.0% [9 of 30] placebo-treated patients).The most common AE was injection-site reaction, occurring in 16.7% (25of 150) of patients treated with any dose of ABT-874 (no reportedinjection-site reactions for placebo-treated patients; p=0.028; table3). There were no statistically significant differences between theincidences of other AEs in the ABT-874-treated patients compared withplacebo-treated patients. The next most frequently reported AEs werenasopharyngitis and upper respiratory tract infection.

Infectious AEs were reported by 32.8% (59 of 180) of all patients(placebo: 23.3%, 7 of 30; all ABT-874-treated patients: 34.7%, 52 of150). The most common infectious AEs reported for any ABT-874 treatmentgroup were nasopharyngitis (12.0%, 18 of 150), upper respiratory tractinfection (10.7%, 16 of 150), and bronchitis and viral infection (both2.7%, 4 of 150). No serious infectious AEs were reported.

Two patients reported malignancies during the study. One placebo-treatedpatient was diagnosed with ovarian cancer, which was ongoing as of day129. One ABT-874-treated patient (200 mg×4) was diagnosed with anon-melanoma skin cancer (squamous cell carcinoma) that was removed onday 133. The medical history for this patient included removal of abenign skin growth in March 2005.

There were no clinically significant hematology, chemistry (includingblood glucose concentrations), or vital sign changes compared withplacebo.

TABLE 1 Baseline demographics and clinical characteristics TreatmentGroup 100 mg 200 mg 200 mg All Placebo 200 mg × 1 eow 200 mg × 4 eowweekly ABT-874 Characteristic N = 30 N = 30 N = 30 N = 30 N = 30 N = 30N = 150 Age, y 49 ± 14.4 52 ± 12.0 45 ± 13.8 43 ± 13.8 44 ± 16.0 46 ±14.0 46 ± 14.1 Male, No. (%) 22 (73.3) 23 (76.7) 22 (73.3) 21 (70.0) 23(76.7) 23 (76.7) 112 (74.7)  White, No. (%) 28 (93.3) 25 (83.3) 28(93.3) 27 (90.0)  30 (100.0) 28 (93.3) 138 (92.0)  Weight, kg 89 ± 17.694 ± 21.2 94 ± 17.9 92 ± 27.8 93 ± 24.1 95 ± 18.0 94 ± 21.9 Duration ofpsoriasis, y 21 ± 12.4 20 ± 13.2 24 ± 14.6 22 ± 14.2 18 ± 11.5 18 ± 10.921 ± 13.0 PASI score 16 ± 2.9  18 ± 6.7  20 ± 6.3  20 ± 7.6  20 ± 6.2 19 ± 6.3  19 ± 6.6  BSA affected, % 21 ± 9.2  24 ± 13.6 28 ± 15.7 24 ±13.0 29 ± 16.8 23 ± 12.6 26 ± 14.5 PGA, No. (%) Mild 1 (3.3) 0 0 0 0 0 0Moderate 20 (66.7) 19 (63.3) 17 (56.7) 13 (43.3) 15 (50.0) 17 (56.7) 81(54.0) Severe  9 (30.0) 11 (36.7) 12 (40.0) 14 (46.7) 13 (43.3) 11(36.7) 61 (40.7) History of PsA, No. (%)  9 (30.0)  7 (23.3) 12 (40.0) 9 (30.0)  6 (20.0)  9 (30.0) 43 (28.7) Previous psoriasis treatment,*No. (%) Topical therapy 19 (63.3) 21 (70.0) 26 (86.7) 15 (50.0) 21(70.0) 23 (76.7) 106 (70.7)  Phototherapy 1 (3.3)  6 (20.0)  4 (13.3)  4(13.3)  3 (10.0)  5 (16.7) 22 (14.7) Systemic nonbiologic  6 (20.0)  4(13.3)  7 (23.3)  5 (16.7)  6 (20.0)  8 (26.7) 30 (20.0) Systemicbiologic  3 (10.0)  3 (10.0)  7 (23.3)  6 (20.0)  4 (13.3)  7 (23.3) 27(18.0) Values are mean ± SD unless otherwise noted. *Within past 12months prior to study treatment. BSA = body surface area; eow = everyother week; PASI = psoriasis area and severity index; PGA = physician'sglobal assessment; PsA = psoriatic arthritis

TABLE 2 Clinical treatment-emergent adverse events summary TreatmentGroup 100 mg 200 mg 200 mg All Placebo 200 mg × 1 eow 200 mg × 4 eowweekly ABT-874 N = 30 N = 30 N = 30 N = 30 N = 30 N = 30 N = 150 EventNo. (%) Any AE 18 (60.0) 18 (60.0) 22 (73.3) 21 (70.0) 21 (70.0) 19(63.3) 101 (67.3)  Any AE at least possibly drug-  3 (10.0)  9 (30.0) 12(40.0) 14 (46.7) 11 (36.7)  8 (26.7) 54 (36.0) related* Any severe AE  3(10.0) 1 (3.3) 0 0 0 1 (3.3) 2 (1.3) Any serious AE^(†) 1 (3.3) 1 (3.3)0 0 0 0 1 (0.7) Any AE leading to 2 (6.7) 1 (3.3) 0 0 0 0 1 (0.7)discontinuation of study drug Any AE at least possibly drug- 0 0 0 0 0 00 related* and serious Any infectious AE  7 (23.3)  7 (23.3)  9 (30.0)13 (43.3) 13 (43.3) 10 (33.3) 52 (34.7) Any serious infectious AE 0 0 00 0 0 0 Any malignant neoplasms 1 (3.3) 0 0 1 (3.3) 0 0 1 (0.7) Deaths 00 0 0 0 0 0 *As assessed by the investigator. ^(†)Serious adverse eventsincluded the following: any event that resulted in death; any event thatwas life-threatening; any event that resulted in admission to thehospital for any length of time; any event that occurred while thepatient was hospitalised and resulted in prolongation of hospital stay;any event that resulted in persistent or significantdisability/incapacity; or any important medical event that requiredmedical or surgical intervention to prevent serious outcome. AE =adverse event; eow = every other week.

TABLE 3 Treatment-emergent adverse events with an incidence ≧5% in anytreatment group by descending frequency of patients treated with anydosage of ABT-874 Treatment Group 100 mg 200 mg All Placebo 200 mg × 1eow 200 mg × 4 eow 200 mg weekly ABT-874 N = 30 N = 30 N = 30 N = 30 N =30 N = 30 N = 150 Event No. (%) Injection-site reaction 0 2 (6.7)  7(23.3)  5 (16.7)  7 (23.3)  4 (13.3) 25 (16.7) Nasopharyngitis 1 (3.3) 4 (13.3)  4 (13.3)  3 (10.0) 2 (6.7)  5 (16.7) 18 (12.0) Upperrespiratory tract infection 2 (6.7) 2 (6.7)  4 (13.3)  3 (10.0)  5(16.7) 2 (6.7) 16 (10.7) Headache 2 (6.7)  5 (16.7) 0 1 (3.3)  3 (10.0)2 (6.7) 11 (7.3)  Injection site pruritus 0 0 1 (3.3) 2 (6.7) 2 (6.7) 2(6.7) 7 (4.7) Injection site erythema 0 0 0  4 (13.3) 2 (6.7) 1 (3.3) 7(4.7) Injection site irritation 0 1 (3.3)  3 (10.0) 2 (6.7) 0 0 6 (4.0)Fatigue 0 2 (6.7) 2 (6.7) 0 0 1 (3.3) 5 (3.3) Pain in extremity 0 1(3.3) 0 0 1 (3.3) 2 (6.7) 4 (2.7) Arthralgia 0 2 (6.7) 0 0 0 2 (6.7) 4(2.7) Viral infection 0 0 0 2 (6.7) 1 (3.3) 1 (3.3) 4 (2.7) Bronchitis 01 (3.3) 0 1 (3.3) 2 (6.7) 0 4 (2.7) Nausea 1 (3.3) 0  3 (10.0) 0 0 0 3(2.0) Otitis externa 0 0 0 0 2 (6.7) 0 2 (1.3) Vomiting 1 (3.3) 0 0 2(6.7) 0 0 2 (1.3) Urinary tract infection 2 (6.7) 1 (3.3) 0 1 (3.3) 0 02 (1.3) Herpes simplex 0 0 2 (6.7) 0 0 0 2 (1.3) Limb injury 0 2 (6.7) 00 0 0 2 (1.3) Pruritus 2 (6.7) 0 0 0 0 0 0 *As assessed by theinvestigator.III. Conclusion

The phase II, multicentre, randomised, double-blind, placebo-controlledtrial described in this Example demonstrated statistically andclinically significant efficacy of ABT-874 in the treatment of moderateto severe chronic plaque psoriasis. With the exception of the ABT-874200 mg×1 treatment group, 90% or more of patients in all ABT-874treatment groups achieved PASI 75 or greater by week 12, compared with3.3% of placebo-treated patients. Even in the group that received only 1dose of study drug (200 mg×1), a majority (63.3%) of patients hadachieved at least PASI 75 by week 12. In addition, almost 100% ofpatients treated with ABT-874 reached PASI 50 or greater, which isconsidered to be a clinically significant improvement (Carlin C S,Feldman S R, Krueger J G, Menter A, Krueger G G. J Am Acad Dermatol2004; 50: 859-66) by week 12. The results for other secondary endpoints,such as PASI 90 and PGA of clear or minimal, were consistent with andsupported the primary efficacy analysis.

Response to ABT-874 was rapid. Statistically significant separationbetween placebo- and ABT-874-treated patients occurred as early as week1 for the mean percentage improvement in PASI scores. Improvement wassustained for the 12-week duration of the trial, even for patients inthe ABT-874 200 mg×1 and 200 mg×4 dosage groups.

ABT-874 was well tolerated, and most AEs were mild. AlthoughABT-874-treated patients were significantly more likely to experience anAE at least possibly related to study drug, most of these were injectionsite-related AEs (injection-site reaction, erythema, pruritus, orirritation). There was no apparent association between an increased doseof ABT-874 and an increased incidence of AEs. Of note, there were nomyocardial or cerebral infarctions.

Immunologic-related events are of particular interest for patientsreceiving anti-IL-12/23 antibodies. The most frequently reportedinfectious AEs were nasopharyngitis, upper respiratory tract infection,bronchitis, and viral infection. There were no serious infectious AEsreported for the duration of this trial. Of the 2 malignancies diagnosedduring the study, ovarian cancer was diagnosed in a placebo-treatedpatient, and non-melanoma skin cancer was diagnosed in anABT-874-treated patient who had a history of a benign skin growth.

In summary, ABT-874 demonstrated statistically and clinicallysignificant benefit for the treatment of patients with moderate tosevere chronic plaque psoriasis, and was well tolerated.

Example 5 Maintenance of Response with the Fully Human IL-12/-23Monoclonal Antibody, ABT-874, in the Treatment of Moderate to SeverePlaque Psoriasis

The efficacy and safety of ABT-874 was evaluated in a 12-week, Phase II,randomized controlled trial and 36-week follow-up phase. The objectiveof the following example was to analyze maintenance of responsefollowing discontinuation of therapy during the second 12 weeks of thisPhase II study of subcutaneous injections of ABT-874 in the treatment ofmoderate to severe plaque Ps.

Adults with Ps affecting ≧10% body surface area (BSA) and a PASI score≧12 were eligible for this 12-week, double-blind, placebo-controlledstudy. Patients were randomized to 1 of 6 arms:

1) 100-mg ABT-874 every other week (eow) for 12 wks;

2) one 200-mg ABT-874 dose at Wk 0;

3) 200-mg ABT-874 every wk for 4 wks;

4) 200-mg ABT-874 eow for 12 wks;

5) 200-mg ABT-874 every wk for 12 wks; or

6) placebo.

The primary endpoint was a ≧PASI 75 response at Week 12. Patients whomet the primary endpoint entered a 36-week blinded/retreatment phase.Treatment with study drug was discontinued, and patients were monitoredfor PASI score at various times during the 36-week follow-up period,including PASI 50, PASI 75 and PASI 90 responses. Maintenance of PASIresponse was evaluated through Week 24.

A total of 180 patients enrolled, 30 in each arm. Baselinecharacteristics were similar between arms (mean values presented except% male): age, 46 years, 74% male; 21 years duration of Ps; PASI=19; and25% BSA affected.

At Week 12, the percentages of patients with ≧PASI 75 were statisticallysignificantly greater in each of the 5 ABT-874 arms vs. placebo (Table4). At Week 24, substantial percentages of PASI 75 responders in theactive treatments arms had maintained at least a PASI score of ≧PASI 50.Further, substantial percentages of PASI 75 responders in the activetreatments arms had also maintained at least a PASI score of ≧PASI 75,as well as a PASI score of ≧PASI 90 (Table 4 and FIGS. 4A-C). Thepercentage of patients maintaining a PASI 75 response over time duringthe 24 week period is depicted in FIG. 4D.

TABLE 4 24-Week Efficacy of ABT-874 Maintenance of Maintenance ofMaintenance of ≧PASI 50 ≧PASI 75 ≧PASI 90 ≧PASI 75 at Response:Response: Response: Wk 12 Wk 24 vs. Wk 12 Wk 24 vs. Wk 12 Wk 24 vs. Wk12 100 mg eow for 93%* 71% 60% 33% 12 wks 200 mg, one dose 63%* 68% 23%7% 200-mg every wk 90%* 82% 60% 23% for 4 wks 200-mg eow for 93%* 89%73% 53% 12 wks 200-mg every wk 90%* 85% 83% 57% for 12 wks Placebo 3% —7% 7% *p < 0.001 vs. placebo, NRI.

In conclusion, ABT-874 was significantly more efficacious than placeboin the treatment of moderate to severe plaque Ps. Substantialpercentages of PASI 75 responders maintained a response of ≧PASI 50,≧PASI 75, and ≧PASI 90 at Week 24, following discontinuation of activetherapy.

Example 6 Maintenance of Re-treatment Response with the Fully HumanIL-12/-23 Monoclonal Antibody, ABT-874, in the Treatment of Moderate toSevere Plaque Psoriasis

The efficacy and safety of ABT-874 was evaluated in a 48-week, Phase II,randomized controlled trial that included a 12-week initial treatmentphase and a 36-week re-treatment phase of patients responding to initialtreatment. The initial 12-week efficacy results and maintenance ofresponse results are described in the above examples. The objective ofthe following example was to examine the re-treatment response duringthe 36-week re-treatment/follow-up phase in patients who lost theirinitial responses of this Phase II study of subcutaneous injections ofABT-874 in the treatment of moderate to severe plaque Ps. The furtherobjective of the following example was to examine safety of subcutaneousinjections of ABT-874 in the treatment of moderate to severe plaque Psthrough 48 weeks.

At baseline, demographics and clinical characteristics were similaracross treatment groups (summarized in Table 5 below).

TABLE 5 Baseline Demographics and Clinical Characteristics TreatmentGroup* Placebo 200 mg × 1 100 mg eow 200 mg × 4 200 mg eow 200 mg WeeklyAll Characteristic (n = 30) (n = 30) (n = 30) (n = 30) (n = 30) (n = 30)(N = 150) Age, yrs   49 (14.4)   52 (12.0)   45 (13.8)   43 (13.8)   44(16.0)   46 (14.0)   46 (14.1) Sex, n (%) male 22 (73) 23 (77) 22 (73)21 (70) 23 (77) 23 (77) 112 (75)  Race, n (%) white 28 (93) 25 (83) 28(93) 27 (90)  30 (100) 28 (93) 138 (92)  Weight, kg   89 (17.6)   94(21.2)   94 (17.9)   92 (27.8)   93 (24.1)   95 (18.0)   94 (21.9)Duration of psoriasis, yrs   21 (12.4)   20 (13.2)   24 (14.6)   22(14.2)   18 (11.5)   18 (10.9)   21 (13.0) PASI score Mean (SD)  16(2.9)  18 (6.7)  20 (6.3)  20 (7.6)  20 (6.2)  19 (6.3)  19 (6.6)Median, IQ 16.1, 3.8  15.0, 7.5  18.7, 7.4  17.0, 10.2 18.0, 10.0 16.8,5.8  17.3, 8.0  BSA affected, % Mean (SD)  21 (9.2)   24 (13.6)   28(15.7)   24 (13.0)   29 (16.8)   23 (12.6)   26 (14.5) Median, IQ 17.5,13.0 17.5, 16.0 22.5, 19.5 20.3, 17.0 22.0, 24.5 19.5, 17.0 20.0, 21.0PGA, n (%)^(†) Mild 1 (3) 0 0 0 0 0 0 Moderate 20 (67) 19 (63) 17 (57)13 (43) 15 (50) 17 (57) 81 (54) Severe  9 (30) 11 (37) 12 (40) 14 (47)13 (43) 11 (37) 61 (41) History of PsA, n (%)  9 (30)  7 (23) 12 (40)  9(30)  6 (20)  9 (30) 43 (29) Previous psoriasis treatment,^(‡) n (%)Topical therapy 19 (63) 21 (70) 26 (87) 15 (50) 21 (70) 23 (77) 106(71)  Phototherapy 1 (3)  6 (20)  4 (13)  4 (13)  3 (10)  5 (17) 22 (15)Systemic nonbiologic  6 (20)  4 (13)  7 (23)  5 (17)  6 (20)  8 (27) 30(20) Systemic biologic  3 (10)  3 (10)  7 (23)  6 (20)  4 (13)  7 (23)27 (18) BSA, body surface area, PsA, psoriatic arthritis. *Values aremean (SD) unless otherwise noted. †Data are presented for only 3 of 5possible categories and therefore do not sum up to 30 for each group.‡Within the 12 months before study treatment.

Adults with psoriasis affecting ≧10% body surface area and a PsoriasisArea and Severity Index (PASI) score ≧12 were randomized to 1 of 6arms: 1) one 200-mg dose ABT-874 at Week 0; 2) 100 mg of ABT-874 everyother wk (eow) for 12 weeks; 3) 200 mg of ABT-874 weekly for 4 weeks; 4)200 mg of ABT-874 eow for 12 weeks; 5) 200 mg of ABT-874 weekly for 12weeks; or 6) placebo. The primary endpoint was a ≧PASI 75 response atWeek 12. Patients who met the primary endpoint entered a 36-weekre-treatment phase. Treatment with study drug was discontinued, andpatients who lost response (≦PASI 50) during weeks 12-36 receivedre-treatment with the same dosing regimen assigned during the initial12-week period. Re-treatment lasted for 12 weeks. Regardless ofdisposition, all patients were monitored for the entire duration of thestudy, or until discontinuation.

Of the 180 patients initially enrolled, 130 (1 placebo) entered theretreatment phase and 58 (all ABT-874) were re-treated. The percentagesof patients who achieved ≧PASI 75 at week 12 and then again at 12 weeksafter re-treatment were as follows for each group: one 200-mg dose, 63%vs. 55%; 100 mg eow, 93% vs. 94%; 200 mg weekly 4 wks, 90% vs. 69%; 200mg eow, 93% vs. 75%; and 200 mg weekly, 90% vs. 83%, respectively. Ofthe total 58 patients who were retreated, 76% achieved ≧PASI 75 at 12weeks after re-treatment.

The improvement in PASI scores over time for the re-treated patients isdepicted in FIGS. 5A-B. Specifically, FIG. 5A displays the meanpercentage improvement from baseline in PASI scores from weeks 4 to week12 in PASI responders, and FIG. 5B displays the mean percentageimprovement from baseline in PASI scores from weeks 4 to week 12 postretreatment in PASI 75 responders.

The percentages of patients who achieved ≧PASI 50 at 12 weeks afterre-treatment were as follows for each group: one 200-mg dose, 82%; 100mg eow, 100%; 200 mg weekly 4 wks, 77%; 200 mg eow, 83%; and 200 mgweekly, 100%. Of the total 58 patients who were retreated, 88% achieved≧PASI 50 at 12 weeks after re-treatment.

The percentages of patients who achieved a PGA of “clear” or “minimal”at 12 weeks after re-treatment were as follows for each group: one200-mg dose, 36%; 100 mg eow, 75%; 200 mg weekly 4 wks, 62%; 200 mg eow,67%; and 200 mg weekly, 83%. Of the total 58 patients who wereretreated, 64% achieved a PGA of “clear” or “minimal” at 12 weeks afterre-treatment.

Adverse events (AEs) occurring ≧5% in at least 1 treatment group indescending order through week 48 were: nasopharyngitis, injection-sitereaction, upper respiratory tract infection, headache, hypertension, andarthralgia. An overview of treatment-emergent adverse events throughWeek 48 is displayed in Table 6 below. An overview of treatment-emergentadverse events with an incidence ≧5% in any treatment group is displayedin Table 7 below.

TABLE 6 Overview of Treatment-Emergent Adverse Events Through Week 48*Placebo* 200 mg × 1 100 mg eow 200 mg × 4 200 mg eow 200 mg Weekly AllABT n = 30 n = 30 n = 30 n = 30 n = 30 n = 30 N = 150 Event n (%) n (%)n (%) n (%) n (%) n (%) n (%) Any AE 18 (60.0) 20 (66.7) 25 (83.3) 25(83.3) 25 (83.3) 21 (70.0) 116 (77.3)  Any AE at least possibly  4(13.3)  9 (30.0) 16 (53.3) 16 (53.3) 13 (43.3) 10 (33.3) 64 (42.7)drug-related^(†) Any severe AE  4 (13.3) 1 (3.3) 0 2 (6.7) 1 (3.3) 1(3.3) 5 (3.3) Any serious AE 1 (3.3) 1 (3.3) 0 1 (3.3) 2 (6.7) 0 4 (2.7)Any AE leading to discontinuation 2 (6.7) 1 (3.3) 0 0 0 0 1 (0.7) ofstudy drug Any AE at least possibly 0 0 0 0 1 (3.3) 0 1 (0.7)drug-related and serious^(†) Any infectious AE  7 (23.3) 10 (33.3) 12(40.0) 14 (46.7) 16 (53.3) 10 (33.3) 62 (41.3) Any serious infectious AE0 0 0 0 1 (3.3) 0 1 (0.7) Any malignant AE 1 (3.3) 0 0 1 (3.3) 0 0 1(0.7) Any lymphomas 0 0 0 0 0 0 0 Any nonmelanoma skin cancer 0 0 0 1(3.3) 0 0 1 (0.7) Any injection-site 0  4 (13.3) 11 (36.7) 12 (40.0) 11(36.7)  6 (20.0) 44 (29.3) reaction-related AE Deaths 0 0 0 0 0 0 0*Placebo data are only for the first 12 weeks of the study: all 12-weekdata previously reported. †As assessed by investigator. AE adverseevent.

TABLE 7 Treatment-Emergent Adverse Events With an Incidence of 5% orMore in any Treatment Group Through Week 48* Placebo* 200 mg × 1 100 mgeow 200 mg × 4 200 mg eow 200 mg Weekly All ABT n = 30 n = 30 n = 30 n =30 n = 30 n = 30 N = 150 Event n (%) n (%) n (%) n (%) n (%) n (%) n (%)Injection-site reaction 0 2 (6.7)  7 (23.3)  8 (26.7)  8 (26.7)  4(13.3) 29 (19.3) Nasopharyngitis 1 (3.3)  5 (16.7)  5 (20.0)  3 (10.0) 4 (13.3)  5 (16.7) 23 (15.3) Upper respiratory tract infection 2 (6.7)2 (6.7)  5 (16.7)  3 (10.0)  5 (16.7) 2 (6.7) 17 (11.3) Headache 2 (6.7) 5 (16.7) 1 (3.3) 1 (3.3)  3 (10.0) 2 (6.7) 12 (8.0)  Injection-siteerythema 0 0 1 (3.3) 14 (13.3) 2 (6.7) 1 (3.3) 8 (5.3) Injection-sitepruritus 0 0 1 (3.3) 2 (6.7) 2 (6.7) 2 (6.7) 7 (4.7) Injection-siteirritation 0 1 (3.3)  3 (10.0) 2 (6.7) 0 0 6 (4.0) Arthralgia 1 (3.3) 2(6.7) 1 (3.3) 0 0 2 (6.7) 5 (3.3) Viral infection 0 0 0 2 (6.7) 2 (6.7)1 (3.3) 5 (3.3) Gastroenteritis viral 0 1 (3.3) 0 2 (6.7) 1 (3.3) 1(3.3) 5 (3.3) Fatigue 0 2 (6.7) 2 (6.7) 0 0 1 (3.3) 5 (3.3)Hypertriglyceridemia 0 1 (3.3) 2 (6.7) 2 (6.7) 0 0 5 (3.3) Pain inextremity 0 1 (3.3) 0 0 1 (3.3) 2 (6.7) 4 (2.7) Bronchitis 0 1 (3.3) 0 1(3.3) 2 (6.7) 0 4 (2.7) Pharyngolaryngeal pain 0 2 (6.7) 0 0 0 1 (3.3) 3(2.0) Influenza 1 (3.3) 0 1 (3.3) 0 2 (6.7) 0 3 (2.0) Back pain 0 0 1(3.3) 0 2 (6.7) 0 3 (2.0) Blood triglycerides increased 1 (3.3) 0 0 2(6.7) 1 (3.3) 0 3 (2.0) Urinary tract infection 2 (6.7) 1 (3.3) 0 1(3.3) 1 (3.3) 0 3 (2.0) Insomnia 1 (3.3) 2 (6.7) 0 1 (3.3) 1 (3.3) 0 3(2.0) Nausea 2 (6.7) 0  3 (10.0) 0 0 0 3 (2.0) Cyst 0 1 (3.3) 2 (6.7) 00 0 3 (2.0) Gastroenteritis 0 0 0 0 0 2 (6.7) 2 (1.3) Rhinorrhea 0 0 0 00 2 (6.7) 2 (1.3) Otitis externa 0 0 0 0 2 (6.7) 0 2 (1.3) Vomiting 1(3.3) 0 0 2 (6.7) 0 0 2 (1.3) Hypercholesterolemia 0 0 0 2 (6.7) 0 0 2(1.3) Blood pressure increased 0 0 2 (6.7) 0 0 0 2 (1.3) Procedural pain0 0 2 (6.7) 0 0 0 2 (1.3) Limb injury 0 2 (6.7) 0 0 0 0 2 (1.3) Pruritis2 (6.7) 0 0 0 0 1 (3.3) 1 (0.7) Psoriatic arthropathy 2 (6.7) 1 (3.3) 00 0 0 1 (0.7) *Placebo data are only for the first 12 weeks fo thestudy; all 12 week data previously reported.

The foregoing data demonstrate that ABT-874 was highly efficacious inthe treatment of moderate to severe psoriasis. Upon loss of response andre-treatment, a majority of patients were able to re-achieve a PASI 75response. Moreover, ABT-874 appears to have a favorable safety profilein the long term.

Example 7 Pharmacokinetics of a Fully Human IL-12/-23 MonoclonalAntibody, ABT-874, in Normal Healthy Volunteers

The tolerability, safety, and pharmacokinetics (PK) of a range of dosesof ABT-874 were evaluated in a randomized, double-blind,placebo-controlled dose-ranging study. The objective of the followingexample was to investigate the pharmacokinetics of intravenous (IV) andsubcutaneous (SC) injections of ABT-874 in healthy volunteers.

The main inclusion criteria were: (i) healthy male volunteers between 18and 45 years of age; (ii) no clinically relevant abnormalities in any ofthe investigations of the screening examination (physical exam, vitalsigns, electrocardiogram, biochemistry, hematology, urinalysis,serology); and (iii) chest x-rays normal within 12 months prior toentering the study. The main exclusion criteria were: (i) smoking morethan 10 cigarettes per day; (ii) drinking more than 30 g of alcohol perday; (iii) positive urine drug screen; (iv) chronic infections,especially by intracellular bacterial pathogens such as Mycobacteriumtuberculosis; and (v) major infections requiring hospitalization or IVantibiotics within the previous 2 years.

Young (18-45 years of age), healthy male volunteers received 2 equaldoses (1 IV and 1 SC administered 8 weeks apart) of 0.1, 0.3, 1.0, or5.0 mg/kg ABT-874 in a 2-period crossover (2×2 Latin square) design.Blood samples for the determination of ABT-874 concentrations werecollected before the first dose (0) and at 0.5, 1, 1.5, 2, 4, 8, 12, 24,48, 72, 120, 168, 336, 504 and 672 hours after dosing. Serumconcentrations of ABT-874 were measured by an enzyme-linkedimmunosorbent assay.

ABT-874 serum concentrations were tabulated individually, described bystatistical characteristics (including geometric mean and geometricstandard deviation) and displayed as individual as well as mean, median,and geometric mean concentration vs. time curves for IV and SC treatmentand each treatment group. The following PK parameters were estimatedusing noncompartmental methods:

Cmax maximum serum concentration (μg/mL)

Tmax time to reach Cmax (hr)

AUC area under the serum concentration-time curve (μg×hr/mL)

t½ half-life (hr)

CL clearance (mL/hr) (for IV administration)

Vz volume of distribution (mL) (for IV administration)

CL/F apparent CL (mL/hr) (for SC administration)

V/F apparent Vz (mL) (for SC administration)

A total of 64 patients were randomized; 12 received ABT-874 and 4received placebo for each dose group. ABT-874 appeared to followbi-exponential kinetics following IV administration, entering theterminal phase approximately 7 days after administration. The mean±SDterminal half-lives for the 0.1-, 0.3-, 1.0-, and 3.0-mg IV doses were81.2±55.6, 147±73.2, 208±79.2, and 196±55.4 hours, respectively. Themean±SD terminal half-lives for the 0.1-, 0.3-, 1.0-, and 3.0-mg SCdoses were 221±103, 161±92.6, 210±90.9, and 208±79.2 hours,respectively. The mean terminal half-life for IV administration rangedfrom 81.2±55.6 hours to 208±79.2 hours. The mean terminal half-life forSC administration ranged from 161±92.6 hours to 221±103 hours. Theoverall mean terminal half-life was 8-9 days.

The pharmacokinetics of ABT-874 (maximum concentration of drug [C_(max)]or area under the curve [AUC]) increased proportionally to dose afterboth IV and SC administrations. The serum concentration-time curve forIV and SC dosing is displayed in FIGS. 6A and 6B, respectively. Thevolume of distribution ranged from approximately 8-10 L after IVadministration to 24-67 L after SC administration. After SCadministration, the time to reach C_(max) was approximately 3-4 days.Bioavailability after SC administration ranged between 42% and 62% forthe doses evaluated. The pharmacokinetic parameters following IV or SCadministration at each dose, including C_(max) (the maximum serumconcentration in μg/mL), AUC (area under the serum concentration-timecurve in μg×hr/mL), t_(max) (time to reach C_(max) in hrs), t_(1/2)(half-life in hrs), CL (clearance in mL/hr) and Vz (volume ofdistribution (mL)), are displayed in Table 8 below.

TABLE 8 PK Parameters (Mean ± SD) in Healthy Human Volunteers FollowingIV or SC Administration of ABT-874 C_(max) t_(max) AUC_(0-∞) t_(1/2) CL*Vz^(†) Cohort Route (μg/mL) (hr) (μg × hr/mL) (hr) (mL/hr) (mL) 0.1mg/kg IV  1.99 ± 0.931 —  146 ± 78.8 81.2 ± 55.6   596 ± 1,850 8,010 ±7,600 SC 0.245 ± 0.100 66.7 ± 10.6 84.4 ± 40.6 221 ± 103 183 ± 248 66,500 ± 135,000 0.3 mg/kg IV 7.99 ± 3.08 — 562 ± 202  147 ± 73.2 50.4± 32.7 8,512 ± 3,746 SC 1.09 ± 1.12 90.0 ± 43.6 244 ± 150  161 ± 92.6183 ± 196 24,800 ± 7,430  1.0 mg/kg IV 27.7 ± 8.33 — 2,410 ± 717    208± 79.2 36.2 ± 9.80 10,400 ± 3,840  SC  2.83 ± 0.633 82.0 ± 23.9 1,000 ±318    210 ± 90.9 91.1 ± 41.2 23,900 ± 8,590  5.0 mg/kg IV  150 ± 50.6 —12,700 ± 3,390   196 ± 55.4 33.6 ± 9.26 9,360 ± 3,360 SC 13.4 ± 5.3482.0 ± 36.1 4,840 ± 2,420  208 ± 79.2 229 ± 480 31,800 ± 19,500 *For SCadministration, CL/F ^(†)For SC administration V/F

The foregoing data demonstrate that ABT-874 administered IV and SC insingle doses between 0.1 and 5.0 mg/kg was well-tolerated by younghealthy male individuals. The pharmacokinetic properties of ABT-874,with its half-life of 8-9 days, are as would be expected for an IgG₁antibody.

Example 8 Maintenance of Re-treatment Response with the Fully HumanIL-12/-23 Monoclonal Antibody, ABT-874, in the Treatment of Moderate toSevere Plaque Psoriasis

The efficacy and safety of ABT-874 was evaluated in a 48-week, Phase II,randomized controlled trial that included a 12-week initial treatmentphase and a 36-week re-treatment phase of patients responding to initialtreatment. The initial 12-week efficacy results and maintenance ofresponse results are described in examples 1-5 above. The objective ofthe following example was to examine the re-treatment response duringthe 36-week re-treatment/follow-up phase in patients who lost theirinitial responses of this Phase II study of subcutaneous injections ofABT-874 in the treatment of moderate to severe plaque Ps. The furtherobjective of the following example was to examine safety of subcutaneousinjections of ABT-874 in the treatment of moderate to severe plaque Psthrough 48 weeks.

The main inclusion criteria for the trial were: (i) adults with clinicaldiagnosis of psoriasis for at least 6 months and stable plaque psoriasisfor at least 2 months prior to screening; and (ii) moderate to severeplaque psoriasis (≧10% body surface area involvement, Psoriasis Area andSeverity Index [PASI] score ≧12 and a Physician's Global Assessment[PGA] of at least moderate disease) at the baseline visit.

A first exclusion criteria for the trial was previous exposure tosystemic or biologic anti-IL-12 therapy. A second exclusion criteria wasinability to discontinue the following therapies before the baselinevisit: topical psoriasis therapies ≧2 weeks prior; ultraviolet (UV)-Blight phototherapy ≧2 weeks prior; psoralen-UV light phototherapy ≧4weeks prior; systemic therapies ≧4 weeks prior; and biologic therapies≧12 weeks prior.

At baseline, demographics and clinical characteristics were similaracross treatment groups (summarized in Table 5 of Example 6, above).

Adults with psoriasis affecting ≧10% body surface area and a PsoriasisArea and Severity Index (PASI) score ≧12 were randomized to 1 of 6arms: 1) one 200-mg dose ABT-874 at Week 0; 2) 100 mg of ABT-874 everyother wk (eow) for 12 weeks; 3) 200 mg of ABT-874 weekly for 4 weeks; 4)200 mg of ABT-874 eow for 12 weeks; 5) 200 mg of ABT-874 weekly for 12weeks; or 6) placebo. The primary endpoint was a ≧PASI 75 response atWeek 12. Patients who met the primary endpoint entered a 36-weekre-treatment phase. Treatment with study drug was discontinued, andpatients who lost response (≦PASI 50) during weeks 12-36 receivedre-treatment with the same dosing regimen assigned during the initial12-week period. Re-treatment lasted for 12 weeks. Regardless ofdisposition, all patients were monitored for the entire duration of thestudy, or until discontinuation.

Outcome measurements included the following: (i) percentage of patientsachieving PASI 75; (i) median time to achieve PASI 75 response afterretreatment; (iii) median time to lose PASI 75 response (iii) percentageof patients with a PGA score of “Clear” or “Minimal” after retreatment.

Statistical analysis was carried out as follows. Intention-to-treat(ITT) analyses were performed by randomized treatment group. For PASIassessments obtained after retreatment with ABT-874, the assessmentswere assigned to study visits according to the number of days after thefirst dose of the retreatment. The proportion of patients achieving PASIresponse (yes/no) are presented according to the derived study visit.All statistical tests were 2-tailed with a significance value of 0.05

Of the 180 patients initially enrolled (30 patients per treatmentgroup), 130 (1 placebo) entered the retreatment phase and 58 (allABT-874) were re-treated. The percentages of patients who achieved ≧PASI75 at week 12 and then again at 12 weeks after re-treatment were asfollows for each group: one 200-mg dose, 63% vs. 55%; 100 mg eow, 93%vs. 94%; 200 mg weekly 4 wks, 90% vs. 69%; 200 mg eow, 93% vs. 75%; and200 mg weekly, 90% vs. 83%, respectively. Of the total 58 patients whowere retreated, 76% achieved ≧PASI 75 at 12 weeks after re-treatment. Amajority of patients were able to re-achieve a PASI 75 response (FIG.7A).

The median time (in days) to achieve PASI 75 during the retreatmentphase across all ABT-874 dosage groups is depicted in FIG. 7B. Themedian time to achieve ≧PASI 75 during retreatment were as follows foreach group: one 200-mg dose, between 60 and 65 days; 100 mg eow, between55 and 60 days; 200 mg weekly 4 wks, between 55 and 60 days; 200 mg eow,between 25 and 35 days; and 200 mg weekly, between 55 and 60 days,respectively.

The median time (in days) to lose PASI 75 following the initial 12 weeksof treatment is depicted in FIG. 7C. The median time to lose PASI 75following the initial 12 weeks of treatment were as follows for eachgroup: one 200-mg dose, between 55 and 60 days; 100 mg eow, between 110and 120 days; 200 mg weekly 4 wks, between 110 and 120 days; 200 mg eow,between 160 and 180 days; and 200 mg weekly, between 180 and 190 days,respectively.

The percentages of patients who achieved a PGA of “clear” or “minimal”(e.g., PGA of 0 or 1) at 12 weeks after re-treatment are depicted inFIG. 7D. The percentages of patients who achieved a PGA of 0 or 1 duringre-treatment were as follows for each group: one 200-mg dose, between35% and 40%; 100 mg eow, between 70% and 80%; 200 mg weekly 4 wks,between 60% and 65%; 200 mg eow, between 60% and 70%; and 200 mg weekly,between 80% and 90%, respectively. Of the total patients who wereretreated, between 60 and 65% achieved a PGA of 0 or 1 afterre-treatment.

Adverse events (AEs) occurring ≧5% in at least 1 treatment group indescending order through week 48 were: nasopharyngitis, injection-sitereaction, upper respiratory tract infection, headache, hypertension, andarthralgia. An overview of treatment-emergent adverse events throughWeek 48 is displayed in Table 6 of Example 6, above. An overview oftreatment-emergent adverse events with an incidence ≧5% in any treatmentgroup is displayed in Table 7 of Example 6, above.

The foregoing data demonstrate that ABT-874 was highly efficacious inthe treatment of moderate to severe psoriasis. Upon loss of response andre-treatment, a majority of patients were able to re-achieve a PASI 75response. Moreover, ABT-874 appears to have a favorable safety profilein the long term.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

1. A method of treating psoriasis in a subject comprising administeringto the subject an antibody, or antigen-binding portion thereof, which iscapable of binding to an epitope of the p40 subunit of IL-12 and/orIL-23, for a first extended period of at least 12 weeks, wherein thesubject achieves at least a Psoriasis Area and Severity Index (PASI) 75response by week 12 of the first extended period, discontinuingadministration of the antibody, or antigen-binding portion thereof, forat least 12 weeks following the first extended period of administrationof the antibody, or antigen-binding portion thereof, wherein the subjectexhibits a loss of response by a decrease in PASI score to less thanPASI 50 following discontinuation, and re-administering to the subjectthe antibody, or antigen-binding portion thereof, for a second extendedperiod of at least 12 weeks, wherein the subject achieves at least aPASI 50 response by week 12 of the second extended period, therebytreating psoriasis in the subject.
 2. The method of claim 1, wherein theantibody, or antigen-binding portion thereof, is administered orre-administered biweekly.
 3. The method of claim 1, wherein theantibody, or antigen-binding portion thereof, is administered orre-administered weekly.
 4. The method of claim 1, wherein the antibody,or antigen-binding portion thereof, is administered or re-administeredin a single dose.
 5. The method of claim 1, wherein the antibody, orantigen-binding portion thereof, is administered or re-administered in adose of about 200 mg.
 6. The method of claim 1, wherein the antibody, orantigen-binding portion thereof, is administered or re-administered in adose of about 100 mg.
 7. The method of claim 1, wherein the psoriasis ischronic psoriasis.
 8. The method of claim 1, wherein the subjectachieves at least a PASI 75 response by week 12 of the second extendedperiod.